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11β-HSD1 -  11 -hydroxysteroid dehydrogenase type 1 
11β-HSD2 -  11 -hydroxysteroid dehydrogenase type 2 
3’ -   3 prime 
5’ -   5 prime 
8-iso-PGF2α -  8-isoprostane 
A ACE -  Angiotensin Converting Enzyme 
ACTH - Adrenal Corticotrophic Hormone 
ADH - Antidiuretic Hormone 
AGT -  Angiotensinogen 
AngI -  Angiotensin I 
AngII - Angiotensin II 
ANOVA - Analysis of Variants 
ASDN - Aldosterone Sensitive Distal Nephron 
AT1 -  Angiotensin Type I Receptor  
AT2 -  Angiotensin Type II Receptor  
AR -  Androgen Receptor 
AUC -  Area Under the Curve 
AQP -  Aquaporin 
B BAC -  Bacterial Artificial Chromosome 
BHT -  Butylated Hydroxyl-Tolulene 
BP -  Blood Pressure 
BSA -  Bovine Serum Albumin 
C cAMP - Cyclic Adenosine Monophosphate 
CAT -  Catalyse 
 CCD -  Cortical Collecting Duct 
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 CD -  Collecting Duct 
CIN -  Clearance of Inulin 
CNS -  Central Nervous System 
CNT -  Connecting Tubule 
CRH -  Corticotropin-Releasing Hormone 
CtBP -  Carboxyl-terminal Binding Protein 
D DCT -  Distal Convoluted Tubule 
DMSO - Dimethyl Sulfoxide 
DOC -  11-deoxycortisol 
DOCA - Deoxycorticosterone Acetate 
DRA -  Downstream Recombination Arm 
DRC -  Dose Response Curve 
E E -  Embryonic day 
ECF -  Extracellular Fluid 
ECV -   Extracellular Volume 
ELISA - Enzyme-Linked Immunosorbent Assay 
ENa -  Sodium Excretion 
ENaC - Epithelial Sodium Channel 
EP -  External Probe 
ES -  Embryonic Stem 
F FCS -  Foetal Calf Serum 
 FENa -  Fractional Sodium Excretion 
 FF -  Filtration Fraction 
G GFR -  Glomerular Filtration Rate 
 GPX -  Glutathione Peroxidase 
GR -  Glucocorticoid Receptor 
 GRA -  Glucocorticoid-Remediable Aldosteronism 
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H H2O2 -  Hydrogen Peroxide 
HCL -  Hydrochloric Acid 
HPA -  Hypothalamic-Pituitary-Adrenal 
 HSD11B2 - 11β-HSD2 human gene 
 Hsd11b2 - 11β-HSD2 mouse gene 
 Hsd11b2-/- - Hsd11b2 transgenic null mouse 
Hsd11b2+/- - Hsd11b2 transgenic heterozygote mouse 
Hsd11b2+/+ - Wild type mouse 
Hox -  Homeobox gene 
Hoxb7+/- - Hoxb7 transgenic heterozygote mouse 
Hoxb7+/+ - Wild type mouse 
HR -  Heart Rate 
 HREs - Hormone Response Elements 
 HSP -  Heat Shock Protein 
 HUVECs - Human Umbilical Vein Endothelial Cells 
I ICM -  Inner Cell Mass 
 ICF -  Intracellular Fluid 
IMCD - Inner Medullary Collecting Duct 
IHA -  Idiopathic Hyperaldosteronism Aldosteronism 
I.P. -  Intraperitoneal 
IP3 -  Inositol triphosphate 
 I.V. -  Intravenous 
K Kb -  Kilobases 
L  LacZ -  β-galactosidase 
LB -  Liquid Broth 
LC -   Liquid Chromotography 
M MABP - Mean Arterial Blood Pressure 
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 MBPR - Maximal Blood Pressure Response 
 MR -  Mineralocorticoid Receptor 
 MS -  Mass Spectrometry 
N NAD+ - Nicotinamide Adenine Dinucleotide  
NADP - Nicotinamide Adenine Dinucleotide Phosphate 
 NADH - Reduced NAD+ 
 NADPH - Reduced NADP 
 Na-K-ATPase - Sodium Potassium Pump  
 NCC -  Sodium Chloride Symporter 
Nedd - Neuronal precursor cell Expressed Developmentally 
Down-regulated 
 NKCC - Sodium Potassium Chloride Symporter 
 NO -  Nitric Oxide 
O O2.- -  superoxide radial 
 OMCD - Outer Medullary Collecting Duct 
P PA -  Primary Aldosteronism 
 PAH -  p-Aminohippuric Acid 
 PBS -  Phosphate Buffered Saline 
 PCR -  Polymerase Chain Reaction 
 PDTC - Pyrrolidinedithiocarbamate 
 PIN -  Plasma concentration of Inulin 
 PMSF - Phenylmethylsulfonyl Fluoride monohydrate 
 PNa -  Plasma Sodium Concentration 
 ppm -  parts per million 
 PR -  Progesterone Receptor 
 PRA -  Plasma Renin Activity 
 PVN -  Paraventricular Nucleus 
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R R2F -  Region to Flox 
RAAS - Renin Angiotensin Aldosterone System 
RAS -  Renin Angiotensin System 
RBP -  Renal Blood Flow 
 REDOX - Reduction-Oxidation reaction 
 RIA -  Radio Immunoassay 
 ROMK - Renal Outer Medullary Potassium (K) channel 
 ROS -  Reactive Oxygen Species 
 RPF -  Renal Plasma Flow 
 RVR -  Renal Vascular Resistance 
S SAME - Syndrome of Apparent Mineralocorticoid Excess 
 SE  - Standard Error 
SBP -  Systolic Blood Pressure 
SGK-  Serum- and Glucocorticoid-inducible protein Kinase 
SHR -  Spontaneously Hypertensive Rat 
 SOD -  Superoxide Dismutase 
SPA -   Scintillation Proximity Assay 
SR -  Salt Resistant 
SS -  Salt Sensitive 
StAR -  Steroidgenic acute regulatory protein 
T TASK - TWIK-related acid sensitive potassium 
TCA -  Trichloroacetic Acid 
 TEMPOL - 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl 
 THE -  Tetrahydrocortisol 
 THF -  Tetrahydrocortisone 
 TLC -  Thin Layer Chromotography 
U UFR -  Urine Flow Rate 
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UIN -  Urinary Inulin concentration  
 URA -  Upstream Recombination Arm 
V VSMC - Vascular Smooth Muscle Cell 
 VSV -  Vascular System Volume 
W WNK -  With no lysine (K) 
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The mineralocorticoid hormone, aldosterone, classically acts via the 
Mineralocorticoid Receptor (MR) to promote sodium transport in 
aldosterone target tissues, such as the kidney, thereby controlling long-term 
electrolyte homeostasis and blood pressure (BP). Aldosterone biosynthesis 
by the adrenal gland is regulated by a negative feedback loop called the 
Renin Angiotensin Aldosterone System (RAAS). The glucocorticoid cortisol 
(corticosterone in rodents), which has a very similar structure to aldosterone, 
shares with aldosterone an equal affinity for the MR. Typically, plasma 
cortisol levels are approximately 1000-fold higher than plasma aldosterone, 
and so the ligand specificity for aldosterone must be imposed on MR by 
other, non-structural, means. This specificity is important in order to retain 
electrolyte and BP balance within the control of the RAAS.   
The co-localisation of the enzyme 11β-Hydroxysteroid Dehydrogenase Type 
2 (11β-HSD2) with the MR in aldosterone target tissues provides the MR 
with the aldosterone specificity it inherently lacks. 11β-HSD2 achieves this 
by converting active cortisol to its inactive 11-keto metabolite, cortisone 
(dehydrocorticosterone in rodents). In humans with the monogenetic 
Syndrome of Apparent Mineralocorticoid Excess (SAME), inactivating 
mutations in the HSD11B2 gene allows cortisol unregulated access to the MR. 
Resultant symptoms include severe hypertension and life-threatening 
hypokalemia. Individuals heterozygous for SAME display no overt 
phenotypes. However, some studies have associated SAME heterozygosity 
and loss-of-function polymorphisms within the HSD11B2 gene with essential 
and/or salt-sensitive hypertension in the general population.     
Targeted disruption of the Hsd11b2 gene in mice (Hsd11b2-/-) faithfully 
reproduces with all the major phenotypes of SAME patients.  Mice 
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heterozygote for the targeted gene (Hsd11b2+/-) have no phenotype and 
display a normal BP. In the present study, Hsd11b2+/- mice were used to 
explore the relationship between reduced 11β-HSD2 enzyme activity and 
salt-sensitive hypertension. On a high salt diet, Hsd11b2+/- mice were found to 
have increased BP and impaired natriuresis, compared to wild-type controls 
(Hsd11b2+/+). Further studies used pharmacological blockade of the Epithelial 
Sodium Channel (ENaC) and MR to ascertain the contributions of these 
pathways towards the observed phenotypes.  These identified a deregulation 
of ENaC activity pertaining to an inability to regulate sodium appropriately.   
Investigations into the contributions of the RAAS and the Hypothalamus 
Pituitary Adrenal (HPA) axis have revealed valuable insights into their roles 
in this model.  There is an implication that the RAAS has increased 
sensitivity in Hsd11b2+/-, further exacerbated by increased dietary sodium, 
and that the regulation of corticosteroids may also be altered. Novel 
observations have suggested that oxidative stress in response to a high salt 
diet could also be involved, as a study administering an antioxidant drug in 
conjunction with a high salt diet prevented the manifestation of a phenotype 
in Hsd11b2+/-.  
Finally, the generation of a floxed Hsd11b2 targeting construct for tissue-
specific deletion of 11β-HSD2 will allow future studies into the contributions 
of specific 11β-HSD2 expression sites (such as the kidney) towards the 














1.1  Hypertension 
  
Hypertension is a complex disorder that affects approximately one quarter of 
the Western population and is a major risk factor for many different causes 
of mortality and morbidity, such as myocardial infarction, stroke, and renal 
failure (Kannel, 2000).  Hypertension is defined as an abnormally high blood 
pressure (BP) that is sustained over a long period of time; a systolic and/or 
diastolic pressure taken at rest that averages 140/90 mmHg or above.  In 
some cases, a hypertensive phenotype can be attributed to a heritable genetic 
condition (Mendelian hypertension) (Lifton et al., 2001).  However, in the 
vast majority of patients diagnosed with hypertension no single underlying 
cause can be identified; this is termed essential hypertension. Although 
essential hypertension has no single identifiable cause, lifestyle factors such 
as obesity, lack of exercise, and a high dietary salt intake can all contribute 
towards the condition (Kunes and Zicha, 2009).   
 
1.1.1 Salt-Sensitive Hypertension 
 
In general, the underlying causes of essential hypertension can be difficult to 
elucidate.  However, numerous studies into human hypertension have found 
a positive correlation between hypertensive populations and a diet high in 
salt content (Elliott and Stamler, 2002; Group, 1988; Khaw et al., 2004; Page et 
al., 1981). Current epidemiological evidence shows that the relationship 
between dietary salt and BP varies between the absence of hypertension in 
populations whose intake is less than 3g per day of salt, to the high incidence 
of hypertension in populations that consume more than 15g of salt per day 
(Meneton et al., 2005).  For example, the Yanomamo Indians of Brazil 
consume a diet very low in salt content (typically 0.46g per day; equivalent to 
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20mmol of sodium) and have no incidences of age-related increases in BP, 
whereas populations in Northern Japan consume in excess of 13.8g of salt per 
day (equivalent to 600mmol sodium) and have the highest rate of age-related 
hypertension in the world (Franco and Oparil, 2006).  In support of these 
observations, reductions of dietary salt intake during controlled studies 
involving hypertensive populations has consistently resulted in reductions in 
BP (Forte et al., 1989; Sacks et al., 2001; Swift et al., 2005; Tian et al., 1995).  
Salt-sensitivity is defined as the response of BP to an acute change in salt 
intake; some individuals can effectively excrete an increased salt load 
without an associated increase in BP, whereas those deemed to be SS cannot 
(Cowley, 1997). A seminal study by Weinberger and colleagues 
demonstrated a SS BP response (defined as a 10 mmHg change in BP) to a 
four hour infusion of saline, when compared to BP measured after one day 
on a 10 mmol diet plus furosemide administration, in 51% of hypertensive 
and 26% of normotensive study participants, thus highlighting the prevelnce 
of SS BP in humans  (Weinberger et al., 1986).The observations made in 
humans highlighting a link between high salt intake and hypertension has 
been further corroborated by studies investigating SS hypertension in animal 
models.  One such example is the Dahl SS rat (Dahl et al., 1962), and 
extensive studies on the mechanism underlying the SS BP of this strain has 
culminated in thorough genetic analysis in attempts to identify candidate 
genes for essential hypertension (Deng, 1998; Kato, 1999). It must be pointed 
out that salt excess is not the cause of all essential hypertension, as the BP 
response of individuals to dietary salt content is heterogeneous. 
 
1.1.1.1 The Kidney and Salt-Sensitive Hypertension 
Epidemiological, migration, medical intervention, and genetic studies in 
humans and animals have provided insights into the relationships that exist 
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between dietary salt, renal salt handling, and BP, and they highlight an 
important link between high salt intake and hypertension (Meneton et al., 
2005).  The evidence suggests that salt handling by the kidneys is an 
important mechanism for the regulation of BP, and that genetic mutations 
affecting this can account for at least some of the molecular causes of 
essential hypertension. 
This theory is further verified by investigations into the molecular 
mechanisms of SS hypertension.  The pathophysiological link between salt 
intake and BP is predictable from the relationship between salt and vascular 
volume homeostasis (Lifton et al., 2001).  Experimental evidence reinforcing 
this link comes from kidney cross transplantations carried out between Dahl 
SS and salt-resistant (SR) rats (Churchill et al., 1992; Dahl and Heine, 1975).  
Dahl et al found that renal homografts from SR rats to hypertensive SS rats 
led to a sharp fall in the recipients BP.  The reverse happened when the 
transplant was in the opposite direction, so that the SS recipient rats became 
uncharacteristically hypertensive.  Churchill et al built upon this further by 
conducting a study into kidney transplants where SR and SS rats had both a 
native kidney and a transplanted kidney of the opposite genotype.  Renal 
clearance studies showed differences between the two different kidneys in 
the same rat, thus concluding that the differences were determined by the 
kidneys genotype, and not the recipients.   
 
1.1.2   Renal Sodium and Water Handling 
 
In order to maintain BP homeostasis the body must be able to appropriately 
match the intake of water and electrolytes (including sodium) with their 
excretion.  This requires the kidneys to be able to respond to fluctuating 
dietary intakes of both and adapt excretion appropriately.  The kidneys 
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achieve this by balancing water and sodium excretion in response to 
hormonal signals such as Anti diuretic hormone (ADH; also known as 
vasopressin) and aldosterone.  This involves a fine balance of reabsorption 
and excretion of the luminal fluid along the nephron (Figure 1.1), and de-
regulation of this system can result in a sustained elevation in BP. 
 
1.1.2.1 Long-term BP Regulation by the Kidney – Guyton’s Model 
Guyton and Coleman’s computer model of circulatory control was 
fundamental in demonstrating that cardiac output and the peripheral 
resistance of the vasculature have a combined effect upon BP regulation via 
pressure natriuresis (Guyton et al., 1972).  An imbalance between sodium 
intake  and  sodium  excretion  can  lead to an  increase  in  vascular system   
volume  (VSV),   thus    causing   parallel   increases  in   arterial   BP 
(Bongartz et al., 2005).  In turn, these changes in BP can directly alter sodium 
excretion so as to normalise VSV and BP via pressure natriuresis; this 
demonstrates the overriding importance of renal sodium handling in long- 
term BP regulation  (Figure 1.2).    Guyton  explains  this  as  a  “kidney-fluid 
mechanism for controlling arterial BP involving an infinite feedback gain 
property”; that is, the kidneys adjust to an elevated BP by increasing their 
excretion of sodium and water so as to reduce VSV, and will decrease 
sodium and water  excretion  in response to a BP fall to increase  VSV and BP 
(Guyton, 1990).   Thus, the renal excretion of both sodium and water is 
carefully regulated so as to maintain a balance for regulation of an 
appropriate BP. 
 
1.1.2.2 Sodium Reabsorption  
Urinary excretion of any given substance is the determined by the balance 
between filtration at the glomerulus and tubular handling (either  
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Figure 1.1. Representation of sodium and water reabsorbed in different segments of the 
nephron as a % of the total amount entering the tubule by filtration at the glomerulus.  
Sodium is represented by purple text, water by pink text, reabsorption by green arrows and 
final excretion by a red arrow.   
 
reabsorption or secretion) (Guyton, 1990). Varying amounts of sodium are 
filtered from circulating  plasma  at  the  glomerulus   (depending   upon   
dietary intake), with the vast majority being reabsorbed back into the 
circulation, and generally a fraction of less than 1% excreted in the urine (see 
Figure 1.1).  The final urinary excretion of sodium can be increased or 
decreased depending upon dietary load.  The reabsorption of sodium is 
mainly   an  active   transcellular  process  driven   by  the  sodium-potassium   
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Figure 1.2 Guyton’s model of long-term blood pressure regulation by the kidney.  An 
increase in extracellular fluid volume causes a volume expansion, which in turn leads to an 
increased cardiac output.  This results in an increase in peripheral resistance, causing a rise 
in mean arterial blood pressure.  The kidney adapts to this by increasing its excretion of 
sodium (known as pressure natriuresis), acting to reduce extracellular volume, and this 
ultimately causes a reduction in mean arterial blood pressure.  Adapted from (Bongartz et 
al., 2005). 
 
ATPase (Na-K-ATPase) pump.  The Na-K-ATPase pump is an example of 
primary active transport, as it moves sodium against its electrochemical 
gradient across the basolateral membrane of tubular lumen cells and into the 
interstitial fluid; the energy for this process comes from the hydrolysis of 
ATP.   
The Na-K-ATPase is responsible for the active reabsorption of sodium into 
the interstitial fluid in most parts of the nephron.  However, this can only 
occur if sodium is reabsorbed from the tubular lumen into cells of the 
nephron at their apical membrane.  This is regulated differently in separate 
segments of the nephron.  In the proximal tubule (the major site of sodium 
reabsorption in the nephron), sodium entry is coupled with hydrogen 
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secretion via the NHE-3 antiporter, or in symport with glucose, amino acids 
and/or phosphate; there is also additional sodium transport across the 
basolateral membrane in symport with bicarbonate (Figure 1.3a).  No sodium 
is reabsorbed in the thin limbs of Henle.  The thick ascending limb of Henle 
reabsorbs sodium via the sodium-potassium-chloride symporter (NKCC) as 
well as paracellularly due to a favourable electrochemical gradient between 
the lumen and the interstitium (Figure 1.3b).  In the distal convoluted tubule, 
sodium crosses the apical membrane either by the sodium-chloride 
symporter (NCC) or via the epithelial sodium channel (ENaC) (Figure 1.3c).  
The last point of sodium reabsorption in the nephron occurs in the principal 
cells of the cortical collecting duct via ENaC (Figure 1.3d).  Although the 
amount of sodium reabsorbed in the collecting duct is relatively small 
compared to other nephron segments, it has been shown that this final “fine 
tuning” of sodium reabsorption is paramount in sodium balance 
homeostasis, and is actively regulated by the renin angiotensin aldosterone 
system (RAAS) via mineralocorticoid receptor (MR) regulation of ENaC 
(discussed in more detail later in this chapter).   
Overall, the reabsorption of sodium from the tubular lumen back into blood 
involves  movement  across  the  apical  membrane of  nephron cells from the 
lumen (by the variety of processes described above), followed by active 
transport out across the basolateral membrane into interstitial fluid by the 
Na-K-ATPase, and finally reabsorbtion from interstitial fluid into peritubular 
capillaries, which occurs passively due to osmotic pressure gradients. 
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a) Proximal Tubule  
 
 










d) Collecting Duct: Principal Cell 
 
 
Figure 1.3. Mechanisms of transport for sodium and water reabsorption in different 
segments of the nephron.  a) In the proximal tubule sodium can be moved across the apical 
membrane by the sodium-hydrogen exchanger (NHE3, purple) or the sodium symporter 
(green).  Sodium is transported across the basolateral membrane by the sodium-potassium-
ATPase (Na-K-ATPase; red; main source of sodium movement across the basolateral 
membrane in all nephron cell-types) or the sodium-bicarbonate symporter (Na HCO3; aqua 
blue).  Water is moved across both membranes by the water channel aquaporin 1 (AQP1; 
blue), and can also move paracellularly through leaky tight junctions.  b) In the thick 
ascending limb sodium is moved across the apical membrane by the sodium-chloride-
potassium co-transporter (NKCC; orange); sodium can also move paracellularly.  The thick 
ascending limb is impermeable to water.  c) Sodium moves across the apical membrane of 
the distal convoluted tubule by either the sodium-chloride co-transporter (NCC; teal) or the 
epithelial sodium channel (ENaC; pink); this segment is impermeable to water.  d) In the 
principal cells of the collecting duct sodium is moved across the apical membrane by ENaC, 
and water is transported via AQP2.  At the basolateral membrane, water moves via AQP3 
and 4. 
 
1.1.2.3 Water Reabsorption  
The water content of urine in relation to other solutes can be varied by the 
kidneys according to the volume of water intake; dilute urine will be 
produced during large intakes of water, and concentrated urine during 
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periods of reduced water ingestion.  The kidney reabsorbs water by osmosis 
only, never active transport, and this is secondary to the reabsorption of 
solutes, principally sodium.   Different parts of the nephron are responsible 
for the reabsorption of different volumes of water (see Figure 1.1 for 
overview). 
Water can be reabsorbed from tubular cells in several different ways 
including diffusion through the lipid bilayer of the cell membrane, in-
between the tight junctions between cells, and across the cell membrane via 
specialised water channels called aquaporins (AQPs). The presence of AQP3 
and 4 in the basolateral membranes of renal cells ensures that the cytosolic 
osmolality is similar to that of the interstitium.  Although the basolateral 
membranes are always water permeable, the permeability of the apical 
membranes and the tight junctions vary depending upon nephron section.   
As with sodium reabsorption, water is reabsorbed in different quantities 
along the nephron.  In the proximal tubule, water is reabsorbed to the same 
extent as sodium (Figure 1.3a).  The proximal tubule is the major site of water 
reabsorption, and this occurs both paracellularly (by osmotic gradient 
between leaky tight junctions) and transcellularly (via AQP1 expression in 
the apical membrane).  The descending limb of Henle reabsorbs water as it is 
relatively water permeable (Figure 1.3b). No water is reabsorbed in the thin 
and thick ascending limbs, as their apical membranes are impermeable to 
water (Figure 1.3c).  As a result of this, the nephron will always reabsorb 
more solute than water before tubular fluid reaches the cortical collecting 
duct, resulting in the tubular fluid entering the collecting duct being 
relatively dilute.  The distal convoluted tubule can alter its water 
permeability to produce either concentrated or dilute urine, depending upon 
hormonal signals. ADH is secreted by the pituitary gland in response to 
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water homeostasis and acts to promote AQP2 insertion at the apical cell 
membrane of collecting duct principal cells (Figure 1.3d).  This permits the 
collecting duct to vary its reabsorption of water by AQP2; AQP2 is the only 
AQP regulated in this way (for review of AQP2 regulation, see (Noda and 
Sasaki, 2006).   
Overall, the final dilution of urine depends upon both the medullary osmotic 
gradient produced by the impermeability of the loop of Henle to water 
compared to solute reabsorption, and to the variable water permeability of 
the collecting duct due to hormonal regulation. 
 
1.1.3   Monogenic Hypertension 
 
Essential hypertension accounts for over 90% of all clinical cases of 
hypertension and it is likely that multiple genes with different degrees of 
functional polymorphisms are involved (McBride et al., 2006).  The exact 
causes of essential hypertension are difficult to identify, as there are many 
different genes involved in the homeostatic control of BP.  It is likely that 
multiple genes with slight functional mutations contribute towards the total 
phenotype of essential hypertension. However, molecular genetic studies 
into monogenic forms hypertension (and hypotension) in humans have been 
vital in improving the understanding of the molecular and physiological 
mechanisms underlying essential hypertension within the general 
population.  
Eight genes have been identified as causing monogenic hypertension, and 
nine that cause monogenic hypotension (Lifton et al., 2001).  A crucial 
observation from both hyper- and hypotension monogenic conditions is that 
in all cases the single gene identified as responsible for the phenotype exert 
their BP effects via renal sodium handling pathways (Figure 1.4).    Mutations  
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Figure 1.4. Monogenic mutations that have been identified as the molecular cause(s) of 
Mendelian hypo- and hypertension in humans (black text).  Green arrows indicate 
hypotensive disorders, red arrows indicate hypertensive disorders, and black text across 
arrows highlights molecular mechanisms causing the disorders.  Adapted from Meneton, 
Jeunemaitre et al. 2005. 
 
that increase sodium reabsorption cause hypertension and those that impair 
it lead to hypotension. 
 
1.1.3.1 Hormones and Hormone Receptors 
Glucocorticoid-remediable aldosteronism (GRA) and the syndrome of 
apparent mineralocorticoid excess (SAME) are both examples of monogenic 
hypertension where the mutation affects hormonal regulation of renal 
sodium handling. Ultimately, these mutations cause an over activation of the 
MR, resulting in inappropriate up regulation of ENaC-mediated sodium 
reabsorption out with the control of the RAAS.  Both of these conditions will 
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be discussed in more detail in context to their disruption of hormonal 
regulation later in this chapter.   
A mutation in the MR receptor itself that permits compounds that would not 
normally activate it to behave as potent agonists has also been identified as a 
cause of Mendelian hypertension.  The MR-S810L mutation allows both 
endogenous hormones, such as progesterone, and pharmacological 
antagonists, such as spironolactone, to activate the MR; the hypertensive 
phenotype becomes particularly prominent during pregnancy, when 
endogenous progesterone levels can increase 100-fold (Geller et al., 2000).    
 
1.1.3.2 Renal Ion Channels and Transporters 
Monogenic mutations in renal ion channels and transporters have also been 
identified as causes of Mendelian hypertension.  The importance of ENaC in 
sodium homeostasis and BP control has been underlined by the direct 
genetic linkage of its genes to genetic hypertension, namely Liddle’s 
syndrome (also known as pseudohyperaldosteronism) (Warnock, 2001).  
Functional ENaC is comprised of three different subunits; α, β, and γ 
(Rossier et al., 1994). Liddle’s syndrome is caused by a mutation in the PY 
motif of either the β or γ ENaC subunits; the PY motif is recognised by the 
 neural precursor cell-expressed developmentally down-regulated (Nedd) type 4 
ubiquitin-protein ligase that is responsible for the ubiquitination and 
degradation of ENaC subunits (Staub et al., 2000).  Mutations in the PY motif 
prevent Nedd4-mediated retrieval from the apical membrane and 
consequent degradation of ENaC, and as a result the channel remains 
constitutively active in the distal nephron.  This results in a hypertensive 
phenotype due to excess salt retention and hypokalemia.  A transgenic 
mouse that was generated using Cre/loxP-mediated recombination (see 
Chapter 6 for details on technique) to delete the c-terminus of the ENaC-β 
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subunit displays Liddle’s syndrome-like phenotypes when exposed to a high 
sodium diet (Pradervand et al., 1999). 
Recent advances in molecular biology of another form of monogenic 
hypertension, Gordon’s syndrome (also known as pseudohypoaldosteronism 
type II), has revealed regulatory elements involved in nephron sodium 
reabsorbtion that were previously unknown.  The molecular etiology of the 
disease is attributed to mutations in either with-no-K (lysine) (WNK) 1 or 4 
(Kahle et al., 2004).  WNKs are members of the serine-threonine kinase family 
and are expressed in the kidney (Yang et al., 2003).  WNK4 normally reduces 
NCC activity by phosphorylating NCC; this phosphorylation acts as a 
molecular tag for degradation.  This results in a reduced abundance of NCC 
at the apical membrane, where it is normally responsible for sodium 
reabsorption (see Figure 1.3c for demonstration of normal NCC role).  
Inactivating mutations in WNK4 result in increased NCC activity as it 
becomes over expressed at the apical membrane; consequently excess 
sodium is reabsorbed (Glover and O'Shaughnessy, 2010).  In contrast, WNK1 
has no direct effects upon NCC per se, but can act as an inhibitory regulator 
of WNK4 action.  Two isoforms of WNK1 have been identified; a WNK1 
transcript that contains a kinase domain, known as the long isoform (L-
WNK1), and a shorter isoform that lacks the kinase domain, know as the 
kidney-specific isoform (KS-WNK1).  L-WNK1 is expressed in many 
different tissues, including along the entire nephron at low levels, whereas 
KS-WNK1 is highly expressed in the aldosterone-sensitive distal nephron 
(ASDN) (O'Reilly et al., 2006). Studies have shown that in the presence of L-
WNK1 WNK4 no longer inhibits NCC, suggesting that L-WNK1 is an 
upstream inhibitor of WNK4 action upon NCC (Yang et al., 2005).   KS-
WNK1 is a dominant-negative regulator of L-WNK1; KS-WNK1 inhibits 
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NCC activity indirectly by inhibiting L-WNK1, which will consequently 
increase WNK4 activity (Kahle et al., 2008).  Therefore, mutations that result 
in a gain-of-function for L-WNK1 or a loss-of-function for KS-WNK1 can 
both cause increased NCC activity and lead to an excess of sodium 
reabsorption. A transgenic mouse generated using a WNK4 mutation known 
to cause Gordon’s syndrome displayed hypertension, hypokalemia and 
hyperplasia of the distal nephron (Lalioti et al., 2006).  Interestingly, cross-
breeding of this transgenic mouse with another transgenic mouse with a 
targeted NCC deficiency rescued the phenotype, further proving that 
molecular cause of Gordon’s syndrome is via WNK effects upon NCC 
function in the distal nephron.         
Overall, characterisations of monogenic forms of hypertension have 
provided important insights into the molecular mechanisms that may 
contribute towards essential hypertension in the general population.  This is 
also true of monogenic hypotension, although it has not been discussed here 
(for review see(Rosskopf et al., 2007)).  The observation that all forms of 
Mendelian hyper- and hypotension have a renal origin demonstrates the 
paramount importance of the kidney in normal BP regulation. 
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1.2 Glucocorticoids and Mineralocorticoids 
 
Glucocorticoids and mineralocorticoids are members of the corticosteroid 
hormone family and are synthesised in the adrenal gland from the common 
precursor cholesterol via the intermediate pregnenolone (Figure 1.5). The 
principal glucocorticoid in humans is cortisol (corticosterone in rodents) and 
the principal mineralocorticoid is aldosterone.  Sharing a common synthesis 
pathway, cortisol and aldosterone are also structurally similar and exhibit a 
degree of cross-receptor affinity and function.  Nevertheless, small 
differences in structure permit important differences in physiological 
function.  Aldosterone classically acts via the MR to promote sodium 
transport in the kidney and gut, thereby regulating long-term electrolyte 
homeostasis and BP control. Cortisol, by comparison, exhibits a wide range 
of metabolic and stress-related response effects. This section will highlight 
the significance of aldosterone and cortisol regulation in BP homeostasis and 
cardiovascular disease, discussing examples of human disease and animal 
models. 
 
1.2.1 Corticosteroid Synthesis 
 
Corticosteroid synthesis occurs principally in the adrenal gland.  The 
biosynthetic pathways of cortisol and aldosterone share a number of 
common intermediates and enzymes, and only become fully exclusive at 11-
deoxycortisol (DOC; cortisol pathway) and 11-deoxycorticoisterone 
(aldosterone pathway) (Figure 1.5a). In rodents, exclusivity occurs at 11-
deoxycorticoisterone (Figure 1.5b).  The reason for the difference between the 
primary  glucocorticoid in humans  and  rodents  (cortisol and corticosterone,  
 38 
































Figure 1.5.  The biosynthesis pathways of aldosterone and cortisol/corticosterone.  In a) 
humans the synthesis pathways become exclusive at 11-deoxycortisol and 11-
deoxycorticoisteroid (cortisol and aldosterone, respectively). In b) rodents, the pathways 

















respectively) is expression of the CYP171A gene product, CYP17.  CYP17 is 
the enzyme responsible for the production of the 11-deoxycortisol 
precursors; 17-OH-pregnenolone and 17-OH-progesterone (see blue text in 
Figure 1.5a).  11-deoxycortisol is then converted to cortisol by CYP11B1.  
DNA methylation of Cyp17a prevents CYP17 production in the adrenal gland 
of rodents (thus they cannot synthesis the cortisol precursor 11-
Deoxycortisol), and instead they utilise corticosterone as their primary 
glucocorticoid (Martinez-Arguelles and Papadopoulos).  This epigenetic 
regulation of CYP17 in rodents can be chemically reversed, thus permitting 
rodents to express CYP17 and synthesise cortisol (Missaghian et al., 2009).  
The final step in cortisol synthesis, the conversion of 11-deoxycortisol to 
cortisol, is catalysed by the enzyme 11 -hydroxylase (CYP11B1), while the 
final three stages of aldosterone synthesis are catalysed by aldosterone 
synthase (CYP11B2).  There is a differential spatial expression of these two 
enzymes in the cortex of the adrenal gland which is divided into three 
distinct zones: zona glomerulosa, zona fasciculata, and zona reticularis.  
Cortisol is synthesised primarily in the zona fasciculata, with a small amount 
being produced by neighbouring cells in the zona reticularis.  11β-
hydroxylase is present in both these zones.  Aldosterone is produced in the 
zona glomerulosa, where aldosterone synthase is exclusively expressed. The 
final step in cortisol synthesis, the conversion of 11-deoxycortisol to cortisol, 
is catalysed by the enzyme 11 -hydroxylase (CYP11B1), while the final three 
stages of aldosterone synthesis are catalysed by aldosterone synthase 
(CYP11B2). 
There is a differential spatial expression of these two enzymes in the cortex of 
the adrenal gland which is divided into three distinct zones: zona 
glomerulosa, zona fasciculata, and zona reticularis.  Cortisol is synthesised 
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primarily in the zona fasciculata, with a small amount being produced by 
neighbouring cells in the zona reticularis.  11β-hydroxylase is present in both 
these zones.  Aldosterone is produced in the zona glomerulosa, where 
aldosterone synthase is exclusively expressed.  
 
1.2.2 Corticosteroid Regulation 
 
1.2.2.1 Glucocorticoids 
Glucocorticoid synthesis is regulated by the hypothalamic-pituitary-adrenal 
(HPA) axis (Figure 1.6).  Adrenocorticotropic hormone (ACTH) is 
synthesised by the posterior pituitary mainly in response to two synergistic 
factors – Corticotropin-Releasing Hormone (CRH) and ADH, both of which 
are produced in the paraventricular nucleus (PVN) of the hypothalamus in 
response to a physiological stress.  ACTH then acts to stimulate the synthesis 
and release of cortisol from the adrenal gland.  Cortisol itself exerts negative 
feedback on the HPA axis by inhibiting both the release and the actions of 
CRH. ACTH also exerts a short-loop negative feedback by inhibiting its own 
secretion.  Plasma cortisol levels fluctuate throughout the day as release 
follows a circadian rhythm.  Most secretion occurs from the third hour of 
sleep to the early hours of wakefulness,  and plasma cortisol  is lower during 
the rest of the day. The rhythm synchronizes, to an extent, with plasma 
ACTH concentration and there is a peak in CRH preceding that of cortisol by 
4-5 hours. There is a well-established circadian variation in cardiovascular 
risk events, with an increase in events in the morning compared to other 
times of day (Giles, 2006), coinciding with elevated glucocorticoid and 
aldosterone levels.   
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Figure 1.6.  Hypothalamus Pituitary Adrenal (HPA) axis and regulation of cortisol release.  
Stress causes a release of corticotrophin release factor (CRF) from the hypothalamus, which 
in turn promotes the release of adrenocorticotropic hormone (ACTH) from the pituitary gland.  
ACTH then acts upon the adrenal gland to increase the synthesis and release of cortisol 
(corticosterone in rodents), which itself acts as a regulator of the HPA axis by inhibiting CRF 
and ACTH release. 
 
1.2.2.2 Aldosterone 
The production of aldosterone from the zona glomerulosa is controlled by 
the RAAS (Figure 1.7) and plasma potassium concentration.   Angiotensin II  
(AngII) and potassium have been shown to exert trophic effect on adrenal 
gland structure, promoting both hypertrophy of the zona glomerulosa and 
increased sensitivity of aldosterone secretion (Quinn and Williams, 1988). 
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Figure 1.7.  Renin angiotensin aldosterone system (RAAS) in the control of blood pressure.  
Signals that indicate reductions in blood pressure and/or the sodium concentration of renal 
filtrate promote the release of renin from granular cells of the juxtaglomerular apparatus.  
Renin cleaves inert angiotensinogen to produce angiotensin I, which is in turn cleaved by 
angiotensin converting enzyme (ACE) into angiotensin II.   Angiotensin II acts to increase 
blood pressure either directly (vasoconstrictive actions) or by promoting the synthesis and 
release of aldosterone from the adrenal gland.  Aldosterone then exerts genomic effects to 
increase sodium reabsorption and blood pressure. 
 
Overall, the net secretion of aldosterone normally results from the 
integration of both of these signals.  
The RAAS begins with the cleavage of the inert peptide angiotensinogen 
(AGT) (which is primarily synthesized in the liver) by the aspartyl protease 
renin to produce angiotensin I (AngI). This is further cleaved by angiotensin 
converting enzyme (ACE) to yield the octapeptide, AngII.  AngII acts via 
angiotensin type 1 and 2 receptors (AT1 and AT2, respectively) to increase BP 
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by increasing vascular resistance and renal sodium reabsorption.  Due to its 
effects upon the vasculature, AngII can be considered as an important 
cardiovascular hormone in its own right, separately from its effects on 
aldosterone synthesis.  AngII also stimulates aldosterone production by 
activation of both early and late stages of steroid biosynthesis (Kramer et al., 
1980), thus completing the RAAS-induced synthesis of aldosterone.  
Classically, the RAAS operates at a systemic level.  Recent evidence, 
however, demonstrates that the RAAS can operate independently at the level 
of the tissue and exert powerful cardiovascular effects quite independently of 
the systemic system (Lazartigues et al., 2007).  
The observation that aldosterone synthesis can occur even when the RAAS is 
suppressed highlights the important regulatory role of plasma potassium 
concentration.  The regulation of aldosterone synthesis by potassium is very 
sensitive, and changes of ± 0.1mM can alter the rate of production 
independently of either AngII or plasma sodium (Quinn and Williams, 1988).  
This sensitivity is due to the high expression of specific potassium channels 
in the glomerulosa cells of the adrenal; namely TWIK-related acid sensitive 
potassium channels 1 and 3 (TASK1 and 3) (Bandulik et al., 2010). These 
channels are active at negative membrane potentials, and as a result 
relatively small changes in extracellular potassium concentration can activate 
voltage-activated calcium channels leading to a calcium influx in these cells 
(Lotshaw, 2001).  This calcium influx, in turn, can induce and activate 
CYP11B2 (see figure 1.5), as well as steroidogenic acute regulatory protein 
(StAR), which is the transport protein that regulates cholesterol transfer 
within mitochondria (the rate limiting step in the production of steroid 
hormones, such as aldosterone) (Spat, 2004).  This provides a feedback loop 
of potassium plasma concentration whereby if plasma potassium rises, the 
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increase in aldosterone synthesis promotes kaliuresis and a redistribution of 
potassium from the extracellular fluid into the cytosol, thereby returning 
plasma potassium levels to normal (Young, 1985). This feedback loop can 
uncouple the secretion of aldosterone from control by AngII under 
conditions of sodium depletion (Cowley and McCaa, 1976). The binding of 
AngII to its type 1 receptor (AT1) also stimulates a variety of signalling 
cascades that lead to an increase in intracellular calcium that increases 
CYP11B2 and StAR expression (Nogueira et al., 2010)  
Abnormal regulation of the RAAS is regularly implicated in hypertension 
(Campese and Park, 2006; Mullins et al., 2006) and the beneficial effects of 
ACE inhibitors and AT1 receptor blockers in patients with cardiovascular 
disease have been demonstrated many times in large scale clinical trials 
(Stojiljkovic and Behnia, 2007).  Similarly, the renin inhibitor, Aliskiren, is 
effective in the treatment of moderate hypertension, although long-term 
outcome data are not yet available (Van Tassell and Munger, 2007). In 
addition, the use of transgenic animals has clearly demonstrated the major 
role of the RAAS in cardiovascular homeostasis; for a detailed review of this 
subject, see (Mullins et al., 2006).   
 
1.2.3 Corticosteroid Receptors and Control of Ligand Access 
 
1.2.3.1 Steroid Receptors 
The glucocorticoid receptor (GR) and the MR are the intracellular hormone 
receptors responsible for binding and mediating the “classic” effects of 
cortisol and aldosterone, respectively.  They belong to subfamily 3C of a 
large and diverse family of transcription factors known as the nuclear 
receptor family.  Other members of subfamily 3C include the progesterone 
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receptor (PR) and the androgen receptor (AR).  GR and MR share a high 
degree of structural homology, reflecting the structural similarities between 
their corticosteroid ligands.  The structural homology is highest at the DNA-
binding domains at 94%, and is 56% between the ligand-binding domains 
(Lu et al., 2006).  This high degree of homology suggests that the two 
receptors are closely associated in evolutionary terms, and are most likely 
descended from a common ancestral receptor (Baker et al., 2007). A polar 
surface within the ligand-binding pocket of MR, absent in GR and other 
receptors of the family, permits preferential binding of aldosterone. 
Nevertheless, the cloning and expression of MR (Arriza et al., 1987) revealed 
considerable ligand-promiscuity with receptor specificity being governed by 
ligand access (to be discussed in more detail later in chapter).  
Un-activated, GR and MR are sequestered in the cytoplasm by a heat shock 
protein (HSP) complex which prevents the receptors entering the nucleus in 
the absence of an appropriate activation signal.  Cortisol and aldosterone 
circulate in plasma bound to plasma proteins, and can easily diffuse through 
the cell membrane into the cytoplasm.  Here they displace the HSP from their 
receptor to allow the formation of a hormone-receptor complex. This changes 
the conformation of the receptor, allowing it to form a homodimer, which 
can now readily enter the nucleus where it will recognise specific hormone 
response elements (HREs) associated with target genes, and act as a ligand-
dependent transcription factor (Figure 1.8).  A recent study has shown that 
GR and MR can form heterodimers that successfully translocate into the 
nucleus; however the downstream effects on DNA transcription of this 
complex are as yet unknown (Nishi and Kawata, 2007).  HREs are typically 
located within a gene enhancer, which can be several kilobases (Kbs) away 
from  the  gene  promoter.   GR and MR,  along  with  PR  and  AR,  recognise  
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GR Transcriptional Activation 
 
 
   
Figure 1.8. Schematic representation of the transcriptional activation of a sequestered GR 
monomer.   Upon ligand binding, the GR monomer is released from its associated heat-
shock protein inhibitory complex and forms a homodimer, which then translocates into the 
nucleus where it instigates transcription of GR-target genes.  MR monomers are regulated in 
a similar manner, and there are recent reports in the literature of GR-MR heterodimers.    
 
response elements whose HRE sequence consists of two hexameric half-sites 
(TGTTCT).  This allows the transcription of genes that mediate GR- and MR-
induced responses to be tightly regulated by appropriate ligand binding and 
hormone-receptor complex conformation.   
 
1.2.3.2 Control of Ligand Access 
The enzymes 11 -hydroxysteroid dehydrogenase type 1 and 2 (11 -HSD1 
and 2) are key determinants of ligand access to the GR and MR, respectively. 
The enzymes interconvert between cortisol (active) and cortisone (inactive), 
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thereby controlling the local concentrations of active glucocorticoids (Figure 
1.9).  
 
Post-Synthesis Glucocorticoid Regulation   
 
 
Figure 1.9. Diagrammatic representation of the in vivo interconversion between active 
(cortisol/corticosterone) and inactive (cortisone/11β-dehydrocorticosterone) glucocorticoids 
by the enzymes 11β-HSD1 and 2, in humans and rodents.  11β-HSD1 and 2 have different 
expression patterns that complement their physiologic roles, and require either NADP(H) or 
NAD(H) co-factor for their enzymatic activity, respectively. 
 
11 -HSD1 has a wide distribution, but its main areas of action, in terms of 
both transcript expression and activity, are the liver, adipose tissue and brain 
(Seckl and Walker, 2004).  11β-HSD1 can control the concentration of 
available glucocorticoids at a more local, tissue-specific level, and an up- 
regulation  of  11β-HSD1  can result  in  increased  generation of  cortisone  to 
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cortisol at a local level. in vivo, 11 -HSD1 governs the extent to which the GR 
is activated by up-regulating active glucocorticoid signalling at a local level 
(Paterson et al., 2005). Due to its widespread distribution and the lack of 
specific inhibitors, functional dissection of the role of the enzyme in specific 
tissues is difficult.  However, significant advances in the understanding of 
this have come from the generation of genetically modified mice. 
11 -HSD2 has a more limited distribution, and is expressed predominantly 
in aldosterone target tissues such as the distal nephron and colon (Brown et 
al., 1996). 11β-HSD2 is also found in non-epithelial cell types such as the 
placenta (Thompson et al., 2002; 2004), the vascular endothelium (Christy et 
al., 2003) and specific regions of the brain (Holmes and Seckl, 2006).   In vitro, 
MR can be activated with equal potency by both aldosterone and cortisol 
(Arriza et al., 1987). In vivo, ligand access to MR is determined by co-
localization with 11 -HSD2 (Figure 1.10).   By catalysing the rapid conversion 
of cortisol into cortisone (which does not activate MR) 11 -HSD2 confers 
aldosterone specificity upon the MR (Funder et al., 1988; Stewart et al., 1987). 
MR and 11 -HSD2 have overlapping distributions in those tissues classically 
held to be aldosterone selective, such as kidney and colon epithelia  (Brown 
et al., 1996).  
Human 11 -HSD1 was originally cloned from the liver (Agarwal et al., 1989) 
and human 11β-HSD2 from the kidney (Agarwal et al., 1995). Although both 
enzymes belong to the same super family of short-chain alcohol 
dehydrogenase reductases, comparison reveals little sequence identity with 
the exception of the regions encompassing cofactor binding (nicotinamide 
adenine dinucleotide (NAD+(P)) or nicotinamide adenine dinucleotide 
phosphate (NAD(P)H)) and the active site (Paterson et al., 2005). In cell 
culture systems, both enzymes are single chain polypeptides localized to the 
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11β-HSD2 Protection of MR Specificity  
 
 
Figure 1.10. Schematic representation of 11β-HSD2 conferring aldosterone specificity upon 
the MR.  11β-HSD2 is co-expressed with MR in principal cells of the collecting duct, where it 
prevents cortisol from binding and activating the MR by converting it into inactive cortisone.  
This maintains MR transcriptional regulation under the control of the RAAS homeostatic 
feedback loop. 
 
membrane of the endoplasmic reticulum, with opposing orientations of their 
catalytic sites (Naray-Fejes-Toth and Fejes-Toth, 1996; Odermatt et al., 1999). 
In vivo, however, homo-dimerisation may provide additional regulation of 
enzyme activity; dimerisation supports full activity of 11 -HSD1 (Maser et 
al., 2002) but inactivates 11 -HSD2 (Gomez-Sanchez et al., 2001).  
 
1.2.4 Glucocorticoids - Cardiovascular Effects 
 
Glucocorticoids are responsible for a wide range of physiological effects, the 
majority of which are united under the common sub-heading of stress 
responses  (Figure 1.11).    The  release  of  glucocorticoids,  following  stress-  
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Figure 1.11. The many effects of glucocorticoids upon various cardiovascular risk factors.   
 
induced stimulation of the HPA axis, promotes the coordination of 
endocrine, immune and nervous system responses to the initial stimuli.  
Examples of this include inducing the mobilisation of energy resources in 
response to physical stresses, such as starvation and the “fight or flight” 
response,  by  stimulating  gluconeogenesis  and  lipolysis,  and  by inhibiting  
glucose uptake by peripheral tissues.  Glucocorticoids also act to suppress 
inflammatory responses, cellular proliferation, and tissue repair, suggesting 
a regulatory role that acts to prevent these responses becoming undisciplined 
and destructive.  Several clinical disorders associated with cortisol 
deregulation - whether a consequence of altered synthesis, HPA axis 
deregulation or GR-mediated effects - have been associated with an 
increased risk of cardiovascular events, which in turn is linked with an 
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increased rate of morbidity and mortality (for review see (Girod and 
Brotman, 2004)).   
Due to the widespread distribution of GR, it is difficult to separate the direct 
primary effects of glucocorticoids upon the heart and vasculature from 
secondary changes arising from activation of GR in other systems (see Figure 
1.11). However, evidence from human patients and transgenic mice has 
helped to establish the nature of these primary responses. That 
glucocorticoids are important cardiovascular hormones is illustrated through 
the extremes of altered glucocorticoid secretion in human conditions.  
 
1.2.4.1 Cushing’s Syndrome 
Cushing’s syndrome is the result of prolonged exposure to excessive cortisol; 
this can be due to an unregulated hyper-secretion of endogenous cortisol, or 
as a result of intensive exposure in the form of exogenous steroid treatment.  
Cardiovascular disease is the main cause of death and disease in Cushing’s 
syndrome patients, and an elevated risk remains even after successful 
treatment of other symptoms (Whitworth et al., 2005);  epidemiological 
studies of Cushing’s syndrome show patients have a mortality rate 4 times 
higher than average due to cardiovascular complications (Etxabe and 
Vazquez, 1994).  Hypertension is one of the major cardiovascular risk factors 
associated with Cushing’s syndrome, being present in ~80% of adult patients 
(Arnaldi et al., 2004).  The key underlying mechanism of hypertension is 
glucocorticoid excess; this can in part be attributed to illicit MR occupation, 
but this is not the only cause as MR antagonists do not fully alleviate the 
hypertension (Whitworth et al., 2005). A recent study investigating the 
contributions of MR and GR towards Cushing’s phenotypes in a mouse 
model of the disease demonstrated that blockade of both receptors was 
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required to fully alleviate the phenotypes, suggesting that both are involved 
in Cushing’s disease   (Bailey et al., 2009). Other BP effects are mediated by 
excessive activation of the RAAS, potentiation of vasoactive substances, 
and/or suppression of vasodilators (for review, see (Magiakou et al., 2006)).  
Hypertension is generally resolved in patients after successful treatment, but 
in a few cases the hypertension persists, suggesting permanent damage to, 
and remodelling of, the renal and cardiovascular systems. 
 
1.2.4.2 Metabolic Syndrome 
The metabolic syndrome is defined as the clustering of a plethora of 
metabolic and cardiovascular phenotypes, including hypertension, 
hyperglycaemia (type 2 diabetes), dyslipidemia, and abdominal obesity 
(Aizawa et al., 2006).  The metabolic syndrome has been shown to be a major 
cardiovascular risk factor, and its prevalence in modern society may be 
related to relatively recent lifestyle changes, such as dramatic increases in 
calorie and salt intake coupled with a rise in sedentary lifestyle habits (Chew 
et al., 2006).  However, the metabolic interactions leading to the clustering of 
metabolic syndrome phenotypes are not completely understood (Grundy, 
2007).  A similarity between the phenotypes of metabolic syndrome and 
Cushing’s disease cannot help but to be noticed, and glucocorticoids 
excess/resistance is a possible underlying cause of metabolic syndrome 
(Walker, 2006).  As GR are ubiquitously expressed throughout all tissues, the 
effects of a global increase in plasma glucocorticoids levels can have many 
varied physiological effects (refer back to Figure 1.11).   
 
1.2.4.3  Glucocorticoid Receptor Polymorphisms 
GR variation exists in the general population, and several GR 
polymorphisms have been identified that seem to be associated with altered 
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glucocorticoid sensitivity and metabolic parameters (for review see (van 
Rossum and Lamberts, 2004)).  The N363S variant is associated with 
hypertension, obesity, angina and coronary artery disease, suggesting a role 
for altered GR variation in these conditions (Lin et al., 2003).  Conversely, the 
ER22/23EK polymorphism is associated with glucocorticoid resistant 
phenotypes (Koper et al., 1997), and carriers tend to be protected from 
cardiovascular damage (van Rossum et al., 2004).   
That no complete loss-of-function mutations in the GR are present in the 
human population indicates that glucocorticoid activity is essential for life. 
Transgenic mice with GR gene mutations, leading to partial or complete 
ablation of GR function support this hypothesis (for review see 
(Wintermantel et al., 2005)) and have not been particularly informative due 
to high levels of neonatal mortality; GR null mice die a few hours after birth 
due to respiratory failure as glucocorticoids are critical in foetal lung 
maturation (Cole et al., 1995).  Studies in GR null heterozygote mice have 
revealed a hypertensive phenotype that is caused by an activated RAAS, 
further highlighting a potential role for GR function in cardiovascular 
disease (Michailidou et al., 2008). 
 
1.2.4.4 11 -hydroxysteroid dehydrogenase type 1 
Due to 11 -HSD1s widespread distribution and lack of specific inhibitors, 
functional dissection of the role of the enzyme in specific tissues is difficult.  
However, significant advances in the understanding of this have come from 
the generation of genetically modified mice. The 11 -HSD1 null mouse has 
elucidated major functions for the enzyme in the response to stress and in 
regulation of the HPA axis (Paterson et al., 2005); for the latter, regeneration 
of glucocorticoids by the liver appears to be particularly important (Paterson 
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et al., 2007). In addition, 11 -HSD1 null mice are resistant to age-related 
cognitive impairment (Yau et al., 2001), indicating roles in the brain.  These 
studies have important implications for human disease, and studies to 
identify 11 -HSD1 specific inhibitors for clinical use are currently underway 
(Webster et al., 2007).  
11 -HSD1 null mice have improved glucose tolerance, a favorable 
lipoprotein profile, and increased sensitivity of their liver and fat stores to 
insulin (Morton et al., 2001). Moreover, on the obese-prone C57BL6/J strain 
background, mice carrying the null mutation were resistant to the weight 
gain induced by high-fat feeding (Morton et al., 2004). That loss of 11 -HSD1 
confers a cardio-protective metabolic profile is intriguing and most probably 
results from a lack of glucocorticoid regeneration in adipocytes (Wolf, 2002). 
However, these mice also had an increase calorific intake, suggesting that 
energy expenditure was also stimulated (Morton et al., 2004).  
The generation of a mouse that over-expresses 11 -HSD1 under the control 
of an adipocyte-specific promoter further highlights the role of the enzyme in 
metabolic function (Masuzaki et al., 2001). The amplification of 
glucocorticoids was relatively modest, and was confined to the adipocyte 
with plasma corticosterone concentrations being normal. Nevertheless, these 
transgenic mice developed central obesity, insulin resistance and glucose 
intolerance. In addition, the animals were hypertensive due to a chronic 
activation of the RAAS (Masuzaki et al., 2003). This clustering of metabolic 
and cardiovascular phenotypes is characteristic of the metabolic syndrome, 





1.2.5 Aldosterone - Cardiovascular Effects 
 
The classical action of aldosterone is as a major regulator of body fluid and 
electrolyte homeostasis.  These effects are exerted by MR expressed in the 
distal nephron to induce sodium and water reabsorption, as well as 
potassium excretion, and contribute towards the regulation of BP 
homeostasis (Booth et al., 2002; Good, 2007).  Aldosterone can also exert non-
classical effects in the heart (Young et al., 2007), vasculature and brain 
(Gomez-Sanchez, 1997) that can also influence BP homeostasis and 
cardiovascular regulation. Both classical and non-classical actions of 
aldosterone can instigate inflammation and fibrosis that can ultimately lead 
to cardiac, vascular, and renal damage.  Indeed, the Framingham Heart 
Study reports a complex, but positive correlation between serum aldosterone 
in the physiological range and cardiovascular risk (Kathiresan et al., 2005).  
In addition, there is a growing body of evidence to suggest that some 
physiological responses to aldosterone are initiated within too short a time 
frame (seconds to minutes) to be the result of a genomic mechanism.  
Membrane transporters have been shown to be activated rapidly by 
aldosterone, such as NHE1, potassium channels NaKATPase and ENaC, and 
increased intracellular concentrations of electrolytes are frequently cited as a 
rapid effect of aldosterone (see review (Harvey et al., 2008)).  There is some 
suggestion that non-genomic effects of aldosterone may be mediated via a 
distinct membrane-associated receptor, and this is supported by the 
observation that rapid responses to aldosterone can be detected in MR 
knockout mice (Haseroth et al., 1999).  In addition, many rapid aldosterone 
actions are not blocked by MR antagonists, such as the kinase-dependent 
activation of NHE1 (Markos et al., 2005).  Others suggest that the rapid 
effects may be mediated via MR either directly, or by induction of 
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intracellular second messengers such as cyclic monophosphate (cAMP) and 
inositol triphosphate (IP3) (for review see (Losel et al., 2004)). 
 
1.2.5.1 Primary Aldosteronism 
Primary Aldosteronism (PA) is disorder characterised by a high aldosterone 
production out with the control of the RAAS, and extracellular fluid volume 
expansion.  Clinical effects include hypertension, cardiovascular damage, 
sodium retention and hypokalemia (Funder et al., 2008).   Causes of PA 
include adrenal adenoma, unilateral and bilateral adrenal hyperplasia 
(idiopathic hyperaldosteronism (IHA)), and the monogenetic disorder, GRA. 
GRA is an autosomal dominant trait that results in an aldosterone synthase 
gene whose expression is under the control of ACTH instead of AngII i.e. 
expressional control is now out with the RAAS (Lifton et al., 1992). This 
causes ectopic secretion of aldosterone, leading to increased renal salt 
reabsorption, and hypertension.    
It is estimated that between 5 – 13% of clinical hypertensive cases and up to 
20% of drug-resistant hypertension are due to PA (Carey 2010).  That such a 
significant percentage of hypertensive cases can be directly linked to an 
excess of circulating aldosterone emphasises how important this hormone, 
and its subsequent regulation by the RAAS, is in BP homeostasis. In addition, 
the high incidence of proteinuria in PA patients (85%) suggests that renal 
damage is a prominent consequence of chronically elevated aldosterone 
(Conn et al., 1964).    
 
1.2.5.2 Mineralocorticoid Receptor Activation and Cardiovascular Disease 
A seminal a study by Brilla and Weber investigated the effects of 
mineralocorticoid excess with relation to cardiovascular function, and 
demonstrated that rats exposed to high levels of both aldosterone and salt 
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developed hypertension and cardiac fibrosis (Brilla and Weber, 1992).  This 
discovery triggered a resurgence in the clinical interest of pathological MR 
activation (Williams and Williams, 2003), with data suggesting that 
mineralocorticoid excess was associated with cardiac abnormalities (Sato and 
Saruta, 2004). 
The potential benefits of MR blockade in treating cardiovascular disease was 
potentiated by the positive outcomes of two major clinical trials; RALES and 
EPHESUS (Pitt et al., 2003; Pitt et al., 1999).  In the RALES study, patients 
with severe heart failure were administered the MR antagonist 
spironolactone, alongside their continuing conventional medication.  This 
produced a 30% reduction in mortality and a 35% lower-frequency of 
hospitalization versus placebo-treated patients. Further verification of the 
beneficial effects of MR blockade and aldosterone antagonism was provided 
by the EPHESUS study in which eplerenone, an antagonist at MR more 
selective than spironolactone, was administered to patients who had suffered 
an acute myocardial infarction.  Again, the results of the MR blockade were 
particularly positive in terms of patient morbidity and mortality.   
These trials showed MR blockade to be beneficial in the treatment of 
cardiovascular disease; however, the underlying mechanisms of action were 
not clear. An obvious explanation is that MR blockade was inhibiting the 
effects of aldosterone in the heart, and was therefore cardio-protective. 
Indeed, it has been shown experimentally that increased aldosterone levels 
coupled with increased salt levels instigates deleterious cardiac and vascular 
pathologic responses (Rocha and Funder, 2002) and aldosterone levels are 
often raised in congestive heart failure (Swedberg et al., 1990). However, 
plasma aldosterone levels were not raised in patients in either the RALES or 
the EPHESUS studies (Pitt et al., 2003; Pitt et al., 1999). Similarly, in Dahl SS 
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rats fed a high salt diet, MR blockade prevented the development of cardiac 
hypertrophy and the onset of chronic heart failure, despite the fact that 
aldosterone was lower in this group than for controls to begin with (Nagata 
et al., 2006).  In this case, the cardio-protective effects of eplerenone were 
independent of the antihypertensive effect of MR blockade, as has been 
reported elsewhere (Levy et al., 2004). Together these data indicate that MR 
activation per se, rather than excess of agonist, is critical to the developing 
pathology of hypertension and cardiovascular disease. 
In contrast to classical aldosterone target tissues, occupancy of cardiac MR by 
glucocorticoids is the physiological norm, as 11 -HSD2 is not expressed in 
cardiomyocytes at physiologically relevant levels (Funder, 2004). This 
indicates that the benefits of MR blockade could be attributed to relief from 
stimulation by glucocorticoids. However, the mode of glucocorticoid action 
at cardiac MR is not clear. Experiments designed to test this hypothesis 
followed the generation of a mouse over-expressing 11 -HSD2 selectively in 
cardiomyocytes (Qin et al., 2003). Surprisingly, these mice developed severe 
cardiac hypertrophy and fibrosis, and died from accelerated heart failure.  
Moreover, an MR antagonist rescued the cardio-pathology, whereas a GR 
antagonist did not. These data indicate that glucocorticoids that normally 
occupy the cardiac MR are acting as agonists rather than antagonists, and 
that aldosterone activation of MR (only observed when 11 -HSD2 prevents 
glucocorticoid occupancy) is detrimental to heart function.  
Targeted disruption in mice of the gene encoding MR has not been 
particularly informative in terms of the role of aldosterone in cardiovascular 
function. Mice over-expressing human MR display only mild 
cardiomyopathy (Le Menuet et al., 2001), and MR null mice die within 8 days 
of birth due to uncorrected salt-wasting (Berger et al., 1998).  Mice in which 
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MR has been knocked down via an inducible antisense transgene have 
severe heart failure (Beggah et al., 2002).  These experiments not only 
indicate the critical role for renal MR in the long term regulation of BP, but 
also demonstrate that activation of the GR does not compensate for loss of 
MR.  Studies using a conditional knockout MR mouse model have allowed 
for the dissection of MR function in different tissues and cell-type. In 
collecting duct-specific knock out mice, ENaC trafficking to the membrane is 
abolished in targeted cells, and affected mice display unregulated sodium 
and water excretion on a low sodium diet accompanied by dramatic weight 
loss; on a standard sodium diet, this can be compensated for by ENaC 
expression in the connecting tubule and the late distal convoluted tubule 
(Ronzaud et al., 2007). 
 
1.2.5.3 Aldosterone Effects upon the Vasculature 
MR have been located in freshly isolated vascular tissue and in both cultured 
vascular smooth muscle cells (VSMC) and the vascular endothelium 
(Duprez, 2007). 11 -HSD2 is also present in human VSMC, adventitial 
fibroblasts and endothelial cells (Cai et al., 2001; Hatakeyama et al., 1999; 
Hatakeyama et al., 2000). Physiologically, both aldosterone and 
glucocorticoids potentiate the action of vasoconstrictors. This effect was first 
described in the 1950s for catecholamines, but is also true for other 
vasoactive agents, notably AngII (Ullian, 1999). There is some evidence to 
suggest that the potentiating effect of corticosteroids differs throughout the 
vasculature. For example, in the DOCA-salt hypertensive rat model, the 
pressor effects of AngII are exacerbated, indicating an increased sensitivity of 
the resistance vasculature to vasoconstrictors (Couture and Regoli, 1980). The 
mechanisms of potentiation have focused on increased receptor density, 
since both aldosterone and glucocorticoids greatly enhance AT1 receptor 
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density (Ullian, 1999); these effects are exclusive to the AT1 receptor 
(Schelling et al., 1994), consistent with the fact that the promoter region for 
the gene contains several steroid response elements (Uno et al., 1994).  
Aldosterone also exerts profound pathological effects in the vasculature. The 
accumulative and slowly-developing disease atherosclerosis is a major cause 
of heart disease.  Disruption of vascular homeostasis predisposes the 
endothelial vessel wall to vasoconstriction, inflammation, and 
atherosclerosis, all of which contribute towards cardiac disease onset.  The 
development and progression of atherosclerosis is largely associated with 
endothelial dysfunction (reviewed (Landmesser et al., 2004)), and it has been 
suggested that the positive clinical outcomes of the RALES and EPHESUS 
studies may be in part due alleviation of vascular endothelial aldosterone 
and/or MR antagonism. Using cultured human umbilical vein endothelial 
cells (HUVECs), Oberleithner et al demonstrated that aldosterone promotes 
remodelling of the endothelium in vitro (Oberleithner, 2005).  They observed 
that aldosterone administration caused the cells to increase in both size and 
stiffness, which, in vivo, could lead to endothelial dysfunction and associated 
pathogenesis.  Endothelial dysfunction can be rescued in the stroke-prone 
spontaneously hypertensive rat by administration of eplerenone (Endemann 
et al., 2004), and aldosterone has also been shown to play a major role in 
AngII-induced vascular inflammation in the setting of high salt intake 
(Rocha and Funder, 2002).    
These findings, together with the positive outcomes of clinical trials, would 





1.2.5.4 11 -hydroxysteroid dehydrogenase type 2 
Inactivating mutations in HSD11B2 cause the clinical disorder SAME. In this 
setting cortisol causes unregulated activation of the MR resulting in severe 
hypertension thought to arise from volume expansion secondary to renal 
sodium retention (Dave-Sharma et al., 1998; Monder et al., 1986; New and 
Wilson, 1999). Dexamethasone, a synthetic glucocorticoid, can be 
therapeutically effective as it will suppress endogenous glucocorticoids due 
its affinity for GR, and does not activate MR (Stewart et al., 1988). In 
addition, dexamethasone may act as a chaperone and stabilize mutant 
enzyme (Atanasov et al., 2007). Nevertheless, neither synthetic glucocorticoid 
nor MR blockade produce a consistent antihypertensive effect (Milford, 
1999).  
SAME has been modeled by targeted disruption of the 11 -HSD2 locus, 
producing a mouse in which the cardinal features of the disorder were 
preserved (Kotelevtsev et al., 1999). Although animals were born in normal 
Mendelian ratios, there was high neonatal mortality in the homozygote null 
animals, and the survivors were hypertensive and severely hypokalemic.  
The RAAS was show to be suppressed and plasma aldosterone was low 
(Bailey et al., 2008; Kotelevtsev et al., 1999). In one patient with SAME, the 
disorder was fully corrected by kidney transplant (Palermo et al., 2000), 
indicating the disease is of renal origin. In support of this, 11 -HSD2 null 
mice have excess renal sodium reabsorption due to activation of ENaC 
(Bailey et al., 2008).   
11 -HSD2 is also expressed in the nucleus of the solitary tract and the 
amygdala of the mouse brain which are regions important to the central 
regulation of BP (Robson et al., 1998; Roland et al., 1995). Thus, SAME may 
reflect over-activation of MR in regions other than the kidney. This is 
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supported by experiments showing that central administration of either 
aldosterone (Gomez-Sanchez, 1986) or 11 -HSD2 inhibitors (Gomez-Sanchez 
and Gomez-Sanchez, 1992) have a sustained hypertensive effect.  In addition, 
inhibition (pharmacological or antisense) of 11 -HSD2 sensitizes the 
vasculature to the vasoconstrictive actions of both AngII (Hatakeyama et al., 
2000) and catecholamines (Souness et al., 2002). Vascular reactivity to 
noradrenalin was enhanced in a patient with SAME (Walker et al., 1992) and 
11 -HSD2 null mice have demonstrated endothelial dysfunction, with 
enhanced sensitivity to vasoactive agents being underpinned by a reduction 
in nitric oxide production (Christy et al., 2003; Hadoke et al., 2001). However, 
the extent of the endothelial dysfunction following targeted disruption of 
11 -HSD2 is dependent on the underlying background strain of the mouse 
and may not, therefore, contribute in a major way to altered BP homeostasis 
(Bailey et al., 2008).  The enzyme is also expressed in the placenta where it 
serves to prevent maternal-fetal transfer of high levels of glucocorticoid.  The 
deleterious effects on fetal development of in utero exposure to high levels of 
glucocorticoid are well documented and such programming is associated 
with low birth weight and adverse cardiovascular risk. This subject has 
recently been reviewed (Seckl and Holmes, 2007).   
Although SAME is an extreme phenotype and very rare within the general 
human population, it illustrates the role that 11 -HSD2 in the kidney, brain 
and vasculature has in the regulation of cardiovascular homeostasis. Indeed, 
it is possible that mild mutations are prevalent in the essential hypertensive 
population (Bocchi et al., 2004), particularly in those individuals with low-
renin or SS hypertension. Human molecular genetic studies in hypertensive 
populations have sought associations between BP and loss-of function-
polymorphisms in 11β-HSD2, with conflicting results (Melander et al., 2003; 
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Poch et al., 2001; Williams et al., 2005). A more direct relationship between 
11 -HSD2 and BP was obtained in non-hypertensive individuals subject to 
salt-loading. For those individuals with a SS BP, the extent of the rise in BP 
following salt load was indirectly related to 11 -HSD2 enzyme activity. That 
is, the lower the activity, the more exaggerated the response to salt-loading.  
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1.3 Aim of PhD:  
Investigating Mechanisms of Salt-Sensitive Hypertension 
in Hsd11b2  Heterozygote Mice 
 
The aim of my PhD was to further investigate the proposal from human 
hypertensive populations that a link exists between SS BP and HSD11B2 
polymorphisms that impair 11β-HSD2 enzyme activity (Ferrari et al., 2000).  
This association between SS BP and reduced 11β-HSD2 activity has been 
observed by association studies only and direct in vivo evidence is so far 
lacking.  An 11β-HSD2 null transgenic mouse model previously generated 
within our laboratory provides an excellent opportunity for studying this 
association directly.   Mice homozygous for the null Hsd11b2 transgene 
faithfully reproduce the major phenotypes of SAME patients (Kotelevtsev et 
al., 1999).  Heterozygous mice (who presumably express 50% 11β-HSD2 
enzyme activity compared to wild type mice) do not present with a 
phenotype on a standard diet.  Our hypothesis was to challenge the Hsd1b2 
heterozygous mice with a high sodium diet to investigate if they have a SS 
phenotype.  Due to a successful kidney transplant in a notable case of SAME 
(Palermo et al., 2000), and evidence obtained in our laboratory that Hsd11b2 
null mice have impaired renal sodium excretion due to unregulated ENaC 
activity (Bailey et al., 2008), the renal origins of any observed phenotypes 
were of a particular interest.  The presence of 11β-HSD2 within the 
vasculature could also affect the sensitivity of these mice to vasoconstrictors, 
such as AngII, and a high sodium diet may exacerbate this; this theory was 
tested in this model.  In addition, mechanisms underlying the cause of a high 
salt diet to effect steroid receptor activation under conditions of reduced 11β-
HSD2 activity were also begun. 
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The expression of 11β-HSD2 in multiple sites throughout the body that are 
important for BP homeostasis (kidney, vasculature, brain, and placenta) 
whether it be via sodium and water balance regulation, altered sensitivity to 
vasoconstrictors, or prenatal programming, ultimately makes the dissection 
of the contribution of individual expression sites towards any phenotype 
complicated and incomplete.  The generation of a tissue-specific Hsd11b2 null 
mouse model would be invaluable towards further research within this field.  
In the hope to achieve this, the construction of an Hsd11b2 floxed targeting 
allele with the aim of generating a kidney-specific Hsd11b2 null mouse model 











Materials and Methods 
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2.1 Animal Breeding and Husbandry 
 
All animal experiments described in this work were performed in accordance 
with the UK Home Office (Scientific Procedures) Act 1986. 
 
2.1.1 Hsd11b2 Heterozygote Line 
 
Mice homozygous for a null mutation in Hsd11b2 (Hsd11b2-/-) were 
previously generated on a mixed background as described (Kotelevtsev et 
al., 1999).  These mice were then crossed for more than 12 generations onto a 
C57Bl6/J background (Bailey et al., 2008). The male mice used in the 
described studies were obtained from heterozygote (Hsd11b2+/-) crosses of the 
congenic Hsd11b2-C57BL6/J line. Mice were genotyped by Southern 
hybridization, as described (Kotelevtsev et al., 1999) and heterozygote 
(Hsd11b2+/-) mice were compared with wild-type (Hsd11b2+/+) animals.  All 
Hsd11b2 mouse genotyping was carried out by Mrs. Nina Kotelevtseva, 
senior laboratory technician. All experimental mice were used between 120-
200 days of age. 
 
2.1.2 Hoxb7 Cre Line 
 
The Hoxb7 Cre line was purchased from Jackson Laboratories (JAX Mice and 
Services, Bar Harbour, Maine, USA) as two breeding pairs.  Homozygous 
mice are not viable, so the line was maintained on the hemizygous 
background (Hoxb7+/-). Hoxb7+/- mice were crossed with C57Bl6/J (background 
strain) mice and subsequent offspring screened for Hoxb7+/- genotype by 
polymerase chain reaction (PCR).   
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Primers for genotyping were as follows: wild-type Forward primer 5’-
CTAGGCCACCGAATTGAAAGATCT-3’; wild-type Reverse primer 5’-
GTAGGTGGAAATTCTAGCATCATCC-3’; transgene Forward primer 5’-
GGTCACGTGGTCAGAAGAGG-3’; transgene Reverse primer 5’-
CTCATCACTCGTTGCATCGA-3’ (all primers synthesised by MWG Bio-
tech, Ebersberg, Germany).  PCR cycle conditions were 94°C 3 minutes, 94°C 
30 seconds, 60°C 45 seconds, 72°C 45 seconds (repeat cycle 35 cycles), 72°C 2 
minutes using Thermo Taq DNA Polymerase (Thermo Scientific Inc., 
Waltham, MA, USA).   
 
2.1.3 ROSA26 Cre Reporter Line 
  
Hoxb7+/- mice were crossed with a ROSA26 Cre reporter strain (breeding 
female generously donated by the Vascular Biology Group, University of 
Edinburgh).  The ROSA26 mouse colony was maintained as a homozygous 
line.  Genotyping for ROSA26 allele was carried out by PCR as follows: 
transgene Forward primer 5’-GCGAAGAGTTTGTCCTCAACC-3’; wild-type 
Forward primer 5’-GGAGCGGGAGAAATGGATATG-3’; common Reverse 
primer 5’-AAAGTCGCTCTGAGTTGTTAT-3’.  PCR Cycle conditions were 
94°C 90 seconds, 94°C 20 seconds, 67°C 45 seconds, 72°C 1 minute (repeat 
cycle 39 cycles), 72°C 10 minutes  using Thermo Taq DNA Polymerase. 
 
2.2 Metabolic Cage Studies 
 
2.2.1 Metabolic Cage Experiment 
 
Cohorts of Hsd11b2+/+ and Hsd11b2+/- mice were housed in metabolic cages 
(Tecniplast, Italy) and allowed free access to water and powdered rodent 
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chow (rat and mouse maintenance (RM1) diet (0.25% sodium and 0.67% 
potassium content), Special Diet Services Ltd., Essex, UK).  After an 
acclimatisation period (at least five days (Gomez-Sanchez and Gomez-
Sanchez, 1991; Hoppe et al., 2009)), experimental collections of faeces and 
urine were made.  Food and water intake and body weight was also recorded 
daily.  Following three days of control measurements, the animals were 
moved onto a high sodium diet (2.5% sodium and 0.5% potassium content, 
Special Diet Services Ltd.) and daily collections and recordings continued for 
three weeks.  All urine and faeces collections were stored at -20°C, with 
additional aliquots for certain assays stored to specification (detailed in assay 
methods to follow).  At the end of the study, animals were sacrificed by 
cervical dislocation, and kidneys removed and stored at -80°C, unless 
otherwise stated. 
 
2.2.2 Metabolic Cage Sample Analysis 
 
2.2.2.1 Urine and Faecal Electrolytes 
Urine samples collected during the metabolic cage studies described above 
were analysed for sodium and potassium concentrations.  Measurements 
were made using a flame photometer (BWB-1 Performance Plus Model, BWB 
Technologies UK Ltd, Essex, UK) at a 1 in 100 dilution (diluted 1 in 1000 from 
diluent concentrate blanking solution, 1% w/v Brij 35, BWB Technologies).  
Results (in parts per million (ppm)) were then converted to molar values and 
multiplied by urinary flow rate to give the excretion in µmol per 24 hours.  
These values were then normalised for body weight in grams.   
Following extraction in nitric acid (as detailed in (Thiesson et al., 2007)) 
faecal sodium content was also measured by flame photometry. 
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2.2.2.2 Sodium and Water Balance 
Values for individual daily sodium balance were calculated by subtracting 
the urinary sodium values (as calculated above) from the amount of dietary 
sodium consumed; final balance values presented as µmol corrected for body 
weight in grams. 
Water balance was calculated by subtracting the volume of urine produced 
in mls added to faecal water content (calculated by weighing faeces before 
and after drying out at 100°C for 24 hours) from the volume of drinking 
water consumed per day.  Final value given as µl per gram body weight. 
 
2.2.2.3 Urinary Steroid Extractions 
Aldosterone, corticosterone and deoxycorticosterone (DOC) were extracted 
from urine and measured by ELISA analysis as described (Al-Dujaili et al., 
2009a; Al-Dujaili et al., 2009b).  Samples from standard sodium diet days 
were reconstituted in a volume equal to the samples initial volume.  In the 
instance of the high sodium diet urine samples, the urine volume is very 
large, thus diluting the steroids.  To ensure concentrations were on the 
standard curve, samples were reconstituted in a lower volume of assay 
buffer so as to make them 4 times more concentrated.  All dilution factors 
were accounted for in subsequent calculations. 
 
2.2.2.4 Urinary Isoprostane Assay 
Urine sample aliquots for isoprostane measurement were collected in 0.005% 
butylated hydroxyl-toluene (BHT) and stored at -80°C as detailed in (Yoshida 
et al., 2009).  The assay was carried out using defrosted samples according to 
manufactures protocol (8-Isoprostane EIA Kit, Cayman Chemicals, Michigan, 
USA).    
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2.3 BP Measurements in Conscious Animals  
 
Systolic BP (SBP) was recorded in conscious and restrained mice using tail 
plethysmography (tail cuff).  Mice were warmed in a heat box at 30°C for 5 - 
10 minutes in order to optimise the signal from the tail vein.  The tail cuff 
measures changes in blood flow in the mouse’s tail via an optical transducer 
inside the cuff.  As the cuff inflates, the optical transducer measures the 
pressure at which the blood vessel is occluded and blood flow stopped i.e. 
the SBP in mmHg.  The data measured were amplified, and viewed on a PC 
via a serial link, from where the data was recorded.  A total of eight 
recordings were made for each measurement – four on the cuff inflation, and 
four on the cuff deflation.  A record was made of the four deflation values, 
and the mean of these calculated as the SBP.  The inflate values were rejected 
as they were usually inaccurate due to the mouse reacting with movement at 
the cuff tightening around its tail. 
Animals were trained to have their SBP recorded using the tail cuff technique 
over a number of weeks until the recordings became stable.  A study 
analysing how significant the effects of training can be towards obtaining 
stable SBP results using the tail cuff technique demonstrates the need for this 
training (Figure 2.1).  This involved firstly training the animals to enter the 
restraint tube repeatedly until this could be achieved with minimum stress.  
They were then left inside the restraint tube for increasing lengths of time, 
before finally attaching the measuring cuff to their tail. Repeated 
measurements were then made over a number sessions until the BP 
recordings reached a stable level (Lorenz, 2002; Meneton et al., 2000). 
Once  stable recordings for SBP were achieved,  the trained mice were placed 
on a high sodium diet for 3 weeks.  During the diet regime, additional SBP 
measurements  were  made  after  weeks  1   and  2  under  exactly  the   same 
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Figure 2.1. Systolic blood pressure measurements by tail plethysmography over a two week 
training period in wild type mice (n = 6). ** P < 0.01; *** P < 0.001. Data are means ± SEM. 
 
experimental conditions.  All experimental measurements were made under 
randomised blinded conditions.     
 
2.4 Renal Clearance Experiments  
 
Renal clearance methods were adapted from (Lorenz, 2002).  
 
2.4.1 Surgical Protocol 
 
Animals were anesthetised with an intraperitoneal (I.P.) injection of Inactin 
(100mg/Kg, IP; Thiobutabarbital Sodium; Sigma).  The jugular vein and 
carotid artery were cannulated using PE10 tubing (Jencons).  The cannulae 
were then connected to a 1ml syringe containing 0.9% saline and 0.9% saline 
plus heparin at 20 units per ml, respectively.  A tracheotomy was performed 
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to maintain a clear airway.  The bladder was cannulated using a 1cm length 
of PE50 tubing (Jencons) into which a length of PE10 tubing was inserted to 
minimise dead space during urine collections.  Surgical suture used in 
surgery was Deknatel silk 5.0 (Teleflex Medical, NC, USA). The vein 
cannulae was subsequently linked to an infusion pump (AL2000 model, 
World Precision Instruments, Sarasota, FL, USA) permitting continuous 
infusion of a saline infusion solution containing 120mM NaCl, 10mM 
NaHCO3, 5mM KCl, 15mM LiCl, 0.5% Inulin-FITC (Fluorescein 
Isothiocyanate; Sigma) plus 2% p-Aminohippuric Acid (PAH; Sigma) at a 
rate of 0.2μl/min/g body weight.  The carotid artery cannula was connected 
to a MLT0699 disposable BP transducer (ADInstruments Ltd, Chalgrove 
Oxfordshire, UK) attached to a ML224 Quad Bridge Amp (ADInstruments 
Ltd) to allow for the conversion of the BP signal to be measured using a 
PowerLab 4/30 data acquisition system (Powerlab, ADInstruments Ltd).  This 
setup allowed for continuous mean arterial BP (MABP) recording (2 Hertz 
sampling rate).  The BP transducer was regularly subjected to a 2-point 
calibration curve (once a week during experimental cohorts) by attaching it 
to a sphygmomanometer and checking that pressure exerted to 50 and 100 
mmHg gave an accurate signal on the PowerLab software. Any discrepancies 
were rectified by changing the unit conversion for BP within the software to 
match what the sphygmomanometer read.  See Figure 2.2 for a photograph 
of a completed surgery.   
Post-surgery there was a 40 minute equilibration period after which a small 
sample of arterial blood (approximately 20µl) was collected into a 
heparinised capillary tube (Hawksley, Lancing, Sussex, UK) and centrifuged 
for 3 minutes in a Haematospin 1400 centrifuge (Hawksley).  The hematocrit 
value was obtained and plasma was stored at -20°C for subsequent analysis.   
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Photograph of Renal Clearance Surgery 
 
      
 
Figure 2.2. A mouse undergoing renal clearance protocol after surgery.  A, Jugular vein 
cannulae; B, Carotid artery Cannulae; C, tracheotomy; D, bladder cannulae. 
 
For the next 40 minute period, urine was collected into a pre-weighed tube 
containing water-saturated mineral oil to prevent sample evaporation.  After 
the 40 minute period, a second arterial blood sample was taken. Next, a bolus 
injection of amiloride (Sigma) was given intravenously (I.V.) at a dose of 
0.1mg/g body weight. After 10 minutes, a second urine collection is made.  
After the third arterial blood sample is taken,  Evans blue dye  (0.5%  in  0.9%  
saline; Sigma) was injected intravenously (I.V.) at a dose of 1µl/g body 
weight and allowed to circulate systemically for approximately 10 minutes.  
After this period, a terminal blood collection was made from the artery 
cannulae into heparinised tubes (Sarstedt AG and Co., Nümbrecht, 






The animal was then sacrificed by I.V. anaesthetic overdose, and the kidneys 
were removed and weighed.                   
 
2.4.2 Sample Analysis  
 
2.4.2.1 Glomerular Filtration Rate Measurements 
Glomerular filtration rate (GFR) was calculated as the clearance of FITC-
labelled inulin, as detailed in (Lorenz, 2002).  FITC fluorescence was 
measured in plasma and urine samples using a Wallac multilabel counter 
(model 1420; Perkin Elmer, Waltham, Massachusetts, USA).  Urine samples 
were diluted 1:10000 and plasma 1:100 in HEPES buffer (pH 7.4) in a black 96 
well plate (Mircofluor Solid Microplate, Nunc, Thermo Scientific).  HEPES 
buffer was used in order to normalise the pH of the samples, as the 
fluorescence reaction is pH dependent.  Samples were excited at 485 nm 
wavelength, and results read at 538 nm.      
GFR was then calculated in mls per minute using the formula CIN = (UIN x V)/ 
PIN; where CIN = clearance of inulin, UIN = urinary inulin concentration, V = 
urine flow rate, and PIN = plasma inulin concentration.   
 
2.4.2.2 Renal Plasma Flow 
Effective renal plasma flow (RPF) was calculated using the standard 
equation, as with inulin clearance, as outlined in (Agarwal, 2002). Briefly, 
urine and plasma samples were diluted in 3.2% trichloro acetic acid (TCA).  
They were then mixed with a solution of 2 parts 0.2% HCL and 1 part 0.1% 
NaNO2.  0.5% NH2SO3NH4 was then added and incubated for 3 minutes at 
room temperature. Next, 0.1% N-(1-napthyl)-ethylenediamine 
dihydrochloride was added, and the samples were incubated at room 
temperature for 45 minutes.  All samples were then transferred in duplicate 
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to a 96 well plate (IWAKI), and PAH concentrations were measured 
colourimetrically on a spectrophotometer at excitation wave length 450 nm 
(Wallac multilabel counter).  Renal blood flow (RBF) was then calculated in 
mls per minutes using the following equation: RBF = RPF/1-hematocrit value. 
Filtration fraction (FF) was calculated as GFR / RPF, and renal vascular 
resistance (RVR) was calculated as MABP / RBF. 
 
2.4.2.3 Plasma and Urine Measurements 
Plasma and urine sodium and potassium levels were measured using an ISE 
electrolyte analyzer (Electrolyte analyzer 9180, Roche, UK).  Plasma and 
urine osmolarities were measured using an osmometer (OMS01 model, 
Vogel, Giessen, Germany).   
Fractional excretion of electrolytes was calculated using the equation FENa = 
ENa / ((PNa x GFR) x 100); where FENa = fractional sodium excretion, ENa = 
urinary sodium excretion and PNa = Plasma sodium concentration.   
 
2.5 Chronic Inhibitor Studies  
 
To identify processes contributing towards the salt-sensitive phenotypes, 
Hsd11b2+/+ and Hsd11b2+/- mice received one of three treatments alongside the 
high sodium diet.  In each set of experiments, mice were housed in metabolic 
cages (see section 2.2) for collections, as described.  After one to two weeks of 
experimental collections, the mice were moved to normal cages, and the 
experiment continued so that in all cases the mice were fed the high sodium 
diet for a total of three weeks.   Mice were then anaesthetised and prepared 






To assess the role of the epithelial sodium channel (ENaC) in the observed 
phenotypes, the ENaC-specific inhibitor benzamil (Sigma) was administered 
via an osmotic minipump (model 2004, Alzet, Cupertino, CA, USA).  
Benzamil was dissolved in a propanediol solution (Sigma) at a concentration 
of 3.35mg/ml to deliver the dose at a rate of 0.7µg/g body weight/day 
(administration protocol modified from (Sepehrdad et al., 2004)) for up to 4 
weeks.  Minipumps were primed in a 0.9% saline solution at 37°C for 40 
hours, and then implanted subcutaneously under Isoflurane gas anaesthesia 
and I.V. buprenorphine as an analgesic (Vetergesic, Pfizer, at 0.01ml/g body 
weight).  Minipumps were subcutaneously implanted between the shoulder 
blades, and surgical wounds were closed with auto-wound clips (Clay 
Adams, BD, NJ, USA).  The animals were placed into a heated recovery box 
until consciousness regained, when they were then placed back into their 
individual metabolic cages.  The mice were allowed three days to recover 




To assess the role of the mineralocorticoid receptor (MR) in the observed 
phenotypes, the MR inhibitor spironolactone (Sigma) was administered via 
an osmotic mini-pump, as with benzamil.  Spironolactone was dissolved in a 
50:50 dimethyl sulfoxide (DMSO) and propylene glycol solution (both 
Sigma) so as to deliver 20 mg/kg per day to the animals, as detailed in 
(MacDonald et al., 2000).  Minipumps were primed and implanted 
subcutaneously, as with benzamil. 
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2.5.2.1 Mass Spectrometry Measurement of Canrenone  
Analysis was carried out to ensure that the delivery of spironolactone by the 
minipumps was at sufficient levels to elicit a physiological effect.  This is 
done by measuring the levels of the spironolactone active metabolite, 
canrenone, in terminal plasma samples of mice from this study.  Briefly, 
100µl of plasma was diluted with 90µl of HPLC grade water and 10µl of an 
internal standard (100ng Alfaxalone (Steraloids Inc., Newport, RI, USA).  A 
10 times volume of ethyl acetate was then added and samples were vortexed 
to mix.  Samples were then centrifuged at 3000 x g for 5 minutes; the 
resulting top layer was transferred to a 5 ml glass vial and dried down under 
oxygen-free nitrogen at 60°C.  The plasma sample was then re-extracted by 
repeating from the ethyl acetate step.  Once dried down, samples were 
reconstituted in 100µl of mass spectrometry (MS) mobile phase solution 
(50:50 5 mM ammonium acetate:MeOH) and transferred to 1.5 ml glass 
autosampler vials with 200µl glass inserts (both from Agilent Technologies 
UK).  Samples were then analysed by liquid chromatography (LC)-MS/MS 
(model Thermo TSQ Quantum Discovery Instrument, Thermo Scientific) by 
the Edinburgh University Wellcome Trust Clinical Research Facility MS Core 




To assess the role of the oxidative stress in the observed phenotypes, the 
antioxidant 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL; 
Sigma) was diluted in drinking water at a concentration of 2mmol/litre 
(administration dose obtained from personal communication with Professor 
Christopher Wilcox).  The TEMPOL drinking solution is light-sensitive, and 
so was protected by wrapping the drinking bottle in silver foil, and fresh 
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solution was made every day.  The experiment then continued as above, 
without the need for the surgery recovery period. 
 
2.6 Renal 11β-HSD2 Enzyme Activity  
 
11β-HSD2 enzyme activity was measured in homogenised kidney extracts by 
calculating the  conversion  rate  of  titrated  (3H)  labelled   corticosterone  to 
dehydrocorticosterone.   
 
2.6.1 Kidney Homogenate Preparation 
 
Kidneys were dissected from Hsd11b2+/+ and Hsd11b2+/- mice and stored at -
80°C until required.  They were then individually homogenised in 1ml per 
100mg tissue of Krebs Buffer (118mM NaCl, 3.8mM KCl, 1.19mM KH2PO4, 
2.5mM CaCl3, 1.19mM MgSO4 and 25mM NaHCO3, 0.2% glucose, pH 7.4) 
using a small metallic bead at the rate of 2 times 30 seconds at 30 times per 
second (Mixer Mill 301 model, Retsch, Haan, Germany), taking care to keep 
the kidney homogenate cold at all times.  The homogenate was then 
centrifuged at 2000 rpm for 5 minutes at 4°C.  The top layer was transferred 
into a clean tube and the remainder discarded.  Total protein concentration of 
the kidney homogenates was measured using a Bradford-base protein assay 
(Bio-Rad Protein Assay, Bio-Rad Laboratories, Hercules, California, USA).  
These values were then used to calculate the protein concentration required 
for the enzyme activity assay.   
 
2.6.2 11β-HSD2 Enzyme Activity Assay 
 
The homogenised kidneys were then used immediately as the source of 11β- 
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HSD2 for an enzyme activity assay (concentration of 0.1 mg/ml).  NAD+ 
(Sigma) was used at a final assay concentration of 100µM as the assay co-
factor (required for 11β-HSD2 enzyme activity).  The substrate 3H-
corticosterone (1,2,6,7-3H-corticosterone, GE Healthcare Life Sciences, 
Anachem, Bucks, UK) was used at a 100nM final assay concentration.  The 
activity assay mix consisted of 180 l homogenated kidney, 50µl cofactor and 
20 l substrate mix to give a final assay volume of 250µl.  Controls for the 
assay included reactions with no protein added and with no co-factor added, 
as well as including an Hsd11b2-/- kidney homogenate.  The assay minus the 
enzyme (i.e. the kidney homogenate) was pre-warmed to 370C in a water 
bath for 15 minutes, with tubes covered with parafilm to prevent evaporation 
(Laboratory film, Pechiney Plastic Packaging, Chicago, IL, UK) to prevent 
evaporation.  Upon addition of kidney homogenate to the assay, the reaction 
was allowed to proceed for 3 minutes before being stopped by the addition 
of 10 volumes of HPLC grade ethyl acetate, removed from the water bath 
and vortexed hard to mix.  The assay tubes were then left to settle and 
separate, and the top aqueous phase was transferred into clean tubes; the 
remaining organic phase was discarded.  Samples were dried down under 
Oxygen-free Nitrogen at 37°C until all liquid had evaporated, and a dry 
precipitate remained at the bottom of the tubes.   
 
2.6.3 Thin Layer Chromatography Assay 
 
The dried down enzyme assay samples were re-constituted 30µl of absolute 
ethanol and vortexed to mix.  Thin Layer Chromatography (TLC) plates 
(Alugram Silicon G/UV254 TLC plates, Macherey-Nagel, GmbH and Co., 
Straubenhardt, Germany) were prepared by drawing a pencil line 2cm from 
the bottom of the plate and lightly marking along the line evenly spaced 
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positions where the samples were to be spotted.  3µl of each sample was 
spotted at a time, allowing sample spots to dry completely before re-spotting; 
this was continued until the entire sample had been applied to the plate.  
Once the samples had all dried completely, the TLC plates were run in a 
glass tank covered with glass lid for approximately 1 hour (until the solvent 
has run about 2cm from the top of the plate) in a solvent mix (92mls 
chloroform + 8mls 95% ethanol).  Once finished, the TLC plates were allowed 
to air dry, and then placed in a light-proof cassette (BAS cassette 2040, Fuji 
Photofilm Co. Ltd., Japan) for exposure against a tritium-sensitive screen 
(Fuji Imaging plate, BAS-TR2040, Fuji) for 72 hours.  The tritium screen was 
then processed using a Fujifilm FLA-2000 plate reader (Fuji) and the AIDA 
Imageanalyzer 344.exe program to analyse densitometry (Raytest, GmbH 
and Co.)  
 
2.7 Renin-Angiotensin-System Measurements 
 
2.7.1 Angiotensin Dose Response Experiments 
 
2.7.1.1 Surgery 
Cohorts of Hsd11b2+/+ and Hsd11b2+/- mice were fed either standard or a high 
sodium diet (as described previously) in normal cages with free access to 
drinking water for a period of 3 weeks.  The animals then underwent surgery 
to cannulate the carotid artery and the jugular vein under Inactin 
anaesthesia, as described in part 2.5.1.  No Bladder cannulation was required 
for this procedure.   
 
2.7.1.2 Dose Response Administration 




administrations of either Angiotensin I or Angiotensin II (Sigma) were I.V. 
injected into the jugular vein at increasing concentrations (Liu et al., 2009).  
Concentrations injected were 0.625, 1.25, 2.5, 5 and 10ng, for both drugs.  
Responses to the injections measured as delta MABP.  MABP was allowed to 
return to baseline measurements and the jugular vein catheter flushed with 
0.9% saline before the next bolus dose was administered to minimise carry 
over effects.   
 
2.7.2 Measurements of RAAS Components 
 
2.7.2.1 Sodium Diet Trunk Blood Culls 
Cohorts of Hsd11b2 +/+ and Hsd11b2+/- mice were fed a standard or high 
sodium diet (as before) in normal cages with free access to drinking water for 
a period of 3 weeks.  The animals were culled by decapitation.  Trunk blood 
was collected in a 0.5M EDTA in heparinised tubes and centrifuged for 5 
minutes at 10 000 rpm to separate plasma and stored immediately on ice.  
Half of the plasma collected (approximately 200µl) was added to 0.1 volume 
of inhibitor cocktail (4mM PMSF (Phenylmethylsulfonyl Fluoride 
monohydrate), 2.5µg/µl o-phenanthroline, 0.16mg/ml captopril, 40µg/ml 
pepstatin, and 4% β-mercaptoethanol, all reagents from Sigma 
(Kantachuvesiri et al., 2001)), and both stored at -80°C until required.  






2.7.2.2 Angiotensinogen and Renin Concentration  
Plasma angiotensinogen and renin concentrations were measured via the 
generation of angiotensin I, as detected by radioimmunoassay (RIA).  For the 
angiotensinogen concentrations, plasma was incubated in an excess of renin 
in order to generate maximal angiotensin I levels from existing 
angiotensinogen.  For the renin concentrations, this was reversed and the 
plasma was incubated with an excess of the renin substrate angiotensinogen.  
Plasma was diluted appropriately with Tris assay buffer (Tris 50 mM, pH 7.4; 
0.175% neomycin sulphate (Sigma), 0.0875% BSA) in quadruplet, and 
incubated with either excess angiotensinogen (previously purified from the 
plasma of a binephrectomised rat; donated by Dr Chris Kenyon) or excess 
renin (previously purified from mouse submaxillary glands; donated by Dr 
Chris Kenyon) in RIA cups (Sarstedt).  This mixture (constantly kept on wet 
ice) was incubated with an in-house available angiotensin I antibody 
(donated by Dr Chris Kenyon); one set of duplicates was incubated at 4°C 
and the other set at 37°C, both for 30 minutes. Iodine-125 (125I)-labelled 
angiotensin I (Amersham) was then added, and the assay was incubated for 
a further 18 hours at 4°C.  The bound and unbound 125I angiotensin I was 
then separated by adding a charcoal suspension to the assay (0.01% 5M HCl, 
0.2% neomycin sulphate, 0.185% EDTA, 0.5% BSA, 0.3 % Dextran T70 
(Sigma), 6% Norit activated charcoal (Sigma)) and centrifuging at 3000 rpm 
for 15 minutes.  Supernatant was removed, and the remaining charcoal pellet 
was counted for emissions on a Wizard 1470 gamma-counter (Wallac). 
 
2.7.2.3 Angiotensinogen and Renin Enzyme Activity  
Plasma angiotensinogen and renin enzyme activity was measured as the 
total angiotensin I generated from endogenous renin and endogenous 
angiotensinogen. Undiluted plasma was assayed with a small amount of 
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either angiotensinogen or renin in order to determine the enzyme activity of 
endogenous renin and angiotensinogen, respectively.  The assay then 
continued as before for the concentration assays (section 2.7.2.2). 
 
2.7.2.4 Plasma Aldosterone Assay 
Plasma samples taken from carotid artery during surgery experiments 
described in section 2.4.1 were analysed for aldosterone concentration.  
Aldosterone concentrations were measured in 100µl of plasma by 
radioimmunoassay, according to manufactures protocol (Coat-A-Count, 
DPC, Los Angeles, California, USA).   
 
2.8 Stress Testing 
 
2.8.1 Restraint Stress Test 
 
Cohorts of Hsd11b2+/+ and Hsd11b2+/- mice (nine per genotype) were single-
housed in normal cages with free access to standard chow and water for one 
week.  These mice were then transferred one at a time to a procedure room 
for blood collection by tail nick technique in order to measure baseline 
corticosteroid plasma levels.  The samples were taken between 7 - 8am, as 
this is when the circadian rhythm of mice determines that their 
corticosterone levels will be at their lowest.  Blood collections were made 
directly into a heparinised tube (Sarstedt) within one minute of disturbing 
each individual mouse’s cage in order to obtain corticosterone levels as close 
to baseline levels as possible.  After a baseline blood sample was collected, 
the mice were transferred to a restraint tube where they were held for 15 
minutes.  After 15 minutes, another blood sample was taken using the same 
tail nick wound in order to measure stress levels of plasma corticosterone.  
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The mice were then returned to their individual cages and allowed to recover 
for 90 minutes, after which a further blood sample was taken, as described 
before.  The mice were then moved on to a high sodium diet for three weeks, 
after which the stress test experiments were repeated exactly as before.  See 
Figure 2.3 for an overview of the HPA testing design.  All blood samples 
were stored immediately on wet ice, centrifuged at 13 000 rpm for 10 
minutes, plasma removed and stored on dry ice temporally; -80°C for long-
term storage. 
 




Figure 2.3.  Baseline plasma measurements were obtained using the tail nick technique 




 mice on a 
standard sodium diet.  Mice were then placed in individual restraint tubes for 15 minutes, 
after which a second plasma sample was taken; the stress sample.  Mice were then returned 
to their individual cages and allowed to recover for 90 minutes after which the third and final 
plasma sample was obtained; the recovery sample.  The same mice were then placed on a 
high sodium diet for three weeks and the experiment was repeated.  Black arrows represent 
when plasma samples were taken during the experiment. 
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2.8.2 Plasma Corticosterone Assay 
 
Plasma samples obtained from the stress test experiments were analysed by 
RIA for corticosterone concentration.  Briefly, plasma samples were diluted 1 
in 10 in borate buffer (0.133 M boric acid, 67.5 mM NaOH, 0.5% BSA, 1% 
methanol, 0.1% ethylene glycol, pH7.4 with HCl).  Diluted plasmas were 
then incubated at 80°C for 30 minutes.  Aliquots of the diluted plasma were 
mixed in duplicate in a 96 well plate (BD Falcon, 96 well flexible plate) with 
1:4000 dilution of sheep antibody to corticosterone (Micropharm Ltd., 
Newcastle Emlyn, Carmarthenshire, UK), 1.5 M 3H-labelled corticosterone, 
and anti sheep scintillation proximity assay (SPA) reagent (1:4 dilution; GE 
Healthcare).  This mixture was incubated overnight at room temperature, 
and then sample wells were counted in a liquid scintillation counter (1450 
Microbeta Plus model, Wallac).    
 
2.9 Generating a Floxed Hsd11b2 Mouse 
 
2.9.1 Construct Design 
 
The Hsd11b2 floxed construct was designed and built using a clone derived 
from the HSD2 B6 BAC RP23-410B24.  The clone pS141 was used in a 
previous gene targeting experiment (Kotelevtsev et al., 1999), and was 
available within the laboratory.  pS141 spans 15Kb of the mouse strain 129Sv 
Hsd11b2 gene, which incorporates all 5 exons of the gene, and exons 4-8 of 
the neighbouring downstream ATP6V0D1 gene.  The polyA sites for both 
genes were included.  The clone had been previously ligated into the 
pBluescript II SK phagemid vector (Stratagene, La Jolla, California, USA).  20 
Kb of the RP23-410B24 BAC was analysed by a web tool 
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(http://tools.neb.com/NEB cutter2) to generate a map of restriction enzyme 
sites.  This was used to generate a step-by-step plan for building the Hsd11b2 
floxed construct. 
The pL451 plasmid was used to provide the upstream loxP element and a 
neomycin selection cassette, flanked by two FRT sites, that were used in the 
final construct.  pL451 had been previously obtained by the laboratory with 
permission to use from Professor Neal Copeland, National Cancer Institute, 
Frederick, Maryland, USA (Liu et al., 2003). 
 
2.9.2 Construct Building 
 
For a schematic representation of the construction of the Hsd11b2 floxed 
targeting construct, see Chapter 6 Part 1, Figure 1a and b. A BamHI digest 
separated the pS141 clone into the main sub-clones for building the construct 
(all restriction enzymes supplied by New England BioLabs, Ipswich, 
Massachusetts, USA; or Roche Diagnostics GmbH, Manheim, Germany; or 
Promega, Madison, Wisconsin, USA).  The digested pS141 DNA was 
separated by gel electrophoresis on an agarose gel (SeaKem LE agarose, 
Lonza Group Ltd, Basel, Switzerland).  The DNA fragments were then 
excised from the gel, purified using GeneClean Turbo kit (QBiogene, 
Cambridge, UK)) and sub-cloned into the pBluescript II vector.  These sub-
clones were manipulated to become the upstream recombination arm (URA), 
the floxed region of the Hsd11b2 gene (exons 2-5), and the downstream 
recombination arm (DRA), as well as separating both the 5 prime (5’) and 3 
(3’) prime external probes (EP) (used for homologous recombination 




2.9.2.1 Recombination Arm Generation 
The URA was engineered to incorporate the upstream loxP element with the 
neomycin cassette flanked by two FRT sites isolated from the pL451 plasmid 
(Figure 2.4) by ligation. A  HindIII restriction site from within the cloning site  
 
pL451 Plasmid 
             
Figure 2.4. pL451 Plasmid Map (Courtesy of Dr. Pentao Liu). 
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of pL451 was deliberately included in the ligated fragment so as to introduce 
a novel site for subsequent homologous recombination screening 
requirements.  The DRA required no further manipulation. 
 
2.9.2.2 Region to Flox Generation 
The sub-clone containing the region to be floxed (Hsd11b2 exons 2-5) had the 
34-base pair downstream loxP site plus a novel BamHI restriction site 
incorporated for subsequent homologous recombination screening.   These 
elements were introduced to the sub-clone using the Linker Tailing method 
(Lathe et al., 1984). Briefly, oligonucleotides were designed (Forward 5’-
GATCCATAACTTCGTATAATGTATGCTATACGAAGTTATAAGGATCCC
-3’; Reverse 5’-GATCGGGATCCTTATAACTTCGTATAGCTACATTATA 
CGAAGT TATG-3’; synthesised by Invitrogen, Paisley, UK) and introduced 
into an open BglII restriction site (oligonucleotides were designed to 
subsequently destroy the opened BglII site).  5µg of each oligonucleotide was 
mixed, heated to 65°C for 20 minutes, and slowly cooled down to 4°C.  0.5µg 
of the oligonucleotide mix was then combined with 0.1µg BglII linearised 
plasmid, 5 x ligation salts (150mM NaCl, 150mM Tris, pH7.5, 38mM MgCl2), 
10 x ligation mixture (2.5mM ATP, 20mM DTT, 2mM Na2EDTA, pH8.0, 
10mM spermidine, 1mg/ml bovine serum albumin (BSA; BDH Lab Supplies, 
VWR, Lutterworth, Leicestershire, UK), 2µl T4 DNA ligase (Invitrogen) and 
PCR-grade water (Invitrogen) to a final volume of 20µl.  After overnight 
incubation at 4°C, 360µl 1xTE buffer (10mM Tris, 1mM Na2EDTA), 40µl 
DMSO (Sigma-Aldrich Co., St Louis, Missouri, USA) and 10µl spermine.HCl 
(100mM), pH 8.0, were added to the mixture and vortexed briefly to mix.  
DNA was precipitated using 300mM NaOAc, pH 5.0, 100mM MgCl2 and 75% 
ethanol, washed twice in ethanol:TE 3:1, and the resulting DNA pellet re-
suspended in 50µl hybridisation buffer (100mM NaCl, 10mM Tris, pH 7.5, 
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5mM EDTA).  DNA was subsequently transformed into chemically 
competent NEB Turbo cells (New England Biolabs) for plasmid propagation.   
 
2.9.2.3 Completing Final Construct 
The completed URA, exons 2-5, and DRA were ligated together to complete 
the Hsd11b2 floxed construct.  25µg of completed construct was linearised 
using restriction enzyme SmaI, and purified by phenol/chloroform extraction 
as follows.  Briefly, 1 volume of phenol (pH 7.9) was added, and mixed by 
constant gentle rotation for 20 minutes.  This was then centrifuged for 5 
minutes at 13 000 rpm and the top aqueous layer removed into a fresh tube.  
Next, half the total reaction volume of phenol was added, along with half 
chloroform:amlyalcohol 24:1, to the aqueous solution. This was mixed for 5 
minutes, and then centrifuged as before for 2 minutes.  Again the top layer 
was removed, and 1 volume of chloroform:amlyalcohol 24:1 was added.  This 
was mixed for 5 minutes and centrifuged for 2 minutes, as before.  The top 
layer was removed, and 1 volume of isopropanol added and mixed until 
homogeneous.  This mix was then centrifuged for 2 minutes, and the 
supernatant from the resulting DNA pellet removed.  The DNA pellet was 
washed in 180µl 70% ethanol.  This was centrifuged for 2 minutes, 
supernatant removed, and the DNA pellet allowed to air dry.  The final DNA 
pellet was then re-suspended in 20µl phosphate buffered saline (PBS; Sigma).   
 
2.9.3 Introducing Completed Construct into Embryonic Stem Cells 
 
Cell culture media (50ml foetal calf serum (FCS) (Sigma), 200mM glutamine 
(GIBCO, Invitrogen), 100mM sodium pyruvate (GIBCO), 5ml non-essential 
amino acids (GIBCO), 0.5ml 1000x β-mercaptoethanol (Sigma), 0.5ml LIF 
(GIBCO) and 450ml 1xBHK21 Glasgows media (GIBCO)) was removed from 
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three T75 flasks (IWAKI, Barloworld Scientific, Stone, Staffordshire, UK) of 
80% confluent embryonic stem (ES) cells. The specific ES cells used had been 
previously derived from a 129 mouse line (agouti coat colour; E14TG2a cell 
line (129/OlaHsd)) (Hooper et al., 1987).  Cells were then washed with 1 x 
PBS (Lonzo, Cambrex, Charles City, Iowa, USA), and 3ml of TVN (trypsin, 
chick serum, ETDA Na salt 1.85g/l, PBS) was added to each flask and 
incubated at 37°C for 5 minutes.  7ml of fresh media was then added to each 
flask, and the contents of all three flasks were pooled together and 
centrifuged at 1000xg for 3 minutes.  The resulting cell pellet was re-
suspended in 780µl PBS.  20µl of prepared linearised floxed Hsd11b2 
construct DNA (as described above) was mixed with the ES cell re-
suspension, and the mixture transferred to a 2mm electroporation cuvette 
(Equibio Ltd, Ashford, UK).  The mixture was then electroporated using an 
Easyject Plus instrument (Equibio) at 240 Volts, 450 µFaraday, and incubated 
at room temperature for 10 minutes in order introduce the targeting 
construct into the ES cell DNA. Next, 10ml fresh media was added and 
seeded between 10 10cm plates (IWAKI) with 19ml of fresh media (i.e. add 
1ml of mixture to each), and incubated at 37°C overnight.  All flasks and 
plates were previously coated with gelatine (GIBCO). 
 
2.9.4 Neomycin Selection of Targeted Embryonic Stem Cells 
 
Electroporated ES cells were grown in standard ES cell media, as described 
above, supplemented with 200µg/ml of the antibiotic G418 (Calbiochem, 
EMD Chemicals Inc., San Diego, USA) for neomycin selection of cells 
positive for targeting construct DNA incorporation.  Cells were fed with 
fresh media plus G418 as required.  Over a number of days, many of the 
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plated cells died off, but resistant ES cells survived to form clusters attached 
to the gelatine matrix of the plates.  
After approximately 2 weeks, surviving clones were picked and transferred 
to individual wells in a 96-well plate (IWAKI).  Briefly, cell culture media 
was changed one hour before picking commenced.  This media was then 
removed and replaced with PBS.  Clones were picked using a P10 pipette tip 
and moved along with 3ml PBS to a well of a 96 well plate containing 5µl 
TVN, and incubated at 37°C for 5 minutes.  Then 150µl of media plus G418 
was added and transferred to another well within a 96 well plate that had 
been pre-coated with gelatine.  When the selected cells became confluent, 
they were moved to 24-well plates (IWAKI), and when confluent again, they 
were subsequently divided for DNA harvesting and freezing down stocks.   
Briefly, fresh media was applied to cell cultures, removed 1 hour later, and 
the cells washed with PBS.  200µl of TVN was added to each well and 
incubated at 37°C for 5 minutes.  Cells were re-suspended in 200µl of fresh 
media, and one-third was transferred to clean tube for DNA preparation.  
This aliquot was centrifuged at 13 000 rpm for 5 minutes, and the pellet 
stored at -20°C.  The remaining two-thirds were transferred into a 15ml 
falcon tube (Greiner Bio One GmbH, Frickenhausen, Germany) for freezing 
down.  The tube was centrifuged at 1000xg for 3 minutes, and the resulting 
pellet re-suspended in 85µl of freezing media (10% DMSO (Sigma), 10% FCS, 
80% media), and finally transferred into a 1.5ml cryogenic freezing vial 
(Nalgene Cryoware, Rochester, NY, USA).  Frozen down stocks were stored 






2.9.5 PCR Screening for Homologous Recombination 
 
ES cell DNA pellets previously selected for targeting construct incorporation 
(by neomycin selection) that had been stored at -20°C were thawed.  
Subsequently, 200µl of lysis buffer (100mM Tris.HCl, pH8.5, 5mM EDTA, 
0.2% SDS, 200mM NaCl, 100µg/ml proteinase K (Roche)) was added, and 
incubated at 55°C overnight with constant, gentle rotation.  Next, 1 volume 
of isopropanol was added and mixed well.  This mix was then centrifuged at 
13 000 rpm for 10 minutes.  Supernatant was removed, and the resultant 
pellet was allowed to air-dry.  Once dry, the pellet was re-suspended in 50µl 
1xTE buffer, and stored short-term at 4°C (long-term storage at -20°C). 
 
2.9.5.1 PCR Screening 
Primers were designed to allow for the detection of targeted insertion of the 
Hsd11b2 floxed construct into ES cells by homologous recombination.  
Primers were designed as follows: Forward A (Hsd11b2 exon 1) 5’-
CTGCTGGCTGCTCTCGACTG-3’; Reverse B (Hsd11b2 exon 2) 5’–
TCTTAGCTGTCTCCTTGCCA–3’; Reverse C (Neomycin cassette) 5’–
TGTCAAGACCGACCTGTCCG–3’; Reverse D (5’ Neomycin insert) 5’–
GGCAGAGCCTATAACGAGTC–3’ (primers synthesised by MWG Bio-tech, 
Ebersberg, Germany).  PCR reactions were carried out using Finnzymes 
Phusion High-Fidelity DNA polymerase (NEB).  PCR program was as 
follows: 98°C for 1 minute, cycle: 98°C 15 seconds, 67°C 30 seconds, 72°C 2 
minutes (repeat cycle 33 times), 72°C 7 minutes.  PCR reactions were carried 
out on a DNA Engine PCR machine (MJ Research DNA). PCR samples were 




2.9.5.2 Fluorescent PCR Screening 
Fluorescent detection PCR reactions with ES cell DNA were carried out using 
an ABI Prism 7000 Sequence Detection System machine.  Primers were 
designed using Primer Express program (Applied Biosystems, 
http://www.appliedbiosystems.com/support/apptech/) as follows: Forward 
(Hsd11b2 exon1) 5’-TGGCTGGATCGCGTTGT-3’; Reverse (loxP site) 5’-
ATGTATGCTATACGAAGTTATTAGGT-3’. A positive control plasmid 
(containing Hsd11b2 exon 1 and a loxP site) was constructed using the 5’ 
external probe and pL451 plasmids described previously, in order to 
optimise reactions and act as a positive control for real reactions.  Negative 
ES cell DNA was spiked with the equivalent molar concentration of 1 copy 
per genome of the positive control plasmid per genome volume of DNA.  
SYBR Green Taq Mastermix (ABI, Foster City, California, USA) was used, 
and PCR cycle was as follows: 95°C 10 minutes, cycle: 95°C 15 seconds, 60°C 
1 minute (repeat cycle 40 times), 72°C 2 minutes. 
 
2.9.6 Southern Hybridisation for Homologous Recombination 
 
ES cell DNA used previously screened by fluorescent PCR (as described 
above) was purified further by phenol/chloroform method, as described 
earlier, with the final DNA pellet re-suspend in 40µl 1xTE buffer.  Half of the 
final volume (20µl) was then used for subsequent reactions, with the 
remainder stored at -20°C.  DNA was digested with either BamHI (3’ external 
probe) or HindIII (5’ external probe) restriction enzymes, separated by gel 
electrophoresis, and transferred to a Hybond nylon membrane (Amersham 
Bioscience, Little Chalfont, Bucks, UK).  Once transfer was complete 
(generally overnight), the membrane was placed in 3MM chromatography 
paper (Whatman International Ltd, Maidstone, UK) and baked at 80 °C for 2 
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hours to permanently bond the DNA to the membrane.  The membrane was 
then pre-hybridised to reduce background by incubating at 65°C for 3 hours 
in warmed hybridisation mix (0.5M NaPO4, 7% SDS, 1mM EDTA, pH 7.4) 
plus 1 mM denatured salmon sperm DNA.  The membrane was then 
hybridised overnight at 65°C with constant agitation, with a phosphate-32 
(32P)-dCTP labelled 3’ or 5’ external probe.  3’ and 5’ external probes were 
isolated from sub-clone plasmids using PstI/ScaI (350 bp fragment) and 
HpaI/XhoI (500 bp fragment), respectively.  10ng of probe DNA was labelled 
with α32P-dCTP (Amersham) for Southern hybridisation using Ready-To-Go 
DNA Labelling Beads (-dCTP; Amersham), according to manufacturers 
protocol.  Labelled DNA was purified through a NAP-5 sephadex column 
(Amersham), and added to hybridisation buffer used previously during pre-
hybridisation. After overnight incubation, hybridised membranes were 
rinsed briefly in 3xSSC buffer (20xSSC = 3M NaCl, 0.3M Na citrate), then 
twice for 15 minutes in 20mM Na2HPO4 pH 7.2, 1mM ETDA pH 8.0, 5% 
SDS, twice for 15 minutes in 20mM Na2HPO4 pH 7.2, 1mM ETDA pH 8.0, 
1% SDS, and then rinsed again in 3xSSC.  Next, membranes were washed in 
0.1% SDS plus 0.5% SSC, and finally in 0.1% SDS plus 0.1% SSC.  All washes 
were carried out at 65°C with constant rotation.  The washed membrane was 
then wrapped in cling film, exposed to BioMax light film (Kodak, Sigma) in a 
light-proof cassette at - 80°C for an appropriate length of time, and the film 
was then developed on a Konica SRX-101 medical film processor (Konica 
Minolta, Tokyo, Japan). 
 
2.9.7 Blastocyst Injection of Embryonic Stem Cells 
 
ES cell clones that were confirmed positive for both 5’ and 3’ end 
homologous recombination by Southern hybridisation were introduced from 
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in vitro culture to a surrogate blastocyst by microinjection. The blastocyst 
injections and implantations were carried out by a University of Edinburgh 
in-house service (Genetic Intervention and Screening Technologies).  
Offspring were screened for ES cell uptake into genome by chimeric coat 
colouring.  Chimeric offspring were then entered into a breeding program 
with C57BL6/J mice, and resultant offspring were screened for germline 
inclusion of the targeting construct by agouti coat colour. 
 
2.9.7.1 Counting Chromosomes in Embryonic Stem Cells  
The Karyotype of the ES cells to be blastocyst injected was checked before 
injection.  1 mg/ml Colcemid (Invitrogen) was added to the ES cell culture 
flasks and incubated at 37°C for one hour.  Then the media was removed, 
and cells were washed with PBS, and incubated with trypsin for 3 minutes.  
The cells were then centrifuged at 1000 rpm for 5 minutes to harvest.  
Supernatant was removed and the cells were re-suspended in 1.5 ml fresh 
medium.  10 ml of 0.075 M KCl (pre-warmed to 37°C) was added slowly 
drop by drop to the tube containing the cells, mixing gently throughout.  
This was then incubated at 37°C for 15 minutes.  Next, 2 - 3 drops of ice-cold 
fixative solution (3:1 mix of methanol:acetic acid), mixed, and centrifuged for 
5 minutes at 1000 rpm.  Supernatant was removed, and up to 10 ml of fresh 
ice-cold fixative solution added drop by drop, as before.  Again the mix was 
centrifuged, supernatant removed and the addition of fixative solution 
repeated.  This procedure was repeated twice more.  After the final fixation, 
the cells were re-suspended in 0.5 ml fixative solution, dropped onto glass 
slides from an approximately 10 cm distance, and allowed to air-dry.  Slides 
were finally viewed under a microscope (Nikon, Tokyo, Japan) and 
chromosome numbers of individual ES cells were counted.  Ten chromosome 
counts were performed on individual cells from each clone that was put 
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forward for microinjection (see Table 2.1 for results of chromosome spreads, 
and Figure 6.7 for photograph of example chromosome spreads).   
 
Clone Number 28 63 182 
Chromosome 
Spread Number Number of Chromosomes (Karyotype) 
1 40 39 40 
2 40 40 41 
3 41 40 40 
4 40 40 40 
5 38 40 38 
6 38 38 40 
7 40 40 40 
8 40 41 40 
9 42 40 41 
10 40 40 40 
% 40 chromosomes 60 70 70 
 
Table 2.1 Chromosome Counting in ES Cell Spreads 
Normal mouse chromosome number (Karyotype) is 40 chromosomes per cell. 
 
2.10 LacZ Expression Detection 
 
2.10.1 Kidney Perfusion Fixation 
 
Mice heterozygous for both Hoxb7 and ROSA26 allele were used for kidney 
fixation perfusions (ROSA26 null littermates were used as controls).  
Animals were anaesthetised I.P. with a mixture of ketamine hydrochloride 
(Vetalar, Pfizer Ltd., Kent, UK) and medetomidine hydrochloride (Domitor, 
Pfizer): 1.5 units of ketamine, 2 units of medetomidine and 8.25 units of 
water  administered  at  0.5ml/g body weight.   Perfusion  was carried out via  
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hepatic artery cannulation using Polyethylene tubing (PE90, Portex fine bore 
polyethylene tubing; Jencons) with 15mls cold PBS over a 5 minute period.  
This was followed by perfusion of 15mls of cold glutaraldehyde fixative 
solution (5mM EGTA, 100mM MgCl2, 0.1M NaH2PO4 and 0.2% 
glutaraldehyde in PBS) over 5 minutes.  The kidneys were removed and 
stored in glutaraldehyde fixative for 2 hours at 4°C.  Kidneys were then 
sliced bivalve and moved to a 15% sucrose solution for 4 hours, followed by 
a 30% sucrose solution overnight, both at 4°C.   
 
2.10.2 Microtome Sectioning 
 
Preserved kidneys halves were mounted in OCT embedding matrix 
(Raymond A Lamb Lab Supplies, Eastbourne, East Sussex, UK) using Bright 
Cryospray 134 (Jencons) for rapid matrix setting.  10µM thick sections were 
then sliced using a microtome (Microtome blades were Carbon Steel C35 
from Feather Safety Razor Co., Osaka, Japan) inside a cryostat (Bright Model 
OTF) onto Super Frost Plus microscope slides (BDH).  Cryostat conditions 
were set to -15°C for specimen and -25°C for chamber.  Section slides were 
stored at -20°C until further use. 
 
2.10.3 X-Gal Staining 
 
Previously mounted kidney sections were transferred directly from -20°C 
storage into β-galactosidase (LacZ) fixative solution (4% paraformaldehyde, 
0.02% NP40, 0.01% sodium deoxycholate, 5mM EGTA and 2mM MgCl2) for 
15 minutes at 4°C.  Slides were then washed twice for 5 minutes each in LacZ 
wash buffer (2mM MgCl2, 0.02% NP40 and 0.01% sodium deoxycholate).  
Next, the slides were stained overnight at 37°C in darkness in LacZ staining 
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buffer (2mM MgCl2, 0.02% NP40, 0.01% sodium deoxycholate, 5mM 
potassium ferricyanide, 5mM potassium ferrocyanide and 1mg/ml X-gal).  
They were then rinsed twice in PBS for 5 minutes each, and transferred to 
eosin solution for 1- 2 minutes.  Slides were then washed in distilled water 
and mounted directly with aqueous mounting medium (Shandon Immu-
Mount, Thermo Scientific).  They were finally sealed with clear nail varnish. 
 
2.11 Statistical Analyses 
 
All data (with the exception of Box and Whisker plots) are presented as 
means ± standard error (SE). After tests for Gaussian distribution, 
comparisons were made using either unpaired t test or analysis of variants 
ANOVA with Bonferroni post hoc test, as appropriate. Balance results are 
resented as Box and Whisker plots, where normal distribution is not 
assumed. Statistical comparisons were made using Prism 5 (GraphPad 










Hsd11b2  Heterozygous Mice 




The principal mineralocorticoid aldosterone is the classical ligand for the 
MR, but similarities in steroid structure permit the glucocorticoid cortisol 
(corticosterone in rodents) to share an equal affinity with aldosterone for the 
MR (Arriza et al., 1987). The co-localisation of MR with the enzyme 11β-
HSD2 in tissues such as the kidney acts to maintain MR-aldosterone ligand 
specificity by converting the active cortisol to its inactive 11-keto metabolite, 
cortisone (dehydrocorticosterone in rodents). A down-regulation in the 
function and/or expression of 11β-HSD2 compromises this specificity by 
permitting cortisol to bind and inappropriately activate MR.  This allows 
glucocorticoids to act as mineralocorticoids at the MR, and the negative 
feedback homeostasis of the RAAS is disrupted.  This in turn results in an 
unregulated increased expression of MR target genes, which are important in 
maintaining electrolyte and BP balance.  Consequences of this deregulation 
can include increased renal sodium reabsorbtion, leading to hypertension 
and potentially permanent renal and cardiac damage.   
SAME is a clinical condition in which mutations in the HSD11B2 gene result 
in ablation of functional protein (also referred to as type I SAME in the 
literature) (White, 2001).   This rare autosomal recessive disease presents in 
childhood with severe hypertension and hypokalemia, with low plasma 
renin and aldosterone levels, all of which can be attributed to MR over-
activation.  Although SAME is rare, the wider clinical significance of 
HSD11B2 functional mutations is highlighted by the following observations.  
In a Brazilian kindred, the heterozygous parent of a SAME patient was found 
to have late on-set mineralocorticoid hypertension, suggesting that 
genotypes in the HSD11B2 gene that lead to reduced (not ablated) enzyme 
function may have a phenotypic correlation (Li et al., 1997).  Patients 
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homozygous for specific HSD11B2 mutations presenting with mild low-renin 
hypertension have been previously termed as type II SAME (Mantero et al., 
1996; Wilson et al., 1998).  An in-depth study into an extensive 
consanguineous Sardinian pedigree with SAME type II showed late on-set 
mineralocorticoid hypertension and impaired cortisol metabolism in affected 
individuals (Li et al., 1998).  Interestingly in this study, the heterozygote state 
was linked to subtle changes in cortisol metabolism, and one such individual 
was hypertensive.  Compound heterozygotes of SAME also exist, where each 
allele contains has a separate HSD11B2 mutation in the affected individual 
(Dave-Sharma et al., 1998; Kitanaka et al., 1997; Lavery et al., 2003).  
Furthermore, epidemiological human studies have shown that HSD11B2 
polymorphic variation is present within the general population (Bocchi et al., 
2004), and some research has highlighted a potential link between certain 
polymorphisms and essential and/or SS hypertension (Alikhani-Koupaei et 
al., 2007; Mariniello et al., 2005).  Interestingly, the phenotypes of some 
essential hypertension patients indicate that a mineralocorticoid effect may 
be contributing towards the hypertension, such as positive correlations 
between BP and plasma sodium levels, and increased urinary cortisol 
metabolites (Ferrari et al., 2000).  These observational studies into the effects 
of mutations affecting 11β-HSD2 enzyme activity emphasise the need to 
investigate the penetrance of HSD11B2 polymorphisms in hypertensive 
populations.  
In depth analysis of impaired 11β-HSD2 enzyme activity in essential 
hypertension is difficult in human subjects.  So far, over 30 different 
HSD11B2 mutations associated with type I and II SAME have been identified 
(Hammer and Stewart, 2006).  However, it is difficult to correlate genotype 
with phenotype severity, as it is complex to predict what effects the genotype 
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has on enzyme function in vivo.  In vitro studies on the enzyme activities of 
specific HSD11B2 mutations have been performed in transfected cell studies, 
but these have shown that the enzyme activity of the mutated 11β-HSD2 is 
greatly impaired, if not completely abolished, failing to predictably correlate 
genotype with phenotype (Lavery et al., 2003; Mune et al., 1995).  Further 
studies of specific HSD11B2 mutations have suggested that mechanisms of 
action may include impaired 11β-HSD2 protein stability leading to a 
shortened enzymatic half-life (Atanasov et al., 2007; Nunez et al., 1999), as 
well as deficiencies in substrate binding capacity (Carvajal et al., 2003). 
To assist physiological investigations into impaired 11β-HSD2 enzyme 
activity, an 11β-HSD2 full knockout mouse was generated by gene targeting 
(Kotelevtsev et al., 1999).  Characterisation of the Hsd11b2 null mouse model 
(Hsd11b2-/-) confirms reproduction of all of the major phenotypes of SAME.  
Investigations using a synthetic glucocorticoid and monitoring of the 
sodium/potassium urinary excretion ratio suggested that the molecular 
mechanism underlying SAME phenotype is inappropriate MR activation by 
endogenous glucocorticoids (Kotelevtsev et al., 1999).  Histological 
examination also revealed that renal damage is present in the distal nephron 
of Hsd11b2-/- mice.  A recent study determined a mechanistic timeline of the 
development and maintenance of SAME in Hsd11b2-/- mice (Bailey et al., 
2008), identifying impaired sodium excretion as a key process in the etiology 
of hypertension.   
A definitive investigation into reduced 11β-HSD2 enzyme activity and a 
direct link to hypertension (SS hypertension in particular) is lacking.  This 
study proposes that the Hsd11b2 heterozygote null mouse (Hsd11b2+/-) may 
represent an ideal rodent model of reduced 11β-HSD2 activity.  Experimental 
investigations using this model could prove informative, especially in the 
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setting of excess dietary salt intake, and play a key role towards 
understanding the contributions that HSD11B2 polymorphisms are having 




3.2.1 Hsd11b2 Heterozygous Mice Have Reduced Enzyme 
Activity and Display a Salt-Sensitive BP 
 
11β-HSD2 enzyme activity was measured in kidney homogenates from 
Hsd11b2 wild-type mice (Hsd11b2+/+) and Hsd11b2+/- mice on a standard or a 
high  sodium  diet  after  three  weeks  (Figure 3.1).   The  Hsd11b2+/-  mice had  
 
11β-HSD2 Enzyme Activity 
 
             

































 mice on a standard and a high sodium diet (n = 6 for both groups on both diets). 
Measured as the % conversion of corticosterone (B) to dehydrocorticosterone (A).  
Hsd11b2
+/-
 mice have a significantly lower conversion rate than Hsd11b2
+/+
 mice on both 
diets; dietary sodium content does not affect either genotype.  *** P < 0.001. Data are means 
± SEM. 
 
approximately 50% 11β-HSD2 enzyme activity when compared to the 
Hsd11b2+/+ mice on either sodium diet; dietary sodium content did not affect 
enzyme activity in either genotype.  These results confirm that Hsd11b2+/- 
mice have a reduced 11β-HSD2 enzyme activity compared to Hsd11b2+/+, 
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proving that having only one functional Hsd11b2 allele decreases enzyme 
activity. 
The effect of dietary sodium upon BP was investigated by using the tail cuff 
method to measure systolic BP (SBP) in Hsd11b2+/- and Hsd11b2+/+ mice (Figure 
3.2).   On a standard sodium diet, SBP was similar for  both genotypes.   High   
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 mice on a standard sodium diet, and after 1 and 2 weeks on a high sodium diet 





on a standard sodium diet.  High sodium diet did not significantly alter SBP in Hsd11b2
+/+
 
mice.  SBP was significantly increased in Hsd11b2
+/-
 mice after 1 and 2 weeks on a high 
sodium diet.  *** P < 0.001. Data are means ± SEM. 
 
sodium diet had no effect upon the SBP of Hsd11b2+/+ mice, confirming that 
Hsd11b2+/+ mice do not have a SS BP.  Hsd11b2+/- mice displayed a significant 
increase in SBP after one week on the high sodium diet compared to a 
standard sodium diet, and also compared to Hsd11b2+/+ mice after one week 
on a high salt diet. This increase remained stable after two weeks on the high 
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salt diet.  These observations show that in conscious Hsd11b2+/- mice, SBP 
increases on a high salt diet compared to Hsd11b2+/+ mice.   
 
3.2.2 Metabolic Studies in Conscious Animals 
 
To investigate the contribution of sodium and water balance towards the SS 
BP of Hsd11b2+/- mice, daily urine and electrolyte excretion was measured in 
Hsd11b2+/- and Hsd11b2+/+ mice on different sodium diets from metabolic cage 
samples.   
 
3.2.2.1 Sodium Balance 
On a standard sodium diet, both genotypes had similar levels of dietary 
sodium intake and urinary sodium excretion; overall sodium balance was 
neutral (Figure 3.3).  When placed on a high sodium diet, the dietary sodium 
intake aptly increased, with both groups of mice consuming similar levels 
throughout the study (Figure 3.3a).  The Hsd11b2+/+ mice responded to the 
increased sodium load with a rapid increase in their urinary sodium 
excretion after one day on the high sodium diet, and maintained a steady 
level of excretion for the duration of the study (Figure 3.3b).  The Hsd11b2+/- 
mice also increased their urinary sodium excretion in response to the high 
sodium diet; however, for the first two days of the high sodium diet regime 
their excretion was significantly less than that of the Hsd11b2+/+ mice (Figure 
3.3b).  This difference in natriuresis is reflected in overall sodium balance, as 
Hsd11b2+/- mice display a significantly positive sodium balance for the period 
of Day 1 - 3 compared with Hsd11b2+/+ mice, which maintain a neutral sodium 
balance (Figure 3.3c). After the first few days, sodium excretion rates were 
comparable between the genotypes, and Hsd11b2+/- mice were restored to a 
neutral sodium balance.  Daily faecal sodium excretion was also measured in 
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a) Daily Dietary Sodium Intake                             
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 mice on a 
standard and a high sodium diet (n = 7 and 10, respectively).  a) Dietary sodium intake and 
b) urinary sodium excretion were measured during 24 hour periods. These data were then 





 mice on either sodium diet; high sodium diet 





 mice on a standard sodium diet; high sodium diet 
caused a significant increase in excretion in both groups (P < 0.001), with Hsd11b2
+/-
 mice 
excreting significantly less than Hsd11b2
+/+
 mice for the first 2 days.  This was reflected in 
sodium balance as Hsd11b2
+/-
 mice had a significantly positive balance compared to 
Hsd11b2
+/+
 mice for high sodium diet days 1 – 3 period.  At all other time points sodium 
excretion and balance were equal between genotypes.  * P < 0.05; ** P < 0.01; *** P < 
0.001. Data are means ± SEM or medians and ranges (c). 
c) 3-Day Sodium Balances 
b) Daily Sodium Excretion 
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these mice and was found not to differ significantly between genotypes, and 
had no significant effect upon sodium balance results (data not shown). 
 
3.2.2.2 Water Balance 
Drinking water intake and urine flow rate (UFR) were not significantly 
different between Hsd11b2+/+ and Hsd11b2+/- mice on a standard sodium diet 
(Figure 3.4a and b); water balance was also similar in both genotypes and 
was always significantly positive (Figure 3.4d).  Hsd11b2+/+ mice greatly 
increased both water intake and UFR after one day on a high sodium diet, 
and these increases were sustained for the duration of the high sodium diet 
study period (Figure 3.4a and b).  Hsd11b2+/- mice also showed polydipsia 
and polyuria following transition to a high sodium diet, and although there 
was a trend during the first 48 hours for drinking water intake and UFR to be 
lower compared to Hsd11b2+/+ mice, this was not statistically significant.  
Water balance was significantly increased for both groups on a high sodium 
diet compared to a standard sodium diet; the two genotypes did not differ in 
their water balance at any period (Figure 3.4d).  
Faecal water content was significantly higher in Hsd11b2+/+ mice compared to 
Hsd11b2+/- mice on a standard sodium diet (Figure 3.4d).  However, once 
placed on a high sodium diet, both genotypes displayed significant 
reductions in their faecal water content.  The faecal water content remained 
similar between the two groups for the remainder of the experiment.  This 
suggests that faecal water content is tightly regulated by dietary sodium 
levels in both genotypes.  Overall, faecal water loss is normally quite small, 
and the comparison of the UFR and the faecal water content during these 
experiments highlights this (compare Figure 3.4b and c).  As a result, faecal 
water values were not included in the overall water balance calculations. 
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 mice on a standard 
and a high sodium diet (n = 7 and 10, respectively).  a) Drinking water intake, b) urine flow 
rate (UFR) and c) faecal water content were measured during 24 hour periods.  These data 
were then used to calculate d) water balance over three-day periods.  Drinking water intake 




 mice on either sodium diet; high sodium 





 mice on a standard and a high sodium diet; high sodium 
diet caused a significant increase in the UFR of both groups (P < 0.001).  Hsd11b2
+/+
 mice 
have a greater faecal water content than Hsd11b2
+/-
 mice on a standard sodium diet. High 
sodium diet significantly decreased the faecal water content for both genotypes (P < 0.001) 
to similar levels to one another.  Sodium balance was equal between both genotypes at all 





 mice.  * P < 0.05; ** P < 0.01. Data are means ± SEM or 
medians and ranges (d). 
 
3.2.2.3 Potassium Balance 
The dietary intake of potassium was not different between the Hsd11b2+/+ and 
Hsd11b2+/- mice at any point during both standard and high sodium diet 
feeding  (Figure 3.5a).   However, the change in sodium diet had a significant  
c) Daily Faecal Water Excretion d) 3-Day Water Balances 
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a) Daily Potassium Intake               
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 mice on a 
standard and a high sodium diet (n = 7 and 10, respectively).  a) Dietary potassium intake 
and b) urinary potassium excretion were measured during 24 hour periods.  These data 
were then used to calculate c) potassium balance over three-day periods. Dietary potassium 




 mice on either sodium diet; however 
moving to a high sodium diet caused a significant decrease in potassium intake (***).  




 mice on a standard 
sodium diet; high sodium diet caused a significant decrease in excretion for Hsd11b2
+/-
 mice 
only for the entire dietary period (***). Potassium balance was equal between both 
genotypes at all time points assessed. * P < 0.05; ** P < 0.01; *** P < 0.001. Data are means 
± SEM or medians ranges (c). 
 
b) Daily Potassium Excretion 
c) 3-Day Potassium Balances 
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effect upon the dietary potassium intake of both groups.   In terms of 24 hour  
urinary potassium excretion, there is no difference between the two 
genotypes on a standard sodium diet (Figure 3.5b).  When the mice are 
moved onto the high sodium diet, the Hsd11b2+/+ mice do not significantly 
alter their urinary potassium excretion compared to the standard sodium 
diet.  The Hsd11b2+/- mice display a significant decrease in their urinary 
potassium excretion compared to their standard sodium diet excretion 
values, and also compared to Hsd11b2+/+  mice for most of the high sodium 
diet period (Figure 3.5b).  Three day potassium balance values did not reflect 
this difference in potassium excretion between the genotypes, as balance 
values were not significantly different from one another for any of the 
periods investigated (Figure 3.5c).  
 
3.2.3 Steroid Concentrations in Plasma and Urine 
 
Plasma concentrations of aldosterone and corticosterone were measured in 
terminal samples obtained from Hsd11b2+/+ and Hsd11b2+/- mice on a standard 
sodium diet and after three weeks on a high sodium diet.  The urinary 
excretion of aldosterone and corticosterone were measured during standard 
and high sodium diet feeding in 24 hour urine samples collected from 
metabolic cages. 
 
3.2.3.1 Aldosterone  
Plasma aldosterone concentration was significantly lower in Hsd11b2+/- mice 
than Hsd11b2+/+ mice on a standard sodium diet (Figure 3.6a).  After three 
weeks on a high sodium diet, plasma aldosterone levels were appropriately 
down regulated for both genotypes, but remained significantly lower in the 
Hsd11b2+/- group than the Hsd11b2+/+ group (Figure 3.6a).    
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 mice on a standard sodium diet or after three weeks on a high sodium diet (n = 9 
for Hsd11b2
+/+
 on standard diet for both steroids; n = 12 and 7 respectively for Hsd112b
+/-
 on 
a standard diet; n = 9 and 7 respectively for Hsd11b2
+/+
 on a high sodium diet; n = 8 and 7 
respectively for Hsd11b2
+/-
 on a high sodium diet).  Urinary b) aldosterone and d) 
corticosterone were measured over three day periods from metabolic cage collected urines 
during both standard and high sodium diet feeding (n = 6 for both groups). Plasma 




 mice on both sodium 
diets; high sodium diet caused a significant decrease in plasma aldosterone in both 





mice; high sodium diet caused a significant decrease in aldosterone 
concentration in both genotypes at Days 1 – 3 (P < 0.05), and then decreases further at 





 mice on a standard sodium diet; high sodium diet had no effect 
upon Hsd11b2
+/+
 concentration, but caused a significant increase in Hsd11b2
+/-
 mice. 





mice on a standard sodium diet.  Both groups had a significant increase on a high sodium 
diet, with the Hsd11b2
+/-
 mice having a significantly greater increase at both Days 1 – 3 and 
11 - 15.  * P < 0.05; ** P < 0.01; *** P < 0.001. Data are means ± SEM. 
c) Plasma Corticosterone d) Urinary Corticosterone Excretion 
 115 
24 hour urinary aldosterone excretion was measured over key periods from 
metabolic cage urine samples.  Urine samples were measured in addition to 
the plasma samples as it was important to corroborate trends observed in 
samples collected under terminal conditions with conscious, unstressed 
levels.  As with the plasma data, concentrations of urinary aldosterone 
excretion were higher in Hsd11b2+/+ mice than Hsd11b2+/- mice on a standard 
sodium diet (Figure 3.6b).  Urinary aldosterone excretion for both genotypes 
was reduced upon induction of the high sodium diet, and the Hsd11b2+/- mice 
displayed decreased concentrations compared to the Hsd11b2+/+ mice.   
 
3.2.3.2 Corticosterone  
Plasma corticosterone was similar between Hsd11b2+/- and Hsd11b2+/+ mice on 
a standard sodium diet (Figure 3.6c).  After three weeks on a high sodium 
diet, the Hsd11b2+/+ mice showed no significant difference in their plasma 
corticosterone levels compared to the standard sodium diet conditions, 
although there  was  a  trend  towards   an  increase.    Plasma  corticosterone  
levels were significantly greater in Hsd11b2+/- mice after three weeks on a 
high sodium diet compared with a standard sodium diet, and also when 
compared with the Hsd11b2+/+ group on the high sodium diet (Figure 3.6c).     
Urinary corticosterone concentration was measured over key periods, as 
with aldosterone.  There was no significant difference in the urinary 
excretion of corticosterone between the two groups on a standard sodium 
diet (Figure 3.6d).  Once moved to the high sodium diet, both groups 
increased their excretion of corticosterone at days 1 - 3, with the Hsd11b2+/- 
group showing a significantly greater increase compared with the Hsd11b2+/+ 
group.  These increases persisted at days 11 - 15 of the high sodium diet 
regime, with the statistical difference between the two groups maintained 
(Figure 3.6d).   
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3.2.4 Renal Clearance Study 
 
Renal clearance surgery was performed upon Hsd11b2+/+ and Hsd11b2+/- mice 
on either a standard sodium diet or after three weeks on a high sodium diet.  
This allowed for acute, in vivo measurements of renal hemodynamics and 
electrolyte status, as well as the response to bolus administration of the 
ENaC antagonist amiloride.   
 
3.2.4.1 Mean Arterial BP 
Mean arterial BP (MABP) was measured by carotid artery cannulation in 
Hsd11b2+/+ and Hsd11b2+/- mice that had been maintained on either standard 
or high sodium diet for three weeks (Figure 3.7).  On a standard sodium diet, 
MABP was comparable between the two genotypes.  A high sodium diet had 
no effect upon MABP of Hsd11b2+/+ mice. After three weeks on a high sodium 
 
 Mean Arterial Blood Pressure                   





















 mice on a standard sodium diet (n = 8 for both groups), and 





mice have similar values for MABP on a standard sodium diet.  High sodium diet does not 
affect MABP of Hsd11b2
+/+
 mice.  Hsd11b2
+/-
 mice have a significantly increased MABP on a 
high sodium diet compared to a standard sodium diet, and also to Hsd11b2
+/+
 mice on a high 
sodium diet.  * P < 0.05; ** P < 0.01.  Data are means ± SEM. 
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diet, the Hsd11b2+/- mice had a greater MABP compared to either sodium-
loaded Hsd11b2+/+ mice, and Hsd11b2+/- mice on a standard sodium diet.  
These direct measurements of MABP corroborate the results obtained for 
SBP in conscious mice, confirming a SS BP phenotype in Hsd11b2+/- mice.   
 
3.2.4.2 Renal Hemodynamics 
The renal hemodynamics of Hsd11b2+/+ and Hsd11b2+/- mice were measured 
after three weeks on either a standard or a high sodium diet.  On a standard 
diet the Hsd11b2+/- mice had a significantly greater glomerular filtration rate 
(GFR) than Hsd11b2+/+ mice (Figure 3.8a).  This difference in GFR was also 
evident in mice fed the high sodium diet for three weeks.  There was no 
effect of sodium diet upon GFR in the Hsd11b2+/- group, however post hoc 
analysis reveals that Hsd11b2+/+ mice had a significantly lower GFR on the 
high compared to the standard sodium diet.  
On a standard sodium diet there was no difference in renal blood flow (RBF) 
between Hsd11b2+/+ and Hsd11b2+/- mice (Figure 3.8b).  After three weeks on a 
high sodium diet, the Hsd11b2+/- group had a significantly lower RBF 
compared to the Hsd11b2+/+ group.   
Filtration fraction (FF) was comparable between the two genotypes on a 
standard sodium diet (Figure 3.8c).  Movement to a high sodium diet caused 
a significant decrease in the FF of Hsd11b2+/+ mice and a significant increase in 
the FF of Hsd11b2+/- mice, compared to their standard values; overall this 
resulted in a highly significant difference between the FF of the two 
genotypes on a high sodium diet.   
On a standard sodium diet, the renal vascular resistance (RVR) was 
comparable between the two genotypes (Figure 3.8d).  High sodium diet had 
no effect upon RVR in Hsd11b2+/+ mice, but resulted in a significant increase in 
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    a) Glomerular Filtration Rate    b) Renal Blood Flow            























































 mice on a standard sodium diet (n = 8 and 9 respectively) or 
after three weeks on a high sodium diet (n = 8 and 7, respectively).  a) Glomerular filtration 
rate (GFR) was greater in Hsd11b2
+/-
 mice on both sodium diets; high sodium diet caused a 
significant decrease in the GFR of Hsd11b2
+/+
 mice and had no effect in Hsd11b2
+/-
 mice. b) 
Renal blood flow (RBF) was comparable between both genotypes on a standard sodium 
diet; high sodium diet caused a significant decrease in Hsd11b2
+/-
 RBF and had no effect 
upon Hsd11b2
+/+





 mice on a standard sodium diet, and a high sodium diet caused a significant 
decrease in FF for Hsd112b
+/+
 mice and a significant increase for Hsd11b2
+/-
 mice, 
compared to standard sodium diet values.  Hsd11b2
+/-
 mice displayed a significantly greater 
FF than Hsd11b2
+/+
 mice on a high sodium diet.  d) Renal vascular resistance (RVR) was 
also equal between genotypes on a standard sodium diet.  Hsd11b2
+/-
 mice displayed a 
significant increase in RVR on a high sodium diet; high sodium diet had no effect upon 
Hsd11b2
+/+
 mice.  * P < 0.05; ** P < 0.01; *** P < 0.001. Data are means ± SEM. 
 
Hsd11b2+/- mice compared to standard sodium diet values and Hsd11b2+/+ 
mice on a high sodium diet. 
 
c) Filtration Fraction d) Renal Vascular Resistance 
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3.2.4.3 Urine and Plasma Electrolytes 
Urinary sodium and potassium excretion, as well as plasma concentrations, 
were measured in anaesthetised Hsd11b2+/+ and Hsd11b2+/- mice after three 
weeks on either a standard or a high sodium diet.   
On a standard sodium diet, Hsd11b2+/- mice excreted significantly less sodium 
in their urine than the Hsd11b2+/+ mice (Figure 3.9a). The increase in dietary 
sodium intake caused an overall significant increase in sodium excretion in 
both genotypes, but sodium excretion was still significantly lower in 
Hsd11b2+/- mice compared to Hsd11b2+/+ mice. The plasma sodium 
concentrations were similar between both genotypes on the standard and the 
high sodium diet, with the high sodium diet causing an overall significant 
increase in concentration across the two genotypes, but with no significant 
difference between the two groups (Figure 3.9b).  
On a standard sodium diet, Hsd11b2+/- mice excreted significantly more 
potassium than Hsd11b2+/+ mice (Figure 3.9c).  After three weeks on a high 
sodium diet, both groups excreted less potassium than on the standard 
sodium diet, and there was no difference in terms of potassium excretion 
between the two genotypes; the overall effect of diet upon potassium 
excretion is highly significant (Figure 3.9c).  The plasma potassium 
concentrations were similar between the two groups on the standard sodium 
diet (Figure 3.9d).  Three weeks on a high sodium diet caused a significant 
decrease in the plasma potassium concentration of Hsd11b2+/- mice compared 
to Hsd11b2+/+ mice, whose plasma potassium levels were not effected by 
changes in sodium diet (Figure 3.9d).   
 
3.2.4.4 Response to Amiloride Administration 
In order to assess ENaC-mediated sodium reabsorbtion, a bolus dose of the 
antagonist   amiloride  was  administered  by  I.V.  injection.  These  data  are  
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a) Urinary Sodium Excretion                     b) Plasma Sodium  























































 mice on a standard sodium diet (n = 8 and 9, respectively) or 
after three weeks on a high sodium diet (n = 8 and 7, respectively).  a) Urinary sodium 
excretion was significantly greater in Hsd11b2
+/+
 mice than Hsd11b2
+/+
 on both sodium diets, 
with the high sodium diet causing an overall significant increase in sodium excretion for both 
genotypes. b) Plasma sodium levels were comparable between both genotypes on both 
diets; a high sodium diet caused a significant increase or both.  c) Hsd11b2
+/- 
mice had a 
greater urinary potassium excretion rate than Hsd11b2
+/+
 mice on a standard sodium diet; 
urinary potassium excretion was decreased in both genotypes to similar levels on a high 
sodium diet.  Plasma potassium was comparable between genotypes on a standard sodium 
diet, high sodium diet caused a significant decrease for Hsd11b2
+/-
 mice and had no effect 
upon Hsd11b2
+/+ 
mice.  * P < 0.05; ** P < 0.01; *** P < 0.001. Data are means ± SEM. 
 
presented as the net change in a given variable, calculated from the same 
individual animal before and after amiloride administration. 
On a normal sodium diet, amiloride administration caused a small decrease 
in the MABP of both groups (Figure 3.10a).  On a high sodium diet it caused 
a  significantly  greater  decrease in  MABP;  again  the  response  was similar  
c) Urinary Potassium Excretion d) Plasma Potassium  
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a) Δ Amiloride MABP                         b) Δ Amiloride GFR 



























































 mice on a standard sodium diet (n = 8 for both groups) or after three weeks on a 
high sodium diet (n = 9 and 7, respectively).  Δ amiloride was calculated as the difference 
between measurements before and after amiloride administration.  a) MABP was 




 mice on a high sodium diet 
compared to a standard sodium; there was no difference between genotypes on either diet.  
b) GFR was not significantly affected by amiloride administration on either diet for either 
genotype.  c)  Amiloride had a significantly greater effect upon urinary sodium excretion in 
Hsd11b2
+/-
 compared to Hsd11b2
+/+ 
on both sodium diets.  High sodium diet significantly 
reduced sodium excretion in Hsd11b2
+/+ 
mice compared to Hsd11b2
+/-
 mice where it had little 
effect.  d) Potassium excretion was reduced significantly mice in Hsd11b2
+/-
 mice on a 
standard sodium diet than in Hsd11b2
+/+
 mice.  High sodium diet caused a significant 
decrease in amiloride-sensitive potassium excretion in both genotypes; the response was 
comparable between genotypes.  * P < 0.05; ** P < 0.01; *** P < 0.001. Data are means ± 
SEM. 
 
c) Δ Amiloride Sodium Excretion d) Δ Amiloride Potassium Excretion 
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between the genotypes (Figure 3.10a).  Acute administration of amiloride 
produced no significant effects upon the GFR of the Hsd11b2+/+ or Hsd11b2+/- 
groups on either the standard or the high sodium diet (Figure 3.10b).   
Amiloride administration increased urinary sodium excretion for both 
genotypes on a standard sodium diet.  The net effect amiloride was 
significantly greater in the Hsd11b2+/- mice compared to the Hsd11b2+/+ mice 
(Figure 3.10c).  On a high sodium diet amiloride-sensitive sodium 
reabsorbtion was abolished in Hsd11b2+/+ mice; this is consistent with an 
appropriate down regulation of ENaC-mediated sodium reabsorbtion 
(Figure 3.10c).  The Hsd11b2+/- mice, however, do not appear to be 
appropriately regulating their ENaC-mediated sodium reabsorbtion in 
response to the high sodium diet; the natriuretic response to amiloride was 
significantly greater than that of the Hsd11b2+/+ mice (Figure 3.10c).   
The effects of amiloride administration on potassium excretion were also 
measured.   On a standard sodium diet, amiloride reduced potassium 
excretion for both genotypes, having a significantly greater antikaliuretic 
effect in the Hsd11b2+/- compared to the Hsd11b2+/+ mice (Figure 3.10d). 
Amiloride had significantly less of an effect upon potassium excretion on the 
high sodium diet compared to the standard sodium diet (Figure 3.10d).  The 
overall effect was similar for both genotypes, although the Hsd11b2+/- group 
showed a trend towards a greater reduction in potassium excretion than the 
Hsd11b2+/+ group (not statistically significant).   
 
3.2.5 Molecular Mechanisms - Benzamil Study 
 
To further assess the contributions of ENaC activity towards the SS 
phenotypes of Hsd11b2+/- mice, metabolic cage and renal clearance studies 
described earlier in this chapter were repeated in Hsd11b2+/+ and Hsd11b2+/- 
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mice on a standard and a high sodium diet with the addition of chronic 
administration of the ENaC antagonist benzamil.  
 
3.2.5.1 Metabolic Cage Studies 
On a standard sodium diet, both Hsd11b2+/+ and Hsd11b2+/- mice had 
comparable levels of urinary sodium excretion (Figure 3.11a).  The rate of 
sodium excretion increased significantly for both groups when they were 
administered benzamil on the standard sodium diet, with values remaining 
comparable between the two groups (Figure 3.11a).   
Sodium balance data for key periods both before and after high sodium diet 
administration illustrated that there were no differences in the sodium 
balance between the two genotypes at any point (Figure 3.11b).  This 
suggests that benzamil administration is rescuing the impaired sodium 
excretion observed in Hsd11b2+/- mice on a high sodium diet (compare Figure 
3.11b with 3.3c).  Water balance also does not vary between the Hsd11b2+/+ 
and Hsd11b2+/- groups at any stage during the study (Figure 3.11c). 
 
3.2.5.2 Renal Clearance Studies 
After three weeks on a high sodium diet with chronic benzamil 
administration, the MABP was similar between the two genotypes (Figure 
3.12a); this suggests that benzamil administration is rescuing the high 
sodium diet-induced increases in BP observed in Hsd11b2+/- mice on a high 
sodium diet (compare Figure 3.12a with Figure 3.2 and 3.7).  GFR was 
significantly greater for Hsd11b2+/- mice compared to Hsd11b2+/+ mice (Figure 
3.12b).  These values were lower than on a high sodium diet alone, although 
the overall significant difference between the genotypes remains (compare 
Figure 3.12b with Figure 3.8a). This implies that the changes in sodium 
balance and MABP observed in Hsd11b2+/- mice  with benzamil treatment are             
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a) Urinary Sodium Excretion - Benzamil Effects              
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Figure 3.11.  Benzamil treatment during a metabolic cage study (n = 6 for both groups).  a) 
Urinary sodium excretion on a standard sodium diet before and after benzamil treatment; 3-
day b) sodium and c) water balances before and after benzamil on a standard sodium diet, 
and with benzamil on a high sodium diet.  Benzamil treatment on a standard sodium diet 
significantly increased urinary sodium excretion in both genotypes.  There was no significant 





 mice during any period.  * P < 0.05.  Data are means ± SEM (a) or medians and 
ranges. 
 
b) 3-Day Sodium Balances – Benzamil Effects 
c) 3-Day Water Balances – Benzamil Effects 
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a) MABP - Benzamil Effects              


































        
 3.12.  Benzamil treatment effects upon MABP and renal hemodynamics.  MABP and renal 





mice after three weeks on a high sodium diet with benzamil treatment (n = 6 for both 




 mice.  b) GFR was 
significantly greater in Hsd11b2
+/-
 mice compared to Hsd11b2
+/+





 mice.  * P < 0.05.  Data are means ± SEM. 
 
not mediated by changes in GFR. 
There was a trend for the Hsd11b2+/- group to have a lower RBF than the 
Hsd11b2+/+ group with benzamil treatment; however, this was not significant 
b) GFR – Benzamil Effects 
c) RBF – Benzamil Effects 
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(Figure 3.12c).  The values for RBF for both groups were less than on a high 
sodium diet without benzamil treatment (compare Figure 3.12c with Figure 
3.8b).   
Benzamil treatment caused a increase in urinary sodium excretion in both 
genotypes compared to non-treatment on a high sodium diet (compare 
Figure  3.13a  with  Figure  3.9a).    In addition,  Hsd11b2+/-  mice  now  excrete  
 
a) Urinary Sodium Excretion            b) Plasma Sodium  




















































 mice on a high sodium diet with benzamil treatment (n = 6 for 





mice in terms of a) urinary sodium excretion, b) plasma sodium, c) urinary potassium 
excretion, or d)  plasma potassium.  Data are means ± SEM. 
   
similar levels of urinary sodium compared with Hsd11b2+/+ mice (Figure 
3.13a).  Potassium excretion was not altered by benzamil treatment in either 
group (Figure 3.13c compared to Figure 3.9b).  Urinary potassium excretion 
was greatly down regulated on a high sodium diet with benzamil treatment 
compared to a high sodium diet alone (compare Figure 3.13c with Figure 
c) Urinary Potassium Excretion d) Plasma Potassium  
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3.9c); there was no significant difference between the two groups.  The 
plasma potassium concentration of Hsd11b2+/- mice was greater after 
benzamil administration, resulting in the significant difference between the 
genotypes being abolished (compare Figure 3.13d with Figure 3.9d). 
Values obtained after acute amiloride administration were not significantly 
different from the pre-amiloride values for any of the measured parameters 
in the renal clearance study for either genotype (data not shown).  Thus, 
amiloride administration had no effect upon the physiology of these mice 
when they were receiving chronic benzamil administration; this can be 
attributed to the chronic mini pump dosing of benzamil being appropriate to 
completely inhibit ENaC activity. 
  
3.2.6 Molecular Mechanisms - Spironolactone Study 
 
To further assess the contributions of MR activation towards the SS 
phenotypes of Hsd11b2+/- mice, metabolic cage and renal clearance studies 
described earlier in this chapter were repeated in Hsd11b2+/+ and Hsd11b2+/- 
mice on  a  standard  and  a high  sodium  diet with chronic administration of 
the MR antagonist spironolactone. 
 
3.2.6.1 Metabolic Cage Studies 
On a standard sodium diet, both Hsd11b2+/+ and Hsd11b2+/- mice had equal 
levels of urinary sodium excretion (Figure 3.14a). Spironolactone 
administration on the standard sodium diet resulted in a decreased rate of 
urinary sodium excretion in Hsd11b2+/+ mice compared with Hsd11b2+/- mice 
(Figure 3.14a).   
Sodium balance data for key periods both before and after high sodium diet 
administration   illustrated  that   there  were  no  differences  in  the   sodium  
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a) Urinary Sodium Excretion - Spironolactone Effects              
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Figure 3.14.  Spironolactone treatment during a metabolic cage study (n = 9 for both 
groups).  a) Urinary sodium excretion on a standard sodium diet before and after 
spironolactone treatment; 3-day b) sodium and c) water balances before and after 
spironolactone on a standard sodium diet, and with spironolactone on a high sodium diet.  
Spironolactone treatment on a standard sodium diet caused a significant decrease in urinary 
sodium excretion in for Hsd11b2
+/+
 mice compared to Hsd11b2
+/-
 mice.  There was no 





 mice during any period.  * P < 0.05.  Data are means ± SEM for a), and as 
the median, interquartile range and full range for b) and c). 
 
b) 3-Day Sodium Balances – Spironolactone Effects 
c) 3-Day Water Balances – Spironolactone Effects 
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balance between the two genotypes at any point (Figure 3.14b).  This 
suggests that spironolactone administration is rescuing the impaired sodium 
excretion observed in Hsd11b2+/- mice on a high sodium diet only (compare 
Figure 3.14b with 3.3c).  Water balance also does not vary between the 
Hsd11b2+/+ and Hsd11b2+/- groups at any stage during the study (Figure 3.14c). 
 
3.2.6.2 Renal clearance studies 
After three weeks on a high sodium diet with spironolactone administration, 
the MABP was significantly reduced for both Hsd11b2+/- and Hsd11b2+/+ mice 
compared to a high sodium diet alone; the significant difference between the 
two genotypes remained (compare Figure 3.15a with Figure 3.7).  This 
suggests that spironolactone treatment is causing a significant reduction in 
BP that is universal in spite of genotype and starting BP.  There was no 
significant difference in the GFR values between the two groups with 
spironolactone treatment (Figure 3.15b).  GFR was increased in Hsd11b2+/+ 
mice on a high sodium diet with spironolactone treatment compared to a 
high sodium diet alone (compare Figure 3.15b and 3.8a); there was no change 
in Hsd11b2+/- GFR with spironolactone treatment.  RBF was reduced in both 
genotypes with spironolactone treatment on a high sodium diet (compare 
Figure 3.15c with Figure 3.8b).  Spironolactone abolished the significant effect 
of genotype upon RBF (Figure 3.15c). 
Urinary sodium excretion was significantly increased with spironolactone 
administration on a high sodium diet compared to high sodium diet alone 
(compare Figure 3.16a with Figure 3.9a). A significant decrease in sodium 
excretion in the Hsd11b2+/- group compared with the Hsd11b2+/+ group 
remained (Figure 3.16a).  There was no difference between the two groups 
for plasma sodium concentration or urinary potassium excretion with 
spironolactone  treatment,   and these values  did not differ significantly from  
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Figure 3.15.  Spironolactone treatment effects upon MABP and renal hemodynamics.  





 mice after three weeks on a high sodium diet with spironolactone 
















b) GFR – Spironolactone Effects 
c) RBF – Spironolactone Effects 
 131 






















































 mice on a high sodium diet with spironolactone treatment (n = 
8 for both groups).  a) Hsd11b2
+/-
 mice excreted significantly less sodium than Hsd11b2
+/+ 




 mice in 
terms of b) plasma sodium, or c) urinary potassium excretion.  d) Hsd11b2
+/-
 mice had 
significantly lower plasma potassium levels compared to Hsd11b2
+/-
 mice.  ** P < 0.01.  Data 
are means ± SEM. 
 
the high sodium diet only study (compare Figure 3.16b and c with Figure 
3.9b and c,  respectively).    Plasma potassium  levels were significantly lower 
for the Hsd11b2+/- mice than the Hsd11b2+/+ mice, reflecting what is seen 
without spironolactone treatment on a high sodium diet (compare Figure 
3.16d with Figure 3.9d). 
 
 




This chapter describes the discovery and initial characterisation of SS 
phenotypes of the Hsd11b2+/- mouse model.  Hsd11b2+/- mice were first 
characterised in conjunction with the Hsd11b2-/- model when it was initially 
generated (Kotelevtsev et al., 1999).  Using Hsd11b2+/+ littermates as controls, 
investigations involving the three different genotypes found striking 
phenotypes associated with the Hsd11b2-/- animals that reflected the 
characteristics of SAME, the human genetic disorder associated with 11β-
HSD2 ablation.  Although the Hsd11b2+/- mice were found to have reduced 
11β-HSD2 enzyme activity in placenta homogenates and reduced renal 11β-
HSD2 mRNA expression, in terms of plasma electrolytes and BP they did not 
differ from the control Hsd11b2+/+ group and displayed no obvious 
phenotypes (Kotelevtsev et al., 1999).      
Interest in the possibility of reduced 11β-HSD2 enzyme activity having BP 
effects arises from epidemiological human studies that have shown HSD11B2 
polymorphic variation is present within the general population (Bocchi et al., 
2004).  In addition, some research has highlighted a potential link between 
certain HSD11B2 polymorphisms and essential and/or SS hypertension 
(Alikhani-Koupaei et al., 2007; Mariniello et al., 2005).  Furthermore other 
human studies into SAME type II (Mantero et al., 1996; Wilson et al., 1998) 
and heterozygosity in the families of SAME type I and II patients (Li et al., 
1997; Li et al., 1998) have suggested that reduced 11β-HSD2 expression may 
be associated with hypertension.  Together, these observations suggested 
that the Hsd11b2+/- mouse model could pose a more interesting model than 
the original characterising study would suggest, especially if challenged with 
a high salt dietary intake.   
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3.3.1 Hsd11b2 Heterozygous Mice Have a Salt-Sensitive 
Phenotype 
 
3.3.1.1 Dietary Salt Intake and 11β-HSD2 Enzyme Activity  
In the study that described the original characterisation of the Hsd11b2+/+ 
model, 11β-HSD2 enzyme activity was measured in placental homogenates 
of Hsd11b2+/+, Hsd11b2+/-, and Hsd11b2-/- mice.  Hsd11b2+/- mice were shown to 
have approximately 67% enzyme activity compared to Hsd11b2+/+ mice 
(Kotelevtsev et al., 1999).  In the current study renal 11β-HSD2 enzyme 
activity was measured using Hsd11b2+/+ and Hsd11b2+/- kidney homogenates, 
and Hsd11b2+/- mice were found to have approximately 50% activity 
compared with the Hsd11b2+/+ mice on both a standard and a high sodium 
diet (measured as the percentage conversion of corticosterone to 
deoxycorticosterone in the presence of NAD+; Figure 3.1).  A control using 
Hsd11b2-/- kidney homogenates in the same assay series showed conversion 
to be minimal (1.3 ± 0.14% conversion; data not shown); this is likely to 
reflect endogenous 11β-HSD1 dehydrogenase activity.  This confirms that 
reduced functional allele number for Hsd11b2 results in reduced renal 
enzyme activity in these transgenic mice.  Also, the enzyme activity results 
indicate that dietary salt content has no effect upon in vivo 11β-HSD2 activity 
for either genotype.   
Previous studies have had conflicting results as to whether or not there is an 
effect of dietary sodium content upon both 11β-HSD2 mRNA expression and 
enzyme activity (Franco-Saenz et al., 1999; Ingram et al., 1996; McKinnell et 
al., 2000).  McKinnell et al reported that renal 11β-HSD2 enzyme activity was 
decreased in rats in a high sodium diet compared to a low sodium diet. 
However, studies into Hsd11b2 mRNA expression showed that in the 
medullary collecting ducts there was no change in expression between the 
 134 
diets.  Franco-Saenz et al compared renal Hsd11b2 mRNA expression 
between Dahl SS and SR rats on a low or a high sodium diet, and found that 
a high salt diet almost doubled Hsd11b2 mRNA expression in both rat 
strains compared to a low sodium diet.  It must be highlighted that both of 
these studies were conducted by comparing low sodium diet values against 
those obtained on a high sodium diet. Clearly there will be a massive 
difference in sodium intake between the two diets in these studies; 
comparisons made during the current study are more reasonable as they are 
between normal and a high sodium diet conditions.  In addition, the 
observation that one of these studies found a decrease in enzyme activity on 
a high sodium diet (and no change in mRNA levels) whereas the other found 
an increase in mRNA levels on a high sodium diet is inconsistent.  Another 
study investigating the effects of dietary salt content upon 11β-HSD2 enzyme 
activity in human subjects (assessed as the urinary steroid metabolite ratio) 
found that their dietary sodium content had no effect upon 11β-HSD2 
enzyme activity in non-hypertensive subjects (Ingram et al., 1996).  
Therefore, the current studies finding that a standard versus a high sodium 
diet has no effect upon 11β-HSD2 enzyme activity is relevant in terms of 
previously published studies. 
 
3.3.1.2 Salt-Sensitive Blood Pressure  
As the literature suggests that the hypertensive phenotype associated with 
11β-HSD2 heterozygosity in humans was linked to high salt diet, the BP 
response of Hsd11b2+/+ and Hsd11b2+/- mice exposed to a high sodium diet was 
investigated.  In both conscious and anesthetised Hsd11b2+/- mice a high 
sodium diet was found to increase BP (SBP and MABP, respectively) 
compared to Hsd11b2+/+ mice (approximately 10mmHg for measurements; 
Figure 3.2 and 3.7).  Hsd11b2+/+ mice did not display a SS-BP, an observation 
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in agreement with published works regarding the C57BL6 mouse strain (Ni 
et al., 2003; Ye et al., 2006).   
The tail cuff SBP measurements for both genotypes on a standard sodium 
diet are greater than would normally be expected for a conscious mouse.  
This is most likely attributable to the stress of the mice being held in a 
restraint tube whilst the measurements are being made.  This stress factor 
was reduced by training the mice to become used to handling and being held 
in the restraint tube (as described in Materials and Methods section; Chapter 
2, section 2.3), but could not be completely removed.  This was why it was 
important to validate these SBP findings with another BP measurement; 
MABP by carotid artery cannulation.   The MABP values obtained were 
lower than the average MABP value for a mouse (approximately 110 mmHg 
at rest).  This is due to the measurements being made under anaesthetic, 
which consequently leads to a reduction in MABP values.  Although the 
values were lower than they would be in conscious animals, the differences 
observed between the genotypes remain characteristic of the SS BP 
phenotype, and consistent with the BP values obtained by tail cuff. 
Overall, these results are direct evidence that reduced 11β-HSD2 activity is 
linked to SS BP in these mice.  They validate indirect observations from 
human population studies suggesting a relationship between HSD11B2 
polymorphisms affecting enzyme activity and SS and/or essential 
hypertension (Agarwal et al., 1994; Alikhani-Koupaei et al., 2007; Carvajal et 
al., 2005; Lovati et al., 1999; Mariniello et al., 2005).   
 
3.3.1.3 Sodium Balance 
Given the important role of sodium handling in SAME and other related 
corticosteroid disorders, it was reasonable to assume that sodium balance 
may be playing an important part in the SS phenotype of Hsd11b2+/- mice. 
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Measurements of urinary sodium excretion in conscious mice revealed that 
Hsd11b2+/- mice displayed a transient blunted natriuresis during the first few 
days of the diet regime, compared to the Hsd11b2+/+ mice (Figure 3.3a).  
Differences in dietary sodium intake between the genotypes were not 
responsible for these observations as food intake was similar throughout 
(Figure 3.3b).  These observations were reinforced by the 3-day sodium 
balance data (periods were divided into 3-day stages as the control data on 
the standard sodium diet was collected over 3 days), and suggest that 
Hsd11b2+/- mice are unable to excrete an increased dietary sodium load as 
efficiently as Hsd11b2+/+ mice at the beginning of a high sodium diet regime.   
Urinary sodium excretion results from the renal clearance experiments 
showed that after three weeks on a high sodium diet Hsd11b2+/- mice continue 
to excrete significantly less sodium than Hsd11b2+/+ mice in an acute setting 
after three weeks on the high sodium diet (Figure 3.9a).  This is in contrast to 
the 24 hour measurements, which show that the natriuresis of Hsd11b2+/- mice 
was equal to that of Hsd11b2+/+ mice at this time point. Important differences 
between these two measurements are that one is obtained from unrestrained 
conscious animals over a 24 hour period, and the other under anaesthesia 
over a 40 minute period. Another difference is that during the renal clearance 
studies the ability of the kidney to handle sodium is being pushed beyond 
normal physiological circumstances due to the infusion of 0.9% saline.  There 
is an implication that there may be a circadian regulation element to the 
discrepancy in sodium excretion.  That is that Hsd11b2+/- mice may have an 
altered circadian rhythm in terms of sodium excretion and BP on a high 
sodium diet.  Certainly in human subjects with SS hypertension, a “non-
dipper” BP phenotype has been observed which is believed to enhance 
nocturnal pressure natriuresis so as to compensate for a diminished 
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natriuresis during the daytime (Kimura et al., 2010).  In addition, balance 
studies from the 1970s using the DOCA-salt rat model highlighted a 
circadian rhythm of DOCA sodium positive balance escape (Mohring and 
Mohring, 1972; Mohring et al., 1970).  It was observed in these studies that 
the sodium balance of the DOCA-salt rats returned to control values between 
7pm – 7am after four days treatment, but that sodium retention persisted 
between 7am – 7pm.  A circadian rhythm of sodium excretion may explain 
the discrepancies observed between these two collection types, and a 
division of the metabolic cage collections into 2 consecutive 12 hour periods 
per day would help to ascertain if there was a circadian element to the 
natriuresis phenotype of the Hsd11b2+/- mice.  
The impaired sodium excretion of the Hsd11b2+/- mice during renal clearance 
studies was not accompanied by an increase in plasma sodium concentration 
compared to Hsd11b2+/+ mice, as under conditions of both a standard and a 
high sodium diet, plasma sodium concentrations were similar between the 
two genotypes (Figure 3.9b).  There was a significant increase in plasma 
sodium concentration on a high sodium diet compared to the standard 
sodium diet (Figure 3.9b), presumably a consequence of the increased dietary 
intake of sodium and corresponding with the increase in urinary sodium 
excretion that both genotypes display when moved to a high sodium diet.  
This observation ties in with the circadian non-dipper phenotype hypothesis, 
so that the BP of Hsd11b2+/- mice would be elevated in an effort to match the 
natriuresis of Hsd11b2+/+ mice over a 24 hour period, thus maintaining stable 
plasma sodium levels at the expense of a high BP.  
 
3.3.1.4 Water Balance 
Water balance in terms of drinking water intake and UFR was analysed 
during the metabolic cage experiments.  At all points of urine output, water 
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intake and overall water balance, there were no significant differences 
between the genotypes (Figure 3.4a, b and c).  For both genotypes at all time 
points, the water balance was significantly different from zero, indicating 
that in relation to water intake and urinary output, the mice were always in a 
positive water balance.  It must be taken into consideration that the 
measurement of any insensible water loss (such as from skin and lungs) and 
water loss from sweat (mice possess sweat glands in their feet) cannot be 
accounted for in these experiments.  It is therefore unlikely that the mice 
were actually in such a positive water balance, especially as water loss from 
these other sources can be significant.  However, what the water balance 
values do highlight is that there is no difference between the 2 genotypes 
even when the sodium balance is significantly positive for the Hsd11b2+/- mice 
during the initial high sodium diet period (Figure 3.3c and 3.4d).  The 
traditional view is that sodium accumulation is accompanied by water 
retention which can lead to an increase in extracellular volume (ECV) and an 
increased BP.  Generally, the kidneys are responsible for the regulation of 
ECV so as to maintain a stable BP by controlling total body sodium content.  
However evidence is accumulating to suggest that large amounts of sodium 
can be accumulated without water retention accompanying it (Titze, 2009).  
In particular, studies performed in rats have found that during high salt diet 
feeding the accumulation of sodium storage in the skin is increased, and 
suggest that the skin is an osmotically inactive sodium reservoir that 
accumulates sodium when dietary sodium is in excess (Titze et al., 2003).  Of 
particular interest it has been found that sodium accumulation is excess in 
comparison to water accumulation in a model of mineralocorticoid excess 
(the deoxycorticosterone acetate (DOCA)-salt rat); 75 – 80% of sodium 
retention was found to be in abundance over water (Titze et al., 2005). This 
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was contributed towards by both osmotically inactive skin storage and an 
osmotically neutral sodium retention balance by potassium loss, thus 
allowing for maintenance of ECV homeostasis despite an increased total 
body sodium accumulation.  Therefore, the absence of any significant 
difference between the water retention of the two genotypes does not 
necessarily mean that the Hsd11b2+/- mice are not in a positive sodium 
balance.     
The one aspect where there was a difference in terms of water excretion 
between the two genotypes is with regards to faecal water content (Figure 
3.4d).  On a standard sodium diet, the Hsd11b2+/- mice had significantly less 
water content in their faeces compared to the Hsd11b2+/+ mice.  Once placed 
on a high sodium diet both genotypes significantly decreased their faecal 
water content to similar levels (Figure 3.4d).  This suggests that faecal water 
content is tightly regulated by an increase in dietary sodium in both 
genotypes.  11β-HSD2 expression is well documented in epithelial cells of the 
colon, where it is assumed to play a protective role in MR activation, 
analogous to the kidney (Fuller and Verity, 1990; Moore et al., 2000).  It is 
possible that under normal dietary conditions the Hsd11b2+/- model is 
displaying increased colonic water reabsorbtion (reflected by a reduced level 
of faecal water content) due to inappropriate activation of MR/GR target 
genes.  Overall, faecal water loss is normally quite small, and the comparison 
of the volume urine produced and the faecal water content during these 
experiments highlights this (compare Figure 3.4a and d).  For this reason 
(and because there is no difference in faecal water content once the animals 
are placed on a high sodium diet) faecal water measurements were excluded 




3.3.1.5 Potassium Balance 
The differences observed for dietary potassium intake for both groups of 
mice when they are moved from a standard to a high sodium diet are most 
likely due to a difference in the dietary potassium content of the two sodium 
diets (Figure 3.5a).  The potassium content of the standard sodium diet was 
0.67%, and in the high sodium diet this was slightly less at 0.5%.  However, 
this 0.16% difference in potassium content is enough to cause a significant 
difference in the dietary potassium intake between the two diets; this is not 
due to the mice eating less food over all on the high sodium diet as this was 
not significantly different (see Figure 4.9c). A decrease in potassium intake 
can trigger a decrease in aldosterone secretion (Williams, 2005), but as the 
lower potassium dietary content is being administered in conjunction with 
very high levels of dietary sodium intake, it is unlikely that these small 
changes in potassium intake would have any significant effect in comparison 
the large changes for sodium.  
In the 24 hour metabolic cage urine samples there was no difference in the 
potassium excretion between the two genotypes on a standard sodium diet, 
and the Hsd11b2+/- mice excreted significantly less than the Hsd11b2+/+ mice for 
the entire high sodium diet period (Figure 3.5b).  This is in contrast to the 
renal clearance urinary potassium excretion values, where on a standard 
sodium diet the Hsd11b2+/- mice excreted significantly more urinary 
potassium than the Hsd11b2+/+  mice, and on a high sodium diet there was no 
difference between the two groups; both had significantly down-regulated 
their potassium excretion compared to standard diet conditions (Figure 3.9c).  
These contrasting results may relate back to the comments made in relation 
to sodium excretion regarding the circadian rhythm of electrolyte excretion, 
and how this may be altered in the Hsd11b2+/- mice on a high sodium diet, 
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and so we will now refer to urinary potassium excretion as the 24 hour 
metabolic cage values. 
Overall, the plasma potassium levels are also conflicting in terms of the 
urinary excretion profile; values are similar between genotypes on a standard 
sodium diet, and Hsd11b2+/- mice display a significantly lower plasma 
concentration compared to Hsd11b2+/+ mice on a high sodium diet (Figure 
3.9d). This suggests that even though the Hsd11b2+/- mice are excreting less 
urinary potassium on a high sodium diet, they also possess a lower plasma 
potassium concentration, compared to Hsd11b2+/+ mice.  The reduced plasma 
potassium levels are consistent with the phenotypes reported for SAME 
patients and the Hsd11b2-/- mouse model, where hypokalemia accompanies 
hypertension.  However, if the potassium lost from the extracellular fluid 
(ECF) is not being excreted in the urine, then where is it moving to?  It is 
known that excess aldosterone can cause potassium to move from the ECF 
into the intracellular fluid (ICF), particularly of muscle cells, which 
ultimately leads to a decrease in plasma potassium levels (McDonough et al., 
2002). These ICF stores act as a buffer against unregulated increases in ECF 
potassium concentrations. This could be due to an MR-mediated increase in 
Na-K-ATPase expression and activity in skeletal muscle tissue.  Although 
aldosterone is very low in Hsd11b2+/- mice on a high sodium diet, we have 
demonstrated that corticosterone levels are greatly increased, so perhaps this 
is stimulating increased Na-K-ATPase potassium uptake in muscle ICF via 
activation of both the MR and the GR (which also mediates Na-K-ATPase 
expression).   
Faecal potassium excretion was not assessed during these studies, and so 
altered excretion and/or reabsorption by this route cannot be discounted as 
contributing towards these results.   In particular, the omission of these 
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values may explain the positive potassium balance observed for both 
genotypes at all periods assessed (Figure 3.5c).  
 
3.3.1.6 Renal Hemodynamics 
The GFR represents the volume of fluid filtered by the kidneys from the 
plasma per unit of time.  GFR can be measured using a substance that is feely 
filtered at the glomerular filtration barrier from plasma, but is neither 
reabsorbed nor secreted within the renal tubules.  A classic example of such a 
substance is the naturally occurring plant polysaccharide inulin, whose 
clearance from plasma can be used as a direct measurement of GFR.  Under 
the experimental conditions of renal clearance, it is possible to directly infuse 
inulin into the jugular vein at a known concentration rate, and to measure its 
clearance as a fraction of how much is measured in the plasma and the urine 
at a certain time point (see Materials and Methods chapter for further 
details).  Variation in GFR is a crucial determinant of renal function, as it will 
effect fundamental changes in renal hemodynamics.    
After three weeks on both the standard and the high sodium diet, Hsd11b2+/- 
mice had a greater GFR than Hsd11b2+/+ mice (Figure 3.8a).  There was also an 
overall effect of diet upon GFR in the Hsd11b2+/+ mice who had a lower GFR 
on the high compared to the standard sodium diet.  This did not happen 
with the Hsd11b2+/- group. Deciphering these results on their own is 
complicated as there are many variables that contribute towards the GFR, as 
with any capillary filtration barrier.  The GFR is determined by the net 
filtration pressure as well as the permeability and the surface area of the 
capillaries.  Increased GFR in the Hsd11b2+/- group is suggestive of increased 
(renal) arterial pressure and/or increased efferent arteriole resistance i.e. 
changes to hydrostatic pressure.  Nonetheless, without knowing more about 
other factors of the renal hemodynamics it is impossible to say what exactly 
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is causing the changes observed here.  GFR will also be increased if the 
kidneys themselves are physically are larger.  However, analysis of kidneys 
weights from the two genotypes shows that they are the same size regardless 
of genotype or diet (data not shown).   
In order to try and establish the causes of the altered GFR in Hsd11b2+/- mice, 
other renal hemodynamic parameters were investigated. The kidney receives 
the highest blood flow of any organ in the body.  This high supply of blood is 
to supply enough plasma for high rates of GFR to be sustained, which in turn 
is required to allow the kidneys to constantly monitor and adapt to any 
changes in electrolyte and water balance.  Thus, the mechanisms that 
regulate RBF are similar to those that govern GFR.  RBF is determined by the 
renal arterial pressure and the contractility of the smooth muscle of the renal 
arterioles.  As it is plasma that is filtered at the glomerular filtration barrier, 
not blood, RBF is calculated using effective renal plasma flow (RPF) and 
hematocrit values (see Material and Methods Chapter for further details).  
Effective RPF can be measured in renal clearance experiments by infusing the 
substance p-aminohippuric acid (PAH), and measuring its subsequent 
concentration in both plasma and urine.  PAH is suitable for these 
measurements as it is freely filtered at the glomerulus, and almost all that is 
not filtered is secreted by the renal tubule within one systemic circulation of 
blood.  This results in a very high extraction ratio (>90%), giving an accurate 
representation of the volume of plasma that the kidney is filtering per unit of 
time.   
There was no difference in the RBF on a standard sodium diet between the 
Hsd11b2+/+ and Hsd11b2+/- groups of mice (Figure 3.8b).  However, after three 
weeks on a high sodium diet, the Hsd11b2+/- group had a significantly lower 
RBF compared to the Hsd11b2+/+ group.  Thus, RBF was affected by a high 
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sodium diet in the Hsd11b2+/- mice. The changes in the GFR and RBF of both 
genotypes on different sodium diets were reflected in the filtration fraction 
(FF) calculations; FF represents the fraction of renal plasma flow that is 
filtered through the glomerular capillaries and is calculated as a ratio of the 
GFR and the RPF.  On a standard sodium diet, the FF was similar for the two 
groups, implying that the difference in GFR was not significantly affecting FF 
as a result of similar RBF being maintained (Figure 3.8c).  On high sodium 
diet, the FF of the Hsd11b2+/+ mice decreases, reflecting the decrease in GFR, 
whereas the Hsd11b2+/- mice have a highly significant increase in FF after 
three weeks on a high sodium diet, presumably a consequence of the 
significant decrease in RBF under these conditions.   
Auto regulation feedback mechanisms are in place to keep the GFR and RBF 
relatively constant when the system is faced with changes in BP.  This in turn 
is designed to keep the levels of water and solutes within balance by 
controlling their renal excretion.  The increased GFR in the Hsd11b2+/- mice 
compared to the Hsd11b2+/+ mice is present regardless of dietary sodium 
content.  This suggests that this genotype has a compensatory increase in 
GFR which maintains a normal BP under conditions of standard sodium diet.  
However, when moved to a high sodium diet, the increase in GFR is still 
observed, but it is now accompanied by an increase in MABP and decrease in 
RPF.  This could be indicative of changes within renal vascular resistance 
(RVR), in that either or both the efferent and afferent arterioles are different.   
Indeed when RVR was calculated, values for both genotypes were equal on a 
standard sodium diet (when RBF and MABP are also equal), and high 
sodium diet had no effect upon Hsd11b2+/+ mice (when RBF and MABP also 
remain the same).  However, the Hsd11b2+/- mice displayed a significant 
increase in RVR on a high sodium diet, which corresponds with their 
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decreased RBF and increased MABP under such conditions (Figure 3.8d).  
This suggests that the renal vasculature is contracted in the Hsd11b2+/- mice 
on a high sodium diet, although it is not possible to deduce whether this is 
occurring in the efferent or the afferent arteriole from these experiments. 11β-
HSD2 activity is present in arteriole smooth muscle cells  (Hatakeyama et al., 
2001) and also vascular endothelial cells (Gong et al., 2008), and the 
contractile response of the vasculature has been linked to glucocorticoid 
metabolism (Souness et al., 2002).  In addition, on a mixed MF1 background, 
Hsd11b2-/- mice were found to have enhanced vascular constriction to 
norepinephrine, and their relaxation response was also impaired (Hadoke et 
al., 2001); it must however be pointed out that these observations may have 
been attributable to the mixed strain background of these mice, as on a 
congenic C57Bl6/J background these experiments are not reproducible 
(Bailey et al., 2008).  This implies that 11β-HSD2 expression in tissues other 
than the kidney may be significantly contributing towards the SS BP 




The phenotype of the Hsd11b2+/- mice on a high sodium diet ultimately arises 
from a deficiency of 11β-HSD2 enzyme activity, and presumably this has 
effects upon the availability, occupancy, and activation of the MR to both 
aldosterone and corticosterone.  Therefore, measuring the concentrations of 
these two hormones in both the urine and plasma of the animals on both 
sodium diets was undertaken in the hope of gaining further insights into the 
mechanisms underlying the observed phenotypes. 
Under standard diet conditions, the plasma and urine aldosterone levels of 
Hsd11b2+/- mice were significantly lower than for Hsd11b2+/+ mice (Figure 3.6a 
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and b).  This suggests that during standard diet conditions, when no BP or 
sodium excretion phenotype is present, reduced 11β-HSD2 activity is 
resulting in a suppressed RAAS.  Presumably, this is a consequence of 
enhanced MR activation under basal conditions due to reduced receptor 
protection by 11β-HSD2.  A decrease in aldosterone typically reflects a 
down-regulated RAAS.   
When the two groups of mice were moved onto a high sodium diet, they 
both down-regulated their urinary and plasma aldosterone concentrations, 
as is appropriate for the increase in dietary sodium intake (Figure 3.6a and 
b).  The urinary aldosterone concentration decreased at Days 1 - 3 of the high 
sodium diet, and then was decreased even further at Days 11 - 15 for both 
genotypes (Figure 3.6b).  The plasma aldosterone concentrations were 
measured after three weeks on either the standard or the high sodium diet, 
and were significantly less for both groups on the high sodium diet. In 
particular, the plasma concentrations of the Hsd11b2+/- group were very low 
on a high sodium diet.  This implies that it is not aldosterone acting at the 
MR that is responsible for the phenotypes observed in the Hsd11b2+/- mice on 
a high sodium diet.   
Plasma and urinary corticosterone levels were similar for both genotypes on 
a standard sodium diet (Figure 3.6c and d).  In terms of urinary 
concentration, there was a significant increase for both genotypes at Days 1 - 
3 of the high sodium diet, and similar levels at Day 11 - 15 also (Figure 3.6d).  
For the high sodium diet periods investigated, the Hsd11b2+/- mice had a 
significantly greater urinary corticosterone concentration than the Hsd11b2+/+ 
mice. Plasma corticosterone concentration was also increased for the 
Hsd11b2+/- group after three weeks on a high sodium diet compared to a 
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standard sodium diet, but did not change for the Hsd11b2+/+ group (Figure 
3.6c).  
When these steroid concentration data are analysed together, they suggest 
that it is increased corticosterone levels in the Hsd11b2+/- mice that are 
responsible for the observed phenotypes, and not aldosterone; although that 
is not to say that the reduced aldosterone levels are not having effects upon 
other physiological parameters in these mice, such as potassium balance, as 
discussed previously.  The increased levels of corticosterone observed in the 
Hsd11b2+/- mice on a high sodium diet are likely to be either the result of 
increased corticosterone synthesis or decreased metabolism (presumably 
caused by a decrease in 11β-HSD2 activity).  In addition, in is important to 
point out that the increase in corticosterone may also be over activating GRs 
as well as MRs.  Therefore, the observed phenotypes could be a consequence 
of activation of either steroid receptor, or a combination of both. The 
properties of both aldosterone and corticosterone, and their respective 
regulatory systems, are investigated in more detail in Chapter 4. 
 
3.3.3 Molecular Mechanisms 
 
Although metabolic cage and renal clearance studies can assess and provide 
valuable insights into the function of many different renal processes, alone 
they are not sufficient to identify the contributions of specific nephron 
segments towards the observed phenotypes i.e. it is not possible to ascertain 
the nephron site(s) responsible for enhanced sodium reabsorption. In order 
to dissect this further, the potent ENaC blocker amiloride, and its derivative 
benzamil, were administered acutely and chronically, respectively. In 
addition, the MR antagonist spironolactone was also administered 
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chronically to the mice during a three week period of high sodium diet 
feeding. 
 
3.3.3.1 Acute ENaC Blockade 
ENaC is responsible for the reabsorption of sodium across the apical 
membrane of cells in the ASDN (see Figure 1.3). ENaC expression and 
activity have been shown to be regulated by MR activation (Snyder, 2005). As 
ENaC deregulation is known to be important in the pathogenesis of 
hypertension due to its involvement in sodium renal reabsorption, we 
decided to investigate the potential role of this sodium transporting channel 
in the Hsd11b2+/- SS phenotype.  To do this, measurements made during the 
renal clearance studies (as described above) were repeated in the same 
animals after intravenous administration of the ENaC blocker amiloride. 
Amiloride administration caused a significant decrease in MABP for both 
groups of mice on a high sodium diet compared to a standard sodium diet 
(Figure 3.10a).  A change this rapid in MABP is unlikely to be due to 
amiloride effects upon renal sodium transport.  The explanation may come in 
the form of ENaC expression in the central nervous system (CNS), and their 
suggested contribution towards the pathogenesis of SS hypertension 
(Abrams and Osborn, 2008).  It is possible that the I.V. dose of amiloride is 
blocking these receptors in the CNS and that this is having an immediate 
impact upon the MABP.  Why this response is exaggerated on a high sodium 
diet is unclear.  The doses of amiloride administered in this study are 
unlikely to be affecting any other sodium transporters, as they have 
previously been rigorously tested for this (Dr. Matthew Bailey, unpublished 
results).   
There was no significant change in GFR due to amiloride administration in 
either genotype on either sodium diet (Figure 3.10b), but there was for 
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sodium excretion (Figure 3.10.c); this demonstrates that these effects of 
amiloride upon sodium excretion are due to ENaC and not a change in GFR.  
The ENaC-mediated sodium reabsorption of the Hsd11b2+/- mice is 
significantly greater than that of the Hsd11b2+/+ mice on a standard, 
suggesting that they have a greater expression and/or activity of ENaC under 
normal conditions.  After three weeks on a high sodium diet, the difference 
between the two groups in terms of ENaC mediated sodium reabsorption 
becomes even more pronounced.  The Hsd11b2+/+ mice completely down-
regulate their ENaC-mediated sodium reabsorption under the high sodium 
conditions, which is to be expected as the suppression of the RAAS due to 
high sodium intake reduces both ENaC expression and activity.  The 
Hsd11b2+/-  mice however do not down-regulate their ENaC-mediated sodium 
reabsorption, and it remains at level similar to that on a standard sodium 
diet; these levels are completely inappropriate for the level of dietary sodium 
intake and the plasma concentration of aldosterone. Therefore, this 
demonstrates that in the face of a high sodium diet and a greatly suppressed 
RAAS, the Hsd11b2+/- mice are still capable of maintaining significant levels of 
ENaC-mediated sodium reabsorption; that is ENaC are deregulated.  This is 
highly suggestive of the increased levels of glucocorticoids observed in these 
mice playing a role in the regulation of ENaC, either via the MR or the GR, or 
more likely a combination of both.   
Potassium excretion was significantly down-regulated in the Hsd11b2+/- 
compared to the Hsd11b2+/+ mice on a standard sodium diet after amiloride 
administration (Figure 3.10d).  The bigger difference in potassium excretion 
is most likely a due to the fact that they excrete more potassium under the 
renal clearance conditions on a standard sodium diet anyway (see above for 
discussion of potassium balance).  The observation that both genotypes have 
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little change in their ENaC-mediated potassium excretion on a high sodium 
diet in response to amiloride is again reflective of the fact that both groups 
excrete significantly less potassium on a high sodium diet during these 
experiments.   
 
3.3.3.2 Chronic ENaC Blockade 
The results of acute ENaC blockade during renal clearance studies 
highlighted a potential role for the sodium channel in the pathogenesis of the 
SS phenotype in Hsd11b2+/- mice. In order to investigate this further, a chronic 
ENaC blockade study was designed whereby the ENaC blocker benzamil (a 
potent amiloride derivative) was administered continuously to both groups 
of mice during both a standard and a high sodium diet feeding regime 
during a metabolic cage study.  A consistent administration of benzamil was 
achieved by surgical implantation of an osmotic mini-pump that would 
deliver the drug at a continuous rate for up to 4 weeks (see Materials and 
Methods Chapter for further details). After three weeks on a high sodium 
diet these mice were prepared for renal clearance.   
The effects of benzamil administration caused a significant increase in 
urinary sodium excretion on a standard sodium diet during the metabolic 
cage control period (Figure 3.11a). This shows that the benzamil dose 
administered is sufficient to cause ENaC blockade, as reflected in an 
increased sodium excretion.  Benzamil administration attenuated the positive 
sodium that had been previously observed in the Hsd11b2+/- mice for the first 
3 day period on a high sodium diet, and there is no difference in water 
balance at any period between the two genotypes, as before (Figure 3.11b 
and c).  Benzamil administration also attenuated the effects of a high sodium 
diet upon the MABP of Hsd11b2+/- mice, and both groups had similar values 
for MABP (Figure 3.12a).  This suggests that increased sodium reabsorption 
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due to deregulated ENaC activity is important in the development of SS BP 
increase in Hsd11b2+/- mice.  Benzamil administration does not however 
rescue the increased GFR of Hsd11b2+/- mice on a high sodium diet; this was 
not entirely surprising as the elevated GFR phenotype is observed in these 
mice on a standard sodium diet, and is therefore not due an increase in 
dietary sodium intake.  The effects of a high sodium diet upon the RBF of 
Hsd11b2+/- mice are attenuated with benzamil treatment (Figure 3.12c) further 
emphasising the role of a high sodium diet in modifying the vascular 
reactivity of these mice.   
In terms of urinary and plasma sodium and potassium measured during 
renal clearance studies, there was no difference for any of these 
measurements during the administration a high sodium diet with benzamil 
treatment (Figure 3.13), suggesting that the deregulation of these parameters 
in Hsd11b2+/- mice is due to ENaC function. The efficacy of the benzamil 
administration upon ENaC blockade was tested by administering an acute 
dose of amiloride during renal clearance studies, as before.  There was no 
difference for any of the parameters measured for either genotype with 
amiloride administration, and so the dosing of benzamil was deemed to be 
sufficient for full ENaC blockade. 
Both the acute and chronic blockade of ENaC with amiloride and benzamil, 
respectively, has highlighted the important role of deregulation of this 
sodium channel towards the phenotype of the Hsd11b2+/- mice.   The 
deregulated activity of ENaC is undoubtedly due to the inappropriate over 
activation of the MR by corticosterone due to reduced 11β-HSD2 activity, 
and may also be contributed to by increased activation of the GR due to high 
levels of circulating corticosterone in these mice on a high sodium diet.  
Other contributing factors could be the deregulation of other proteins that 
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themselves act to regulate ENaC trafficking and activity, such as Nedd4-2 
(Kamynina et al., 2001) and the WNKs (Huang and Kuo, 2007), both of which 
are also regulated by MR and GR transcription.  
 
3.3.3.3 Chronic MR Blockade 
The ENaC blockade studies demonstrate that regulation of this channel is 
deregulated in the Hsd11b2+/- mice and contributes towards their SS 
phenotype.  In addition, both plasma and urinary steroid measurements 
suggest that an elevation in corticosteroid levels on a high sodium diet are 
also contributing towards their phenotype.  As both ENaC density and 
activity can be regulated by MR activity, MR over activation due to reduced 
11β-HSD2 activity and increased corticosteroid levels is a possible molecular 
mechanism for the SS phenotypes of Hsd11b2+/- mice.  To investigate this 
further, a chronic MR blockade study was designed whereby the MR 
antagonist spironolactone was administered continuously to both Hsd11b2+/+ 
and Hsd11b2+/- mice during standard and high sodium diet feeding regime 
during a metabolic cage study.  A consistent administration of 
spironolactone was achieved by surgical implantation of an osmotic mini-
pump, as with the benzamil study (see Materials and Methods Chapter for 
further details). After three weeks on a high sodium diet these mice were 
prepared for renal clearance.   
The administration of spironolactone on a standard sodium diet during 
control metabolic cage collections caused a significant natriuresis in the 
Hsd11b2+/- mice compared to the Hsd11b2+/+ mice (Figure 3.14a).  This suggests 
that MR activation is contributing towards sodium reabsorption in the 
Hsd11b2+/- mice on a standard diet.  Spironolactone administration has 
previously been shown have mild natriuretic effects (Sica, 2005). 
Spironolactone administration alleviated the significantly positive sodium 
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balance of Hsd11b2+/- mice on a high sodium diet, and there were no 
differences between the two genotypes for water balance (Figure 3.14b and 
c).   
Although spironolactone reduced the MABP of Hsd11b2+/- after three weeks 
on a high sodium diet compared to a high sodium diet alone by 
approximately 14 mmHg (87.5±1.54 versus 101.4±2.11, respectively), it also 
reduced the MABP of Hsd11b2+/+ mice by a similar amount (75.4±2.43 versus 
89.95±2.4, respectively).  Therefore, the effects of spironolactone are having a 
BP lowering effects of a similar magnitude regardless of genotype, and so the 
BP reducing effects seen here are not indicative of a “rescued” Hsd11b2+/- SS 
phenotype as a result of MR blockade.  This is unusual as the BP lowering 
effects of spironolactone are well reported within hypertensive population 
studies (Nishizaka et al., 2003) but would not be expected to take place in 
normotensive subjects, such as the Hsd11b2+/+ mice (Pratt et al., 2001).  
Another interesting observation is that although at first it appears that 
spironolactone administration had attenuated the increased GFR and 
decreased RBF of Hsd11b2+/- mice compared to Hsd11b2+/+ mice on a high 
sodium diet (Figure 3.15b and c) it actually appears as though the 
spironolactone dosing has altered these parameters in the Hsd11b2+/+ mice to 
give similar values to those of the Hsd11b2+/- mice.   
In terms of urinary excretion and plasma concentrations of sodium and 
potassium, spironolactone would be expected to increase sodium excretion 
and decrease potassium excretion so that plasma potassium concentration 
increases.  A common side-effect of spironolactone treatment in hypertensive 
patients is the onset of hyperkalemia due to decreased potassium excretion (a 
consequence of reduced ENaC and Na-K-ATPase activity under MR 
blockade) (Jansen et al., 2009).  Although urinary excretion is increased 
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approximately 10-fold with spironolactone administration on a high sodium 
diet compared to without under renal clearance conditions (Figure 3.16c), the 
significant difference between the two genotypes remains, and plasma 
sodium levels are as without spironolactone treatment.  Most strikingly, 
potassium excretion and plasma potassium levels are largely unaltered with 
spironolactone treatment (Figure 3.16c and d). 
The unexpected results observed with spironolactone treatment prompted 
further investigation of the dosing regime by analysing terminal plasma 
samples from the mice for the presence of the spironolactone active 
metabolite, canrenone, by MS analysis (see Materials and Methods chapter).  
Canrenone is measured rather than spironolactone itself as the plasma 
concentration half life of spironolactone is 1.4 days compared to 16.5 days for 
canrenone (Sica, 2005).  Canrenone was undetectable in the terminal plasma 
samples of all spironolactone-treated mice (data not shown).  This suggests 
that the dosing regime adapted for use from the published study by 
MacDonald et al was not suitable for these experiments and that full MR 
blockade was not being achieved (MacDonald et al., 2000). This means that it 
is possible the vehicle solution of DMSO and propylene glycol used to 
solubilise spironolactone for the mini-pump dosing (spironolactone is 
notoriously difficult to solubilise in aqueous fluids (Sica, 2005)) may be 
having physiological effects.  Although administration of this vehicle by 
mini-pump was reported not to cause any significant physiological changes 
in the original study (MacDonald et al., 2000), as vehicle control experiments 
were not performed here, there is a distinct possibility that the vehicle may 
be causing some of the effects observed here.  A study that used a sheep 
model to investigate the cardiovascular effects of water-miscible solvents that 
are routinely used as drug carriers placed DMSO as causing a moderate 
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effect, and propylene glycol as having a marked effect (Laurent et al., 2007). 
In addition, DMSO is known to have significant effects upon membrane 
permeability (Jacob and de la Torre, 2009; Notman et al., 2006) which had 
been shown to promote the osmotic absorption of fluid in microvessels in 
vitro (Glass et al., 2006).   Therefore, the effects of the spironolactone vehicle 
could well be having phenotypic effects that, in addition to the dosing of 
spironolactone being too low, are also responsible for the phenotypes 
observed in this study.    
Although there was not enough time within the scale of these studies to 
repeat the chronic MR blockade with spironolactone in a different dosing 
regime, these experiments have since been successfully carried out.  The 
spironolactone dosing was improved by dissolving the drug into silicon 
pellet and implanting this subcutaneously into the mice; canrenone 
measurements showed there was significant levels in their plasma.  For 
further details, see the submitted manuscrpublished scientific paper in 
Appendix 2 of this thesis.  
 
3.3.4 Summary 
In summary, studies described within this chapter have proved that reduced 
enzyme activity of 11β-HSD2 in Hsd11b2+/- mice is responsible for a SS 
phenotype.  Salt sensitivity in this model is associated with an increased BP, 
impaired sodium excretion and a failure to regulate ENaC-mediated sodium 
reabsorption appropriately for salt and steroid status.  These phenotypes are 
observed in combination with changes to renal hemodynamics, and 
aldosterone and corticosteroid concentrations.  Investigations into the 
molecular mechanisms underlying these phenotypes have shown ENaC 
blockade to alleviate symptoms.  Unfortunately, a study investigating MR 
blockade gave indefinite data.  Therefore, the molecular mechanisms behind 
 156 
this SS phenotype need to be investigated in more detail; further studies of 
this thesis will investigate the effects of Hsd11b2 heterozygosity on BP and 
steroid profiles (chapter 4), also and its effects upon steroid receptor 













The regulation of aldosterone and corticosterone, the two main MR ligands, 
may be altered in Hsd11b2+/- mice on a high sodium diet.  The rationale 
behind this theory comes from observations made in the previous chapter, 
Chapter 3.  Firstly, impaired ligand specificity of MR for aldosterone and 
improved corticosterone access, as demonstrated by a reduced 11β-HSD2 
enzyme activity in Hsd11b2+/- mice, could alter the dynamics of these two 
corticosteroids in relation to MR regulation; this in turn could have feedback 
effects upon their production and/or regulation.  Secondly, high sodium 
intake was shown to have a significant effect upon the concentrations of both 
aldosterone and corticosterone and this was exacerbated in Hsd11b2+/- mice 
compared to Hsd11b2+/+ mice; this suggests that the regulation of 
mineralocorticoids and glucocorticoids may be distorted in Hsd11b2+/- mice.   
 
4.1.1 Mineralocorticoid Regulation  
 
4.1.1.1 Aldosterone and the RAAS   
Aldosterone homeostasis is regulated by the RAAS homeostatic feedback 
loop (see Introduction Chapter and Figure 1.6).  In the instance of ablated 
11β-HSD2 enzyme activity, SAME patients have been shown to have a 
down-regulated RAAS, as endogenous renin activity and aldosterone 
concentration are typically low (Quinkler and Stewart, 2003). In addition, 
Hsd11b2-/- mice also have a suppressed RAAS, with plasma concentrations of 
renin and aldosterone, as well as kidney renin mRNA, significantly reduced 
compared to Hsd11b2+/+ littermates (Bailey et al., 2008; Kotelevtsev et al., 
1999).  These observations suggest the RAAS is successfully regulated in 
 159 
response to the severe hypertension observed in SAME patients and the 
Hsd11b2-/- transgenic mouse model.   
Reduced aldosterone levels in Hsd11b2+/- mice on a standard sodium diet 
suggest a down regulated RAAS when no BP phenotype is present; an 
indication that lower concentrations of aldosterone may be required in order 
to maintain a normal phenotype under normal dietary conditions.  
Aldosterone levels are decreased further on a high sodium diet, implying 
that the RAAS is being appropriately regulated in response to increased 
sodium intake, albeit to a greater extent than in Hsd11b2+/+ mice.  These 
results suggest that Hsd11b2+/- mice have a constitutively suppressed RAAS 
that is exacerbated by a high sodium diet.  This has implications for RAAS 
components other than aldosterone, such as the aldosterone pre-cursor 
AngII.  In order to investigate RAAS regulation further, RAAS parameters 
were measured using stress-free terminal blood collections from Hsd11b2+/+ 
and Hsd11b2+/- mice on standard and high sodium diets. 
 
4.1.1.2 AT Receptors and the RAAS   
AngII acts upon the adrenal gland to stimulate the production of 
aldosterone, so a reduction in aldosterone concentration implies that AngII is 
also down-regulated in Hsd11b2+/- mice.  In addition, AngII has BP regulation 
effects other than promoting aldosterone synthesis.  AngII mediates its 
effects via the AngII Type I and Type II receptors (AT1 and AT2) with the 
majority of physiological AngII effects are mediated by the AT1 receptor.  
These include vasoconstriction, modulation of the central sympathetic 
nervous system, and changes in renal sodium handling (de Gasparo et al., 
2000).  Together, AngII effects mediated by AT1 receptors serve to increase 
BP.  The actions of AngII at AT2 receptors are less well understood, however 
recent studies suggest they may exert counter-regulatory effects to oppose 
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AT1-mediated vasoconstriction (for recent review see (Carey and Padia, 
2008)).  A constitutively suppressed RAAS could have feedback effects upon 
AT receptors, such as adaptive changes in the expression and/or binding 
properties of AT1 receptors in the Hsd11b2+/- mice, and these changes could be 
exaggerated further under high dietary sodium.  To investigate this, the 
vasoconstrictive response of Hsd11b2+/+ and Hsd11b2+/- mice to acute AngI and 
AngII administration were assessed.   
 
4.1.2 Glucocorticoid Regulation  
 
The HPA axis is responsible for the homeostatic regulation of glucocorticoid 
synthesis and release (see Introduction Chapter and Figure 1.7).  Plasma 
corticosterone concentrations are comparable between Hsd11b2+/+ and 
Hsd11b2-/- mice on a standard sodium diet (Bailey et al., 2008), and SAME 
patients do not exhibit elevations in plasma cortisol concentration, despite 
evidence of impaired metabolism (Ulick et al., 1979; White et al., 1997).  
These findings support the concept that the phenotype of SAME patients and 
Hsd11b2-/- mice arise from improved glucocorticoid access to MR as a result 
of lack of 11β-HSD2 enzyme activity, and not an elevation in glucocorticoid 
concentration.  In addition, the normal levels of plasma cortisol in SAME 
patients is indicative of an intact HPA axis negative feedback mechanism 
acting to maintain steady concentrations of circulating cortisol despite 
impaired metabolism (Palermo et al., 1996).   
In light of these important findings, the observation made in Chapter 3 that 
an increased sodium intake significantly increases corticosterone 
concentrations in Hsd11b2+/- mice is intriguing; corticosterone concentrations 
were also increased in Hsd11b2+/+ mice, but to a lesser extent. The increase in 
corticosterone concentration during exposure to a high sodium diet 
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corresponds with the timescale of when the phenotype of the Hsd11b2+/- mice 
presents, and suggests that sodium intake is fundamental to the increased 
levels observed.  Increased corticosterone levels could be the result of either 
increased corticosterone production or decreased metabolism (i.e. a longer 
half-life), or a combination of both.  Further investigations into the cause(s) of 
increased corticosterone concentrations are important, as they may be central 
as to why the Hsd11b2+/- phenotype presents only on a high sodium diet.  
Experiments were performed to assess how the HPA axis of these mice 
responded to stress, as an observed weight-loss phenotype implied the high 
sodium diet was initiating a stress-related phenotype; the Hsd11b2+/- mice 
may not be able to adapt to environmental stresses such as a change in diet 
as efficiently as the Hsd11b2+/+ mice.  These experiments also allowed for 
analysis of the acute post-stress metabolism of corticosterone, an important 




4.2 Results: Aldosterone Regulation 
 
4.2.1 RAAS Plasma Analysis  
 
Measurements were made of key RAAS components in the plasma of 
Hsd11b2+/- and Hsd11b2+/+ mice on both standard and high sodium diets.  
Plasma angiotensinogen (AGT) concentration was similar in both Hsd11b2+/+ 
and Hsd11b2+/- mice, and was not affected by dietary sodium content (Figure 
4.1).   
 
Plasma Angiotensinogen Concentration 
 















































 mice on a 
standard (n = 6 and 5, respectively) and high (n = 6 for both groups) sodium diet.  There was 
no difference between the two groups and no effect of sodium diet upon plasma 
angiotensinogen concentration.  Data are means ± SEM. 
 
Circulating renin was measured as both plasma concentration and plasma 
renin activity (PRA).  On a standard sodium, diet the plasma renin 
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concentration was comparable between Hsd11b2+/+ and Hsd11b2+/- mice 
(Figure 4.2a).   
 
a) Plasma Renin Concentration 




































 mice on a standard (n = 6 for both groups) and high (n = 5 and 7, respectively) 
sodium diet.  Plasma renin concentration and activity are significantly greater in Hsd11b2
+/- 
mice on a high sodium diet compared to a standard sodium diet.  Diet has no effect upon 
Hsd11b2
+/+
 mice for either measurement.  All data are means ± SEM.  * P < 0.05; *** P < 
0.001. 
 
After three weeks on a high sodium, Hsd11b2+/- mice displayed a significant 
increase in plasma renin concentration compared to both sodium-loaded 
Hsd11b2+/+ mice and Hsd11b2+/- mice on a standard sodium diet.  PRA was 
b) Plasma Renin Activity 
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similar between both groups on a standard sodium diet (Figure 4.2b).  The 
high sodium diet had no effect upon the renin activity of Hsd11b2+/+ mice, but 
caused a significantly greater level of PRA in Hsd11b2+/- mice. 
 
4.2.2 Angiotensin I and II Dose Responses 
  
4.2.2.1 Maximal BP Response  
Increasing doses of AngI and II were administered to anaesthetised 
Hsd11b2+/+ and Hsd11b2+/- mice with MABP measured throughout.  The 
maximal BP response (MBPR) was calculated by subtracting the baseline 
MABP value before, and maximal MABP recorded after, the drug 
administration (see Figure 4.3 for details). 












Figure 4.3.  An example of a typical MABP dose response curve generated in response to 
AngI or AngII administration.  Red lines on Y axis demonstrate the difference between 
baseline BP and maximal BP response to administration; presented as the maximal BP 
response.  The horizontal dotted line represents the bottom range of the area under the 
curve measurements, as determined by baseline BP.  The specific BP response shown here 
was generated from an Hsd11b2
+/+
 mouse administered 1.125ng of AngI on a standard 
sodium diet. The black arrow demonstrates the moment of AngI IV administration. 
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On a standard sodium diet genotype had a significant effect upon the MBPR 
of the two groups across a range of AngI doses, with Hsd11b2+/- mice 
displaying an increased sensitivity compared to Hsd11b2+/+ mice, irrespective 
of dose concentration   (Figure 4.4).     This pattern persists following 3 weeks 
  


















































 mice on a standard sodium diet (n = 5 and 6, 
respectively) and on a high sodium diet (n = 5 for both groups), Hsd11b2
+/-
 mice have 
greater BP response compared to Hsd11b2
+/+
 mice on both sodium diets, with a high sodium 
diet significantly increasing values for both groups. The response under both dietary 
conditions is highly significantly different in terms of genotype (***) and significantly different 
in terms of AngI dose concentration. All data are means ± SEM.  * P < 0.05; ** P < 0.01; *** 
P < 0.001. 
 
on a high sodium diet, with AngI administration causing larger MBPR in 
Hsd11b2+/- mice compared to Hsd11b2+/+ mice (Figure 4.4).  When MBPR 
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values are compared within genotypes on different sodium diets, it becames 
apparent that the high sodium diet is increasing MBPR for both genotypes 
compared to standard sodium diet values (Figure 4.4).   
The MBPR for AngII on a standard sodium diet shows a similar relationship 
for both genotypes to that of AngI, with Hsd11b2+/- displaying a greater 
MBPR  compared  to  Hsd11b2+/+  mice  at  all  doses  (Figure 4.5).   After  three  
 



















































 mice on a standard sodium diet (n = 6 and 5, 
respectively) and on a high sodium diet (n = 5 for both groups), Hsd11b2
+/-
 mice have 
greater BP response compared to Hsd11b2
+/+
 mice on both sodium diets, with a high sodium 
diet significantly increasing values for both groups.  The response under both dietary 
conditions is highly significantly different in terms of genotype AngII dose concentration (***). 
All data are means ± SEM.  * P < 0.05; ** P < 0.01; *** P < 0.001. 
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weeks on a high sodium diet, the Hsd11b2+/- mice continue to display 
increased MBPR compared to the Hsd11b2+/+ mice (Figure 4.5).  Comparison 
of the MBPR within genotypes on different sodium diets shows that high 
sodium diet had a significant effect upon increasing the MBPR for both 
Hsd11b2+/+ and Hsd11b2+/- mice (Figure 4.5).  The responses to AngII were 
larger than those to AngI at all points for both genotypes on both sodium 
diets.  It is important to point out that for these dose response experiments 
the vehicle used to administer AngI and II (0.9% saline) had no effects upon 
BP recorded (results not shown).  The injection volume for each dose is 50µl, 




In vivo ACE Activity 
 
























mice, measured as 
the ratio between the AngI and AngII maximal BP responses on a standard (n = 5 for both 
groups) and high (n = 5 for both groups) sodium diet.  Hsd11b2
+/-
 mice have significantly 
greater ACE activity on a high sodium diet compared to the Hsd11b2
+/+
 mice.  Data are 
means ± SEM.  *** P < 0.001. 
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Calculating the difference between the AngI and AngII MBPR in individual 
mice as a ratio allowed for an in vivo estimation of Angiotensin Converting 
Enzyme (ACE) activity.  On a standard sodium diet both groups have similar 
levels  of  ACE activity  (Figure 4.6).  On  a  high  sodium diet,  the  Hsd11b2+/+   
mice have down regulated their ACE activity in response to the high sodium 
diet.  Hsd11b2+/- mice have a significantly greater ACE activity than Hsd11b2+/+ 
mice on a high sodium diet, and have not adjusted their ACE activity 
appropriately for the dietary sodium content, displaying similar values to 
those measured on a standard sodium diet.   
It is important to point out that enzymes other than ACE can also catalyse 
the conversion of AngI to AngII, such as chymostatin-sensitive angiotensin-
generating enzyme (chymase) (Urata et al., 1993).  The catalytic activity of 
chymase for the conversion of AngI to AngII has been shown to be 20-fold 
greater than that of ACE (Dell'Italia et al., 1995).  A study investigating the 
contribution of ACE versus chymase was carried out using an ACE knockout 
mouse model (Wei et al., 2002).  These studies showed that while chymase 
may provide an important mechanism in maintaining steady-state AngII 
levels in AngII-target tissues, ACE activity is essential to AngII formation in 
vascular space.  Therefore, this interpretation of ACE activity may not be 
entirely accurate as other enzymes can also catalyse the same reaction. 
 
4.2.2.2 Area under the Curve Analysis  
The extent of the response to the AngI and II doses described above were 
also   analysed by measuring the area under the   BP curves produced in  
response to these administrations (does response curves (DRC); see Figure 
4.3 for example). This analysis allowed for the investigation of potential 
effects of genotype and/or sodium diet upon the magnitude of the BP 
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response.  The magnitude and duration of a BP response to AngI and II can 
provide insight(s) into the receptor ligand relationship. 
On a standard sodium diet Hsd11b2+/- mice have a significantly greater BP 
response than Hsd11b2+/+ mice to AngI in terms of area under the curve 
(AUC) analysis (Figure 4.7a).  This difference was significant in terms of both  
 













































Figure 4.7.  Area under the curve (AUC) values for BP responses to acute AngI IV 




 mice on a 
standard sodium diet (n = 4 for both groups) and a high sodium diet (n = 4 for both groups),.  
Hsd11b2
+/-
 mice have greater AUC values compared to Hsd11b2
+/+
 mice on both sodium 
diets, with a high sodium diet significantly increasing values for both groups.  All data are 
means ± SEM.  * P < 0.05; *** P < 0.01; *** P < 0.001. 
 
genotype and dose concentration, especially at the higher end of the dose 
range.  A similar pattern was also observed after three weeks on a high 
sodium diet, although AUC values for both Hsd11b2+/+ and Hsd11b2+/- mice 
were greater than on a standard sodium diet (Figure 4.7b).  When the effects 
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of dietary sodium content were compared across individual genotypes, the 
effects of a high sodium diet upon AUC was significant in both groups 
compared to a standard sodium diet; values were always greater in 
Hsd11b2+/- mice than Hsd11b2+/+ mice (Figure 4.7c and d).   
AngII administration on a standard sodium diet had a significantly greater 
effect upon the AUC values in Hsd11b2+/- mice compared to Hsd11b2+/+ mice 
(Figure 4.8a).  This was especially prominent at higher AngII concentrations.   
 












































Figure 4.8.  Area under the curve (AUC) values for BP responses to acute AngII IV 




 mice on a 
standard sodium diet (n = 4 for both groups) and a high sodium diet (n = 4 for both groups).  
Hsd11b2
+/-
 mice have greater AUC values compared to Hsd11b2
+/+
 mice on both sodium 
diets, with a high sodium diet significantly increasing values for both groups.  All data are 
means ± SEM.  * P < 0.05; ** P < 0.01; *** P < 0.001 
. 
A similar pattern was observed after three weeks on a high sodium diet, 
again with dose concentration having an effect (Figure 4.8b).  AUC values 
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were greater at all dose concentrations for both genotypes on a high sodium 
diet compared to a standard sodium diet (Figure 4.8c and d), with Hsd11b2+/- 
mice always having greater values than Hsd11b2+/+ mice.   
 
4.3 Results: Corticosterone Regulation 
 
4.3.1 Body Weights and Food Intake  
 
The body weights and food intake of Hsd11b2+/+ and Hsd11b2+/- mice were 
recorded daily during the metabolic cage experiments described in Chapter 
3.  Upon further investigation, these data suggested that there may be a 
stress-related phenotype occurring in the Hsd11b2+/- mice on a high sodium 
diet. 
In relation to individual body weight, Hsd11b2+/- mice lost significantly more 
weight than Hsd11b2+/+ mice during the high sodium diet feeding period 
(Figure 4.9a).  The body weight difference between the two genotypes is 
shown in terms of the total body weight difference over this period in Figure 
4.9b.  Daily food intake was also recorded over this period; there was no 
significant difference for food intake between Hsd11b2+/+ and Hsd11b2+/- mice 
for the entire period of high sodium diet feeding (Figure 4.9c).    
At the end of the high sodium diet regime the mice were culled and certain 
tissues were dissected for further analysis.  This included the epididymal fat 
pads, the weights of which were calculated in relation to total body weight.  
The epididymal fat pads were analysed to try and ascertain the source of the 
weight-loss observed in the Hsd11b2+/- mice.  The fat pads of the Hsd11b2+/- 
mice weighed significantly less than those of the Hsd11b2+/+ mice (Figure 
4.9d).  This demonstrates that the total body weight losses observed in the 
Hsd11b2+/- mice over the high sodium diet period are reflected in epididymal  
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 mice (n = 7 and 8, 
respectively).  a) The daily body weights were recorded for mice in metabolic cages during 
high sodium diet feeding and presented as % body weight loss from baseline 
measurements; b) presents data in a) as the total difference in body weight over the high 
sodium diet feeding period; c) daily food intake recordings made over the same period; d) 
post-mortem weights of dissected epididymal fat pads.  Hsd11b2
+/- 
mice lost significantly 
more weight on a high sodium diet compared to Hsd11b2
+/+
 mice.  This was not due to a 
decrease in food intake, and was reflected in their epididymal fat pad weight.  All data are 
means ± SEM.  * P < 0.05; ** P < 0.01 *** P < 0.001. 
 
fat pad deposits.  Kidney and adrenal weights were also analysed, and no 




c) Daily Food Intake Recordings d) Epididymal Fat Pad Weights 
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4.3.2  HPA Axis Testing – Corticosterone Response 
 
The ability to respond to stress was assessed in Hsd11b2+/+ and Hsd11b2+/- mice 
on both a standard and a high sodium diet by measuring corticosterone 
levels before and after exposure to an intense, short-term stressor (see 
Chapter 2, Figure 2.3 for experimental design).   
The two genotypes had similar baseline corticosterone plasma concentrations 
on the standard sodium diet; these values remained stable for both groups of 
mice after three weeks on the high sodium diet (Figure 4.10a).  After 
exposure to stress, plasma corticosterone concentration increased greatly, 
with values for both genotypes on both diets comparable (Figure 4.10b).  The 
animals were then allowed 90 minutes to recover from the stress.   After this 
recovery period, a final plasma corticosterone concentration measurement 
was obtained.  On a standard sodium diet there was no difference between 
the recovery corticosterone concentrations of Hsd11b2+/+ and Hsd11b2+/- mice 
(Figure 4.10c); values were greatly reduced compared to stress plasma 
corticosterone concentrations.  After three weeks on a high sodium diet, the 
recovery corticosterone concentration for Hsd11b2+/- mice was significantly 
greater than on a standard sodium diet, and than that of Hsd11b2+/+ mice on a 
high sodium diet.  
As the increased concentration of plasma corticosterone after recovery on a 
high sodium diet in high sodium diet fed Hsd11b2+/+ mice suggests an 
impaired corticosterone metabolism, these values were analysed further in 
order to calculate the % decay (calculated as a % of the stress measurement 
corticosterone concentration remaining in the recovery measurement 
concentration).  As predicted by the recovery plasma corticosterone 
concentrations, on a standard sodium diet the % decay of plasma 
corticosterone   in   Hsd11b2+/+  and   Hsd11b2+/-  were  similar  to  one  another  
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a) Baseline Plasma Concentration  b) Stress Plasma 
Concentration 




















































 mice on a standard, and after three weeks on a high, sodium diet 
(n = 9 for both groups).  There was no difference in terms of baseline and stress plasma 
corticosterone concentrations.  Hsd11b2
+/- 
mice had a significantly greater recovery plasma 
corticosterone concentration compared to Hsd11b2
+/+
 mice on a high sodium diet.  d) These 
values were then calculated as the % decay of plasma corticosterone concentration 
compared to stress values; Hsd11b2
+/-
 have a significantly lower rate of decay than 
Hsd11b2
+/+ 
mice on a high sodium diet.  All data are means ± SEM.  * P < 0.05. 
 
(Figure 4.10d).  After three weeks on a high sodium diet, the % decay for the 
Hsd11b2+/- group was significantly decreased compared to Hsd11b2+/+ mice, 
and also to Hsd11b2+/- mice on a standard sodium diet. 
  




This chapter describes investigations into the regulation of aldosterone and 
corticosterone in Hsd11b2+/- mice in relation to their SS phenotype.  
Regulation of the homeostatic feedback loops controlling production of these 
hormones (the RAAS and HPA axis, respectively) is important as they are 
equal in their affinity for the MR.  MR activation is key in the phenotype of 
this mouse model as reduced 11β-HSD2 activity changes the way in which 
these ligands can interact with the receptor. 
 
4.4.1 Aldosterone Regulation  
 
4.4.1.1 RAAS Analysis  
The reduction in concentration of both urinary and plasma aldosterone 
observed in Hsd11b2+/- mice when they are moved from a standard to a high 
sodium diet implies that they have a functional RAAS that is responding 
appropriately to an increased dietary sodium load.  However, the 
significantly lower aldosterone concentrations of Hsd11b2+/- mice compared 
to Hsd11b2+/+ mice on both diets implies that there is a tonic suppression of 
the RAAS in these mice even when no BP or sodium retention phenotype is 
present. This suggests that on a standard sodium diet reduced aldosterone 
concentrations are required to maintain normal BP and natriuresis in the face 
of impaired 11β-HSD2 enzyme activity.  This is presumably to prevent over-
activation of the MR by aldosterone as the reduced 11β-HSD2 activity is 
permitting improved glucocorticoid access to the MR.  In light of these 
results, investigations were carried out to assess RAAS regulation in 
Hsd11b2+/- mice in more depth.  Plasma concentrations and enzyme activities 
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of certain RAAS parameters under both standard and high sodium diet 
conditions were measured.   
AGT is an inactive peptide that is the precursor of AngI.  Genetic linkage 
studies involving AGT have found a strong correlation between sequence 
variations in the AGT gene and essential hypertension within the human 
population (Jeunemaitre et al., 1992).  In addition, transgenic mouse studies 
in which the AGT gene was expressed in increasing copy number from 1 to 4 
showed correlation between AGT gene copy number and BP; BP rose 
approximately 8mmHg for each increase in gene copy number (Kim et al., 
1995).  Given its effects upon BP homeostasis, it was therefore important to 
investigate if AGT was playing a role in this model of increased BP.  Plasma 
concentrations of AGT were comparable between Hsd11b2+/- and Hsd11b2+/+ 
mice on both sodium diets; dietary sodium content had no effect upon 
concentration. Therefore, AGT deregulation is unlikely to be involved in the 
BP increase of Hsd11b2+/- mice on a high sodium diet. 
Renin is the enzyme responsible for the cleavage of AGT into AngI, and is 
produced in specialised cells of the juxtaglomerular apparatus known as 
granular cells.  Renin can be released in response to a number of different 
physiological stimuli such as a fall in systolic BP, reduced concentration of 
sodium in the distal nephron (as detected by the macula densa), or 
sympathetic nervous system activity via β1 adrenergic receptors (Schweda et 
al., 2007).  Two methods were used to measure renin in this study in order to 
obtain both plasma concentration and enzyme activity (PRA).  This is 
important as renin plasma concentration is not always a reflection of PRA 
and vice versa.  PRA assesses the rate-limiting enzymatic step in the 
production of AngI (and therefore also AngII) and also takes into account 
substrate (AGT) availability.  As AGT availability has already been 
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discounted as contributing towards increased BP in this model by direct 
measurements, differences in PRA can therefore be assessed in light of renins 
enzymatic activity alone.  Plasma renin concentration was increased in 
Hsd11b2+/- mice on a high sodium diet.  This is in contrast to the suppressed 
RAAS that was predicted from the low plasma and urinary aldosterone 
concentrations previously reported in Chapter 3.  This suggests that the 
Hsd11b2+/- mice are releasing inappropriate levels of renin in response to a 
high sodium diet.  Results from the PRA assay also show that Hsd11b2+/- mice 
have inappropriately elevated PRA under increased sodium diet conditions, 
demonstrating that the increase in plasma renin concentration is not an 
adaptive mechanism to combat low PRA.   
In light of the observed increase in PRA, the decreased plasma potassium 
concentration observed in Hsd11b2+/- mice on a high sodium diet in Chapter 3 
may be significant (Figure 3.9d).  Studies from the 1970s in both humans and 
rats found a relationship between reduced plasma potassium concentrations 
and increased PRA (Brunner et al., 1970; Sealey et al., 1970).  These studies 
demonstrated that PRA was increased in states of potassium depletion 
associated with a low plasma aldosterone concentration.  They hypothesised 
that increased PRA may play a role in the renal conservation of potassium 
under conditions of low aldosterone, and that potassium may modify renin 
secretion directly by acting on the juxtaglomerular cells of the kidney, or by 
inducing changes in renal tubular secretion.  This hypothesis may go some 
way towards explaining the reduction in urinary potassium excretion 
observed in Hsd11b2+/- mice on a high sodium diet compared to on a standard 
sodium diet and Hsd11b2+/+ mice on both diets (Figure 3.9c).  That is, reduced 
plasma potassium concentrations in the Hsd11b2+/- mice on a high sodium 
diet may be stimulating an increase in the release and/or activity of renin so 
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as to conserve potassium.  Another potential explanation comes from a 
recent study which found increased levels of urinary catecholamine excretion 
in Hsd11b2-/- mice (Bailey et al., 2008).  This implies that the sympathetic 
nervous system may be promoting excess renin release via activation of β1 
adrenergic receptors. Urinary catecholamine measurements in Hsd11b2+/- 
mice could identify if the high sodium diet causes changes in sympathetic 
nervous system activity.  
The studies described here are limited to plasma concentrations of RAAS 
parameters.  While this is extremely useful for analysing renin and 
angiotensin effects at a circulating systemic level, the contributions of intra-
tissue Renin-Angiotensin System (RAS) have not been assessed in these 
studies.  In particular, many studies have implicated the intra-renal RAS as 
an important factor in hypertension; especially as there can be marked 
differences between renin and angiotensin levels in the kidney and the 
plasma, and even within different compartments of the kidney; for review 
see (Kobori et al., 2007).  Additional analysis of tissue RAS parameters could 
provide further insights into the development of elevated BP and impaired 
natriuresis on a high sodium diet in Hsd11b2+/- mice. 
 
4.4.1.2 Angiotensin Dose Responses  
A tonic suppression of the RAAS in Hsd11b2+/- mice may have feedback 
effects upon the function of AT receptors, such as AT1.  Altered levels of 
circulating RAAS components could cause adaptive changes in the 
expression and/or binding properties of AT receptors in Hsd11b2+/- mice; 
these changes could be exaggerated further under high dietary sodium as the 
RAAS is further suppressed.  To investigate this theory, the BP response to 
I.V. doses of both AngI and AngII were measured in Hsd11b2+/+ and Hsd11b2+/- 
mice on both a standard and a high sodium diet.  In addition to providing 
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information about the AT receptors by using both AngI and AngII, and 
measuring the difference between the responses to each, these studies 
provided further information about ACE activity.   
AngI and II were administered in increasing doses, with any BP changes 
observed being allowed to return back to baseline measurements before the 
next injection dose.  The time frame of this experiment is not long enough to 
observe any genomic effects that the I.V. injections may cause. Therefore, all 
observations can largely be interpreted as the vasoconstrictive effects of 
AngII on the vasculature, although as it was not possible to measure heart 
rate (HR) during these experiments due to technical restraints, the 
contribution of HR changes in response to AngI and AngII administrations 
cannot be discounted. 
The BP response to AngI was significantly greater in the Hsd11b2+/- group 
compared to the Hsd11b2+/+ group on both sodium diets; however the 
response was greater for both genotypes on a high sodium diet (Figure 4.4).  
A similar pattern was observed with AngII administration, although the 
responses were always greater than with AngI (Figure 4.5).  This shows that 
although high dietary sodium is causing changes in the AT receptor response 
to AngI and AngII in both genotypes, the affect is always greater in the 
Hsd11b2+/- group.  The extent of the BP response to the AngI and II doses 
were further analysed by calculating and analysing AUC values.  On a 
standard and a high sodium diet, for both AngI and AngII, Hsd11b2+/- mice 
had a significantly greater AUC BP response compared to Hsd11b2+/+ mice.  
This shows that both genotype and sodium diet effect the BP response as 
measured in this way.  The magnitude and duration of the BP response to 
AngI and II suggests that the receptor ligand relationship is altered in 
Hsd11b2+/- mice, and this is further exacerbated by a high sodium diet. 
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Investigations by Ruan et al have revealed how AT1 receptors adapt in rats 
exposed to high or low sodium diets (Ruan et al., 1997).  These investigations 
showed that on high sodium diet there was a parallel increase in AT1 receptor 
mRNA and receptor density in afferent arterioles, implying a casual link 
between dietary sodium and AT1 receptor expression.  Overall, receptor 
expression increased two-fold on high sodium diet compared with low 
sodium diet.  Further investigations for the current studies could investigate 
whether a change in receptor density accounts for the different responses to 
AngI and II observed on different sodium diets, and also if there is a 
difference between genotypes on the same diet.  In addition, GR activation 
has been proposed to up regulate AT1 mRNA and receptor expression (Guo 
et al., 1995; Sato et al., 1994), and this presents a potential correlation between 
the observed increases in corticosterone concentration and the exaggerated 
responses to AngII on a high sodium diet in Hsd11b2+/- mice.  Thus, the 
increased concentrations of glucocorticoids in these mice may promote 
increases in AT1 receptor expression, thus explaining at least in part the 
potency of AngII bolus injections.  Furthermore, some studies have found a 
link between increased glucocorticoid levels and increased AT1 receptor 
ligand binding (Shelat et al., 1999a; Shelat et al., 1999b), although it should 
also be pointed out that others find no link between the two (Ruan et al., 
1997; Sato et al., 1994).  In addition, changes in the expression of AT2 
receptors may also be contributing to the increased vascular contractility 
observed in Hsd11b2+/- mice.  Increased AngII levels (Bonnet et al., 2001) and 
a sodium restricted diet (Siragy et al., 2000) have both been shown to increase 
AT2 receptor expression, so it is entirely possible that the suppressed RAAS 
and increased sodium intake could be having the opposite effect in the 
Hsd11b2+/- mice.  Whether the increased dietary sodium intake is modifying 
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receptor number and/or ligand binding efficiency in AT1 and AT2 receptors 
remains to be established.  Quantitative PCR and studies using AT receptor 
antagonists, such as Losartan, would help to address this.  It is also worth 
noting that there may be additional differences between the genotypes in 
terms of small resistance vessels that may also be having an effect upon the 
observed differences in their response to AngI and II.  Resistance vessels are 
the primary site of vascular resistance, the hallmark of arterial hypertension.  
AngII is involved in the contractile response to flow in resistance arteries, 
and both AngII and dietary salt can be responsible for structural changes 
within the vascular (Simon, 2004).    A study by Csiky et al demonstrated that 
in normotensive rats, 7 - 10 day treatment with a high salt diet potentiated 
the vasoconstrictor responses to AngII, independently of BP changes (Csiky 
and Simon, 1997).  The authors go on to suggest a possible mechanism for 
this change: extracellular sodium is a determinant of the transmembrane 
sodium gradient, which in turn determines the magnitude of vasoconstrictor 
responses to agonists whose mode of action includes stimulating sodium 
influx, such as AngII.  Therefore, the increases we see in vasoconstriction in 
response to AngI and II in both sets of mice may be due to these effects of a 
high sodium diet, the results of which could be magnified in Hsd11b2+/- mice 
compared to Hsd11b2+/+ mice due to differences in resistance vessel 
remodelling. 
In addition, the difference in the responses to AngI and AngII between the 
genotypes implies that there may be a difference in ACE activity and/or 
concentration.  ACE activity was investigated further by calculating the ratio 
of the AngI to AngII BP response.  This showed that the Hsd11b2+/- mice do 
not appropriately adapt their ACE activity in response to a high sodium diet 
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as the Hsd11b2+/+ mice do.  This implies a further failure of the RAAS to adapt 
appropriately to a high sodium diet in Hsd11b2+/- mice. 
  
4.4.1.3  11β-HSD2 and AT Receptors  
In addition to AngII and sodium levels potentially affecting AT receptor 
expression, it has been ascertained from preeclampsia studies that a decrease 
in 11β-HSD2 activity may also contribute towards an altered expression of 
AT receptors (Lanz et al., 2003).  In normal pregnancies, there is a resistance 
to translate high AngII plasma levels (caused by a natural RAAS activation 
during pregnancy) into increased BP.  However, this resistance is lost in 
preeclampsic pregnancies, where sensitivity to AngII increases (Gant et al., 
1973) and a higher expression of AT1 receptors is observed (Thapa et al., 
2004).  Preeclampsia has been associated with reduced levels of 11β-HSD2 
activity, linking increased sensitivity to AngII with reduced 11β-HSD2 
activity (Causevic and Mohaupt, 2007).  These effects are thought to be 
mediated via increased glucocorticoid levels (in the face of reduced 
metabolism by 11β-HSD2) up-regulating AT1 receptor expression.  Whereas 
in preeclampsia it has been suggested that high levels of AngII may be 
negatively regulating 11β-HSD2 expression via actions mediated by the AT 
receptors (Lanz et al., 2003), these observations can be translated to studies in 
the Hsd11b2+/- mice as they have a genetically modified reduction in 11β-
HSD2 activity.   
 
4.4.2 Corticosterone Regulation  
 
4.4.2.1 Body Weights and Food Intake 
The body weights of individual mice were recorded daily during the 
metabolic cage studies described in Chapter 3.   Before any experimental 
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measurements were made, the mice were given 5 days to acclimatise to being 
housed in the metabolic cages.  At the beginning of the acclimatisation 
period body weight decreased for both groups of mice.  This was not 
unexpected as mice typically lose weight upon introduction to a metabolic 
cage due to the stress of a new environment; the 5 day acclimatisation period 
was deliberately introduced to try and minimise the interference of this 
natural stress upon experimental measurements (Gomez-Sanchez and 
Gomez-Sanchez, 1991; Hoppe et al., 2009).  After 5 days the body weights of 
the mice in both groups stabilised and experimental measurements began.  
Body weights remained relatively stable during the 3 day period of control 
collections on a standard sodium diet.  However, once placed on a high 
sodium diet, the % body weight change in Hsd11b2+/- mice declined 
significantly compared to the Hsd11b2+/+ mice.  The weight loss observed in 
the Hsd11b2+/- group upon high sodium diet induction, combined with the 
observation that both groups eat similar amounts of food, implies that the 
change in sodium diet is inducing a weight-loss phenotype in Hsd11b2+/- 
mice.  This weight loss might reflect an altered fat metabolism as post-
mortem analysis of epididymal fat pads revealed that they weighed 
significantly less in Hsd11b2+/- mice than Hsd11b2+/+ mice after three weeks on 
a high sodium diet (Figure 4.9d).  Studies of mouse 11β-HSD2 expression 
sites have found no evidence of 11β-HSD2 expression in fat tissue (Moore et 
al., 2000) so this decrease is probably attributable to the overall weight loss 
phenotype.  In addition, differences in water retention are unlikely to 
account for the weight differences as both genotypes were always equal for 
water balance (Chapter 3, Figure 3.4d). 
Published studies concerning salt and glucose tolerance may help to explain 
the weight loss and smaller fat pads in Hsd11b2+/- mice on a high sodium diet.  
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There is literature linking SS and glucose tolerance (Giner et al., 2001).  Some 
studies suggest that the serum- and glucocorticoid-inducible kinase (SGK1) 
may be involved in pathogenesis of glucose intolerance as salt intake-
induced low aldosterone levels would decrease SGK1 transcription, thus 
decreasing SGK1-dependent uptake of glucose into tissues such as fat and 
liver (Boini et al., 2006; Ullrich et al., 2005).  However, as the Hsd11b2+/- mice 
will likely maintain SGK1 expression due to high circulating glucocorticoid 
levels, Hsd11b2+/- mice are unlikely to develop insulin-resistance via this 
route.  Therefore, an inappropriate over-expression of SGK1 under 
conditions of high sodium diet could be involved in the weight-loss 
phenotype observed; the opposite effect of a suppressed RAAS may occur in 
Hsd11b2+/- mice on a high sodium diet due to MR over activation by excess 
glucocorticoids.  Investigating SGK1 expression and the glucose tolerance of 
these mice may help to assess these contributions towards this salt-induced 
phenotype. In addition, the corticosterone concentrations observed in 
Chapter 3 may indicate an inability of Hsd11b2+/- mice to regulate their HPA 
axis appropriately on a high sodium diet.  This is of particular note as 
stressful situations are known to provoke weight loss.   
 
4.4.2.2 HPA Axis Testing 
A series of experiments were designed to test the HPA axis in Hsd11b2+/- mice 
and their ability to react to stressful situations on both a standard and a high 
sodium diet.  These experiments showed that a high sodium diet had no 
effect upon the production of corticosterone under conditions of acute stress.  
However, what they did highlight was a deficiency in the metabolism of 
plasma corticosterone after exposure to stress in Hsd11b2+/- mice on a high 
sodium diet.     
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A previous study in which the anxiety state and HPA axis stress reaction was 
investigated in Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- littermates showed that 
Hsd11b2-/- mice display an increased anxiety phenotype compared to 
Hsd11b2+/+ mice (Holmes et al., 2006).  The Hsd11b2+/- mice displayed no 
anxiety phenotype, and neither the Hsd11b2+/- nor the Hsd11b2-/- mice had any 
changes in HPA axis reactivity testing for corticosteroid or ACTH levels 
compared with Hsd11b2+/+ littermates.  However, it is important to point out 
that these experiments were carried out on a standard sodium diet and so it 
was deemed important to investigate this on a high sodium diet.  Whilst 
suggesting there is a stress phenotype associated with 11β-HSD2 ablation, 
but not reduced activity, it should be pointed out that these studies also 
found a significant difference between the birth weights of the three 
genotypes.  That is, there was a direct correlation between 11β-HSD2 activity 
and birth weight, with Hsd11b2+/+ mice being heaviest, Hsd11b2-/- mice the 
lightest, and Hsd11b2+/- mice falling in the middle.  This suggests that 
Hsd11b2+/- mice may have a body weight phenotype, as reflected by 
epididymal fat pad weight analysis.  Also, the stress tests used here were 
measurements of acute stress, not chronic exposure as is taking place with 
exposure to a high sodium diet.  Therefore, the possibility of a chronic stress 
phenotype relating to body weight changes may well still be relevant.   
 
4.4.2.3 Glucocorticoid Metabolism 
The emergence of reduced glucocorticoid metabolism under conditions of 
impaired 11β-HSD2 function is highlighted by studies in SAME patients 
measuring urinary levels of cortisol and cortisone metabolites (5α- and 5β-
tetrahydrocortisol (THF) and tetrahydrocortisone (THE), respectively) 
(Monder et al., 1986).  An increased THF/THE ratio is routinely used as a 
biochemical marker of SAME as the higher ratio is associated with reduced 
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11β-HSD2 activity.  This can be interpreted as more cortisol is being 
metabolised via this pathway due to deficiencies in the 11β-HSD2 
metabolism to corticosterone route, therefore the ratio of cortisol metabolite 
to corticosterone metabolite is greater. 
A reduction in corticosteroid metabolism in Hsd11b2+/- mice (therefore 
leading to the increased concentrations observed in both plasma and urine) 
could reflect reduced 11β-HSD2 enzyme activity.  However, since this 
activity is not further modified by high sodium intake (Figure 3.1), it is not 
clear why differences in corticosterone levels are only evident on a high 
sodium diet.  Therefore, if the ability of 11β-HSD2 to metabolise 
corticosterone has not changed in this setting, then some other reaction to the 
increased sodium intake must be causing corticosterone levels to increase.  
Of particular interest is the observation that corticosterone concentrations 
increase in Hsd11b2+/+ mice as well as Hsd11b2+/- mice on a high sodium diet, 
although not to the same extent (Figure 3.6).  This suggests that the high 
sodium diet per se may enhance corticosterone levels, an effect amplified by 
low 11β-HSD2 activity.  
Whatever the cause(s) of the corticosteroid increase it appears that in 
Hsd11b2+/- mice, under normal dietary conditions, the reduction in 
corticosteroid metabolism is not sufficient to cause a measurable phenotype 
in terms of BP.  Under these conditions, the reduction in 11β-HSD2 activity is 
presumably compensated for by other forms of metabolism, such as the 5α- 
and β-reductases.  However, when the levels of corticosterone are increased 
on a high sodium diet, the compensatory pathway of metabolism can no 
longer sustain the level of metabolism required to maintain a normal 
phenotype, and the Hsd11b2+/- mice present with an elevated BP and 
impaired natriuresis.  To address the mechanism of this effect further, it will 
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be important to establish the effect of increased sodium intake upon other 
factors involved in both glucocorticoid production and metabolism, such as 
ACTH levels and 5α- and β-reductase metabolites, respectively.  It will also 
be important to investigate other potential consequences of increased sodium 




In summary, the studies described here show that the regulation of both 
aldosterone and corticosterone appears to be deregulated in Hsd11b2+/- mice 
on a both standard and a high sodium diet.  On a standard sodium diet, this 
does not result in a phenotype (as far as is measured within the experiments 
presented here); the deregulation of both steroids is exacerbated by a high 
sodium diet, and it is only then that the natriuresis and BP phenotypes of the 
Hsd11b2+/- mice present.  This suggests that high levels of dietary sodium are 
inducing changes in these mice that render them unable to cope 
physiologically, as they could before on a standard sodium diet, in the face of 
reduced 11β-HSD2 enzyme activity.  Mineralocorticoids and glucocorticoids, 
via their many physiological effects, undoubtedly play an important role in 
the mechanism(s) of the SS phenotype of Hsd11b2+/- mice, although exactly 














There is strong evidence from a number of studies that SS BP may be linked 
to renal oxidative stress (Manning et al., 2005; Taylor et al., 2006; Tian et al., 
2005). Oxidative stress-induced changes in intracellular reductive-oxygen 
reaction balance may determine the ligand specificity of transcription factor 
regulation (Liu et al., 2005; Zhang et al., 2002).  A link between sodium 
intake, oxidative stress and MR ligand specificity begins to emerge that may 
further explain why reduced 11β-HSD2 activity causes a SS BP increase. 
 
5.1.1 Oxidative Stress  
 
Reactive oxygen species (ROS) are highly reactive, short-lived derivatives of 
oxygen metabolism that are produced in all biological systems and play an 
important role physiologically.   Examples of endogenously produced ROS 
include superoxide radical (O2.-), hydrogen peroxide (H2O2), and nitric oxide 
(NO), which all play important roles in vascular biology (Roberts and 
Sindhu, 2009).  ROS are normally inactivated and rendered harmless by a 
series of endogenous antioxidant enzymes (such as superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase (GPX)) and also by dietary 
antioxidant compounds (such as Vitamin C and E).  Oxidative stress occurs 
when the net amount of ROS produced exceeds the buffering capacity of the 
antioxidants available; this can be the result of increased ROS production, 
decreased availability of antioxidants, or a combination of the two.  Under 
conditions of oxidative stress, elevated ROS levels can act to enhance lipid 
peroxidation, cause DNA damage and induce protein modifications, thus 
leading to cellular dysfunction.   
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5.1.2 Oxidative Stress and Hypertension 
 
Oxidative stress has been well documented in models of AngII-dependent 
hypertension (Kawada et al., 2002; Wilcox, 2002).  However, there is also 
substantial evidence of oxidative stress in the development hypertension 
where the RAAS is suppressed (Beswick et al., 2001; Nicod et al., 2000).  A 
link between oxidative stress and high BP causing renal inflammation and 
damage has also been demonstrated in models of SS hypertension, such as 
the Dahl SS rat (Meng et al., 2002; Tian et al., 2008).  These studies may be 
relevant in the Hsd11b2+/- model of SS hypertension where the RAAS has 
been shown to be suppressed on a high sodium diet (Chapter 4).   
Although ROS are short-lived, they leave a detectable trace of modified 
oxidative products which act as surrogate markers for oxidative stress.  Two 
such markers, the F2-isoprostanes and NADPH oxidase subunits, are up 
regulated in different models of experimental hypertension (Paravicini and 
Touyz, 2008). The F2-isoprostanes are a family of eicosanoids produced by 
the oxidation of arachidonic acid by ROS that are frequently used as marker 
of oxidative stress in vivo (Davi et al., 1999; Pratico et al., 2001; Roberts and 
Morrow, 2000).  NADPH oxidase is a major producer of ROS in both the 
kidney and the vasculature.  NADPH oxidase consists of a number of 
subunits, both cytosolic and membrane-bound, which form the functional 
enzyme complex.  These include p47phox, p67phox (both cytosolic), 
gp91phox, Nox1, Nox4 and p22phox (all membrane-bound).  Different 
subunits have different expression patterns throughout the kidney (for 
review of kidney NAPDH oxidases see (Gill and Wilcox, 2006)).  NADPH 
oxidase can be regulated by vasoconstrictive hormones, such as AngII, as 
well as by growth factors and mechanical stimuli such as shear stress and 
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stretch (Lassegue and Clempus, 2003).  In addition, pharmacological 
approaches suggest that the effect of RAAS activation in AngII-dependent 
hypertensive models may in part be attributable to MR in Nox2-/- mice (Johar 
et al., 2006) and Ren-2 transgenic rats (Lastra et al., 2008). 
 
5.1.3 Increased Salt Loading and Oxidative Stress  
 
A study where a high sodium diet was fed to normal rats who did not 
develop SS hypertension highlighted a potential direct link between high 
sodium intake and renal oxidative stress (Kitiyakara et al., 2003).  
Measurements of urinary markers of oxidative stress (8-isoprostane (8-iso-
PGF2α) and malonyldialdehyde) and real-time PCR assessment of NADPH 
oxidase subunits showed that salt loading per se was inducing oxidative 
stress in the kidneys of normal rats.  Another more recent study reinforces 
these observations as again high sodium loading in rats resulted in increase 
urinary excretion of 8-iso-PGF2α and increases in both NADPH oxidase 
subunit expression and enzyme activity (Johns et al., 2010).   
 
5.1.4 Treatment of Hypertension with Antioxidants 
 
Further evidence of the potential importance of oxidative stress and high BP 
comes from studies where hypertension has been successfully treated with 
antioxidants (for review see (Manning et al., 2005).  In spontaneously 
hypertensive rats (SHR) a two week administration of the SOD mimetic 
antioxidant 4-hydroxy-2, 2, 6, 6-tetramethyl piperidinoxyl (TEMPOL) 
reduced both BP and renal excretion of F2-isoprostanes (Schnackenberg and 
Wilcox, 1999).  TEMPOL treatment of DOCA-salt hypertensive rats, along 
with another antioxidant pyrrolidinedithiocarbamate (PDTC), attenuated 
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both the high BP and renal inflammation observed in this hypertensive 
model (Beswick et al., 2001).  In addition to the successes of SOD-mimetic 
antioxidants, the administration of Vitamin C and E to Dahl SS rats on a high 
sodium diet significantly reduced renal O2.- release, blood pressure, and renal 




The contribution of oxidative stress towards the SS phenotype of Hsd11b2+/- 
mice was investigated in conscious and anaesthetised mice.  Urinary levels of 
the oxidative stress marker 8-iso-PGF2α were measured in mice on a 
standard and then a high sodium diet using the metabolic cage approach as 
described previously.  Parallel studies were performed in which mice 
received the antioxidant drug TEMPOL in combination with a high sodium 
diet.  Renal clearance experiments were also performed to investigate BP and 
renal function.  This is of particular relevance as changes in local oxidative 
stress balance have been shown to be involved in the regulation of receptor-
ligand activation of the GR (Okamoto et al., 1999; Tanaka et al., 1999), a 
dynamic that is altered in Hsd11b2+/- mice due to improved glucocorticoid 




5.2.1 Metabolic Cage Studies 
 
The daily urinary excretion of the oxidative stress marker 8-iso-PGF2α was 
measured in conscious Hsd11b2+/+ and Hsd11b2+/- mice first on a standard, and 
then on a high, sodium diet.  8-iso-PGF2α levels were similar between the 
two genotypes on a standard sodium diet (Figure 5.1).   
 
Urinary 8-Isoprostane Levels 
 
 









































































on a standard and a high sodium diet (n = 4 for both groups).  There was no difference 
between the two groups on either sodium diet.  High sodium diet causes a significant 
increase in 8-isoprostane levels on Day 1; P < 0.001. Data are means ± SEM. 
 
Transition to a high sodium diet caused a substantial increase in urinary 8-
iso-PGF2α excretion in both genotypes and there was no significant 
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difference between the two genotypes during the time points investigated.  
These results suggested that a high salt diet was causing oxidative stress in 
both genotypes, and the effect of the antioxidant drug TEMPOL was 
therefore measured. 
TEMPOL did not affect sodium excretion on a standard sodium diet in either 
Hsd11b2+/+ or Hsd11b2+/- mice (Figure 5.2a).  The natriuretic response to high 
sodium feeding was unaffected by TEMPOL in Hsd11b2+/+ mice.  Hsd11b2+/- 
mice showed an improved sodium excretion and no longer exhibited a 
period of positive sodium balance (Figure 5.2b and c compared with Figure 
3.3b and c, Chapter 3).   
TEMPOL treatment did not change the 24 hour urine flow rate water on a 
standard sodium diet in either genotype, with both Hsd11b2+/+ and Hsd11b2+/- 
mice excreting similar volumes (Figure 5.3a).  The urine flow rate on a high 
sodium diet is similar for the two groups during TEMPOL treatment (Figure 
5.3b), and in agreement with this, water balance is not significantly altered 
by the change in dietary sodium content during TEMPOL treatment (Figure 
5.3c).   
 
5.2.2 Renal Clearance Studies 
 
After three weeks on a high sodium diet with TEMPOL administration, mice 
were prepared for renal clearance surgery.  MABP measurements showed 
that TEMPOL treatment attenuated the BP increases observed in Hsd11b2+/- 
mice on a high sodium diet; both genotypes had similar values (Figure 5.4a 
compared to Figure 3.7).  In terms of renal hemodynamics, TEMPOL 
treatment also appeared to attenuate the increased GFR previously observed 
in Hsd11b2+/- mice compared to Hsd11b2+/+ mice on both a standard and a high 
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Figure 5.2.  TEMPOL treatment metabolic cage study (n = 8 for both groups).  Urinary 
sodium excretion a) on a standard sodium diet before and after TEMPOL treatment, and b) 
recorded daily on a standard and high sodium diet with TEMPOL treatment.  TEMPOL 
treatment on a standard sodium diet had no effect upon urinary sodium excretion.  High 
sodium diet caused a significant increase in urinary sodium excretion (P < 0.001); there was 




 mice.  c) Sodium balance was calculated 
using sodium intake and urinary sodium excretion over 3 day periods.  There was no 
significant difference between genotypes during any period.  Data are means ± SEM for a) 
and b), and as the median, interquartile range and full range for c). 
 
 
c) Sodium Balance during TEMPOL Treatment 
b) Daily Sodium Excretion during TEMPOL Treatment 
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Figure 5.3.  TEMPOL treatment metabolic cage study (n = 8 for both groups).  Urine flow 
rate (UFR) a) on a standard sodium diet before and after TEMPOL treatment, and b) 
recorded daily on a standard and high sodium diet with TEMPOL treatment.  TEMPOL 
treatment on a standard sodium diet had no effect upon UFR.  High sodium diet caused a 





 mice.  c) Water balance was calculated using drinking water intake and urinary 
UFR over 3 day periods.  There was no significant difference between genotypes during any 
period.  Data are means ± SEM for a) and b), and as the median, interquartile range and full 
range for c). 
b) Daily Urine Flow Rate during TEMPOL Treatment 
c) Water Balance during TEMPOL Treatment 
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Figure 5.4.  Measurements made during renal clearance surgery after 3 weeks on a high 
sodium diet with TEMPOL treatment of a) mean arterial BP (MABP) and b) glomerular 




 mice have similar 
values for MABP and GFR.  Data are means ± SEM. 
 
sodium diet (Figure 5.4b compared to Figure 3.8a, Chapter 3).  Measurements 
of  the  urine  excretion  and  plasma  concentration of sodium and potassium 
were also obtained.  These were not different for any of the values between 
the genotypes on a high sodium diet with TEMPOL treatment (Figure 5.5a - 
d).   
After baseline measurements for MABP, GFR, and plasma electrolytes had 
been made, measurements were repeated in the same mice after an I.V. dose 
of the ENaC blocker amiloride. Differences in MABP and GFR measurements 
after amiloride administration were not significantly different between the 
two genotypes (Figure 5.6a and b). Differences in the urinary excretion of 
sodium and potassium were also measured; there was no difference in terms  
b) GFR 
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a) Urinary Sodium         b) Plasma Sodium 
 









































Figure 5.5.  Urine and plasma electrolytes (n = 8 for both groups).  Measurements made 
during renal surgery after 3 weeks on a high sodium diet with TEMPOL treatment of a) 
urinary sodium, b) plasma sodium, c) urinary potassium, and d) plasma potassium 
concentrations.  There is no significant difference in the plasma and urinary concentrations 




 mice.  Data are means ± 
SEM. 
 
of potassium excretion, but Hsd11b2+/+ mice exhibited a significantly greater 
increase in urinary sodium excretion after amiloride administration than 
Hsd11b2+/- mice (Figure 5.6c and d). 
 
c) Urinary Potassium       d) Plasma Potassium 
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Figure 5.6.  The effects of amiloride administration during renal surgery after 3 weeks on a 
high sodium diet with TEMPOL treatment upon a) MABP, b) GFR, c) urinary sodium 
excretion, and d) urinary potassium excretion (n = 8 for both groups).  There is no significant 
difference in the effect of amiloride upon MABP, GFR, or urinary potassium excretion 
between the two groups.  Amiloride causes significantly more sodium excretion in 
Hsd11b2
+/+
 mice compared to Hsd11b2
+/-
 mice, where it has little effect.  * P < 0.05.  Data 
are means ± SEM. 
 
5.2.3 TEMPOL Effects upon 8-Iso-PGF2α Urinary Excretion 
 
To establish if the observed improvements in the SS phenotype of Hsd11b2+/- 
mice during TEMPOL treatment was a consequence of reduced renal 
oxidative stress, 8-iso-PGF2α levels were measured in 24 hour urine 
collections. 
On a standard sodium diet, TEMPOL administration caused no difference in 
8-iso-PGF2α excretion between Hsd11b2+/+ and Hsd11b2+/- mice (Figure 5.7a).  
On Day 1 of the high sodium diet, there was no significant change in 8-iso-  
c) Urinary Sodium    d) Urinary Potassium 
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a) Urinary 8-Isoprostane Levels during TEMPOL Treatment  



















































































































































































































 mice only on both diets (n = 4 for both genotypes). There was no difference 
between the two groups on either sodium diet. High sodium diet causes a significant 
increase in 8-isoprostane levels on Day 2 (P < 0.001), with Day 1 not differing significantly 
from the standard sodium results. TEMPOL treatment had an overall significant effect upon 
8-isoprostane excretion in Hsd11b2
+/+
 mice on different sodium diets (P < 0.001), with post-
hoc significance at Day 2 and 7 on a high sodium diet. TEMPOL also had an overall 
b) Urinary 8-Isoprostane Levels during TEMPOL Treatment - Hsd11b2+/+ 
c) Urinary 8-Isoprostane Levels during TEMPOL Treatment - Hsd11b2+/- 
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significant effect upon 8-isoprostane excretion in Hsd11b2
+/-
 mice between the two sodium 
diets (P < 0.001), with post-hoc significance at Day 2 on a standard sodium diet and Day 7 
on a high sodium diet.  * P < 0.05; ** P < 0.01; *** P < 0.001.  Data are means ± SEM. 
 
PGF2α levels compared to on a standard sodium diet for either group. On 
Day2 of the high sodium diet, there was a significant increase in 8-iso-PGF2α 
excretion that continued on Day 7 and Day 14. 
The 8-iso-PGF2α levels on the standard and high sodium diets were then 
compared within the individual genotypes.  There was no significant effect 
of TEMPOL treatment on the 8-iso-PGF2α excretion on a standard sodium 
diet or on Day 1 of the high sodium diet for either Hsd11b2+/+ and Hsd11b2+/- 
mice (Figure 5.7b and c, respectively).  However, both groups showed an 
unexpected trend for increased levels of 8-iso-PGF2α after Day 2 on the high 




This chapter describes a salt-induced increase in urinary excretion of the 
oxidative stress marker 8-iso-PGFα in both Hsd11b2+/+ and Hsd11b2+/- mice.  
TEMPOL administration in conjunction with a high sodium diet prevented 
the development of both impaired natriuresis and increased BP in Hsd11b2+/- 
mice, but did not alter the excretion of 8-iso-PGFα. 
 
5.3.1 A High Sodium Diet Increases Oxidative Stress 
 
The salt-induced increase in the urinary excretion of 8-iso-PGF2α was similar 
in both groups, and was not exacerbated by reduced enzyme activity of 11β-
HSD2.  Therefore, it is the high sodium diet per se that is causing the 
perceived increases in oxidative stress and not a secondary effect of the 
hypertension observed in Hsd11b2+/- mice on a high sodium diet.  This is in 
agreement with previous studies where a high sodium diet has been shown 
to cause oxidative stress independently of increased BP (Johns et al., 2010; 
Kitiyakara et al., 2003).  The identification of increases in additional markers 
of oxidative stress, such as using real-time PCR to quantify NADPH Oxidase 
subunits in the kidney, would further support this finding that a high salt 
diet induces oxidative stress in these mice. 
 
5.3.2 Antioxidant Administration Rescues Hsd11b2+/- Salt-
Sensitive Phenotype  
 
Administration of TEMPOL was used in an attempt to provide anti-oxidant 
therapy. TEMPOL is a small molecule cell-permeable SOD  mimetic that 
catalyses the dismutation of O2.- into metabolic oxygen & H2O2, and acts as an 
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important antioxidant defence in cells (for review see (Wilcox and Pearlman, 
2008)).  Many of the phenotypes associated with salt-loading in Hsd11b2+/- 
mice were attenuated by TEMPOL administration.  Surprisingly, TEMPOL 
actually increased ENaC-mediated sodium reabsorption in the Hsd11b2+/+ 
mice on a high sodium diet with TEMPOL administration (Figure 5.6c).  This 
suggests that TEMPOL administration was somehow causing ENaC not to be 
down regulated in Hsd11b2+/+ mice on a high sodium diet.  Analysis of 
plasma aldosterone and glucocorticoid levels in these mice during TEMPOL 
treatment may provide further insights as to why this may be.   
Overall, these studies showed that administration of TEMPOL at the same 
time as the high sodium diet was therapeutically successful.  However, this 
effect cannot be attributed to the restoration of a favourable REDOX state as 
TEMPOL did not reduce 8-iso-PGFα excretion in either group, and this was 
even increased at some time points.  In many studies of oxidative stress-
related hypertension, TEMPOL administration is sufficient to reduce both BP 
and 8-iso-PGF2α levels (Brands et al., 2004; Knight et al.; Schnackenberg and 
Wilcox, 1999; Welch et al., 2005).  However, some studies also describe the 
ability of TEMPOL to reduce BP without effecting 8-iso-PGF2α levels.  
Williams et al reported that TEMPOL administration in Sprague-Dawley rats 
had no effect upon plasma 8-iso-PGF2α levels after three days on a high 
sodium diet compared to no-TEMPOL controls, despite lowering arterial BP; 
after seven days, 8-iso-PGF2α levels were actually increased compared to 
controls (Williams et al., 2004).  A different study using TEMPOL to treat 
ACTH-induced hypertension followed a similar pattern. TEMPOL treatment 
at day 8 of ACTH treatment reversed hypertension and pre-treatment for 
four days before ACTH administration partially prevented it, but 8-iso-
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PGF2α levels remained elevated under both circumstances (Zhang et al., 
2003).   
There are several possible explanations for these findings. SOD mimetics, 
such as TEMPOL, may cause accumulation of H2O2 in the kidney (Makino et 
al., 2003).  This potentially happens due to the method of SOD action.  SODs 
work to reduce ROS by catalysing O2.- to metabolic oxygen and H2O2.  H2O2 is 
a much less reactive ROS than O2.-, and unlike O2.- it can diffuse across cell 
membranes avoiding excessive accumulation in regions of production 
(Antunes and Cadenas, 2000).  This means that a high concentration of 
TEMPOL may be leading to reduced levels of highly reactive O2.- at the 
expense of increased levels of less-reactive H2O2.  The increased levels of 
H2O2 may then result in the high levels of 8-iso-PGF2α excretion observed 
during TEMPOL treatment in both Hsd1b2+/+ and Hsd11b2+/- mice.  The dosing 
of TEMPOL chosen for this study (2 mmol/l administered on drinking water 
– see Materials and Methods Chapter) has been previously used in many 
published studies of TEMPOL administration in rats; perhaps it is too high a 
dose for studies in mice and caused increased production of H2O2 which lead 
to increased levels of 8-iso-PGF2α.   
In addition, some studies suggest that TEMPOL administration may decrease 
central sympathetic nerve responses, which could also explain the rescue of 
increased BP and impaired natriuresis without reducing 8-iso-PGF2α levels 
(Lu et al., 2004; Shokoji et al., 2003); sympathetic nerve function in these 
studies could be assessed by measuring the levels of catecholamines in 24 
hour urine collections.  However, other studies in which TEMPOL rescues 
increases in blood pressure in spontaneously hypertensive rats show 
catecholamine levels not to be affected by TEMPOL administration (Welch et 
al., 2005).  It will be important to measure the concentration of 
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catecholamines in the urine of Hsd11b2+/+ and Hsd11b2+/- mice before and 
during TEMPOL treatment to confirm the action of TEMPOL rescue in these 
experiments.  TEMPOL treatment has also been shown in numerous animal 
studies to restore the agonist-induced endothelium-dependent vasodilation, 
and this may well be contributing to the anti-hypertensive effects seen in 
these experiments (Simonsen et al., 2009).  In addition, the modulation of 
potassium channels has also been suggested as a mechanism for the 
antihypertensive actions of TEMPOL. TEMPOL-induced vasodilation was 
enhanced in perfused mesenteric arteries from DOCA salt hypertensive rats, 
and these effects could be reduced by application of a vascular large-
conductance calcium-activated potassium (BKCa) channel blocker (Xu et al., 
2005).  In addition, TEMPOL may also enhance vasodilation through 
modulation of ATP-sensitive potassium channels (Chen et al., 2007).  This 
may be particularly relevant to the Hsd11b2+/- model as potassium 
homeostasis has been shown to be altered (see Chapter 3).  
These studies could also be repeated using a different antioxidant drug to see 
if the rescue effects of TEMPOL can be replicated.     
 
5.3.4 11β-HSD2, REDOX Balance and MR Regulation 
 
The suggestion that oxidative stress caused by a high sodium diet may be 
contributing to the SS phenotypes of Hsd11b2+/- mice is particularly 
interesting in terms of 11β-HSD2 activity and MR ligand-activation 
regulation, and may be a reason why the SS phenotypes only occur on a high 
sodium diet.  Studies using cloned 11β-HSD2 protein have shown that in 
vitro conversion of cortisol to corticosterone displays a linear dose response 
(Ferrari et al., 1996).  Glucocorticoids therefore technically have “improved” 
access to MR in the Hsd11b2+/- mice at all times, but this appears to have no 
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physiological consequences under normal sodium diet conditions.  Further 
investigations studying the binding of tracer 3H-aldosterone in kidney, colon, 
heart and hippocampal extracts, suggest that MR are always highly occupied 
by glucocorticoids, but not always activated (Funder and Myles, 1996).  This 
poses the question why does glucocorticoid activation of MR, and the 
consequential detrimental effects, only occur when the system is exposed to 
increased levels of sodium?  A possible explanation begins with studies 
showing a link between increased salt intake and renal oxidative stress (Gill 
and Wilcox, 2006).  If a high sodium diet changes the oxidative stress state of 
the kidney, then the local REDOX (reduction-oxidation reaction) balance 
would be altered.  It has been suggested that changes in the REDOX balance 
of MR and 11β-HSD2 target tissues may alter the ability of glucocorticoids to 
activate the MR (Funder, 2005).  That is, under a normal REDOX state, 
glucocorticoids can occupy MR, but do not necessarily activate them. 
However, when something acts to change the intracellular REDOX state, 
such as high sodium diet, this permits glucocorticoids to activate the MR.   
REDOX state is also affected by the balance between reduced and oxidised 
molecular pairs, including NAD(P)H/NAD(P).  This is a balance that will be 
affected locally by a reduced activity of 11β-HSD2, as the conversion of 
cortisol to cortisone by 11β-HSD2 requires the reduction of NAD to NADH.  
It has been estimated that under resting conditions the intracellular levels of 
NAD are approximately 700-fold greater than NADH, and that generation of 
NADH by 11β-HSD2 can produce major changes to this ratio (Funder, 2004).  
In a physiological situation where the conversion of cortisol to cortisone is 
reduced, such as the Hsd11b2+/- mice, the local REDOX balance will be altered 
compared to normal.  And if excessive ROS is being produced under 
conditions of a high sodium diet, these two factors together may contribute 
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towards MR transcriptional activation becoming altered due to a REDOX 
imbalance, thus permitting glucocorticoids to cause unregulated increases in 
MR activity.  The REDOX-sensitive activation of other transcription factors 
has previously been demonstrated, such as the carboxyl-terminal binding 
protein (CtBP) (Fjeld et al., 2003; Liu et al., 2005; Zhang et al., 2002).  In 
addition, in vitro studies showing REDOX-dependent regulation of GR 
nuclear import increase the possibility that MR activation may be regulated 




In summary, these studies show that a high sodium diet is inducing 
oxidative stress in both Hsd11b2+/+ and Hsd11b2+/- mice, and that treatment 
with the antioxidant TEMPOL alleviates the SS phenotypes of Hsd11b2+/- 
mice.  This suggests a direct link between salt intake, the REDOX balance of 
11β-HSD2 expressing cells, and the ability of glucocorticoids to activate MR, 
as the SS phenotype of Hsd11b2+/- mice.  This is particularly relevant as 
previous studies have suggested that MR is always occupied by 
glucocorticoids, but not always activated.  REDOX balance may work in 
synergy with 11β-HSD2 to prevent MR activation by glucocorticoids under 
normal circumstances, but when REDOX balance is altered, it acts as a 





Chapter 6 Part 1 
 






The expression of 11β-HSD2 in sites other than the kidney could have 
important contributions to the phenotypes observed in the Hsd11b2+/- SS 
model described in earlier chapters, and also in SAME patients and the 
Hsd11b2+/+ mouse model.  In order to dissect the contributions made towards 
the phenotype by reduced or removed 11β-HSD2 activity at these different 
sites of expression, a targeting construct was developed to allow for 
conditional spatial deletion of the Hsd11b2 gene by homologous 
recombination.  This was achieved by employing Cre/loxP recombinase 
technology (for reviews see (Branda and Dymecki, 2004; Ryding et al., 2001)),  
which requires the flanking of the region of genomic DNA that encodes for 
the functional protein of interest by 2 loxP sites.  The gene of interest is then 
said to be “floxed”. When the 2 loxP sites are in the same orientation, Cre (a 
site-specific bacterial recombinase) can recombine the DNA strands on either 
side of the floxed region, thus deleting the floxed gene (Ghosh and Van 
Duyne, 2002).  Expression of Cre recombinase can be regulated spatially or 
temporally, by placing it under the transcriptional control of either a tissue-
specific or an inducible promoter.  Thus, when the mouse with a floxed gene 
of interest is crossed with a transgenic mouse expressing Cre recombinase in 
a tissue or cell-type specific manner, the resulting offspring will have 
conditional deletion of the gene of interest.  Expression of the gene will be 
normal in all other expression sites other than that targeted by Cre 
recombinase expression. This chapter describes the molecular techniques 
used for building a transgenic mouse model with a floxed Hsd11b2 gene.   
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6p1.2 Results  
 
6p1.2.1 Targeting Construct Design 
 
6p1.2.1.1 Clone pS141 
The plasmid clone pS141 (previously derived in the research group from 
bacterial artificial chromosome (BAC) RP23-410B24) was used to generate the 
original Hsd11b2-/- mouse model (Kotelevtsev et al., 1999).  The pS141 clone is 
15 kilo bases (Kb) in length, and spans the entire Hsd11b2 gene, as well as 
additional upstream and downstream areas.  This clone was already 
available within the research group (a kind gift from Dr. Yuri Kotelevstev), 
and had been previously transformed into a commercially available 
pBluescript vector (Stratagene), and was used to develop the new Hsd11b2 
floxed construct.  The pS141 clone was transformed into competent E. coli 
cells; positive uptake of the pS141 was confirmed by ampicillin-resistance, 
which is conferred by the pBluescript vector.  Positive colonies were grown 
in liquid broth (LB) culture, and DNA from these was purified (as described 
in Materials and Methods Chapter). 
Approximately 20 Kb of the RP23-410B24 BAC sequence (which spans the 
15Kb genomic clone pS141) was analysed by a web tool 
(http://tools.neb.com/NEB cutter2) to generate a map of restriction enzyme 
sites.  This was subsequently used to design a step-by-step construct building 
strategy (Figure 6.1).  To begin with, the purified pS141 plasmid DNA was 
digested with the restriction enzyme XbaI to separate out the founding sub-







Hsd11b2 wild type allele 
Hsd11b2 floxed allele 




Figure 6.1. Hsd11b2 Floxed Targeting Construct.  a) Hsd11b2 floxed construct design.  b) 



















































































HSD2 exons ATP6V0D1 exons Neomycin cassette LoxP site FRT site Digest site
b) Schematic Flow Diagram of hsd11b2 Floxed Targeting Construct 
Construction 
 
hsd11b2 floxed allele 
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6p1.2.1.2 Upstream Recombination Arm 
The pS141 sub-clone that was to become the upstream recombination arm 
(URA) initially contained Hsd11b2 exon 1 with both upstream and 
downstream intron sequence (labelled as “1” in Figure 6.1).  Exon 1 was 
separated from this sub-clone by a SacI restriction enzyme digest, and put 
aside for future use as a 5 prime end (5’) external probe (EP) for detecting 
homologous recombination of the completed construct.  The sub-clone 
(labelled “1a” in Figure 6.1) now contained sequence from intron 1.  A 
fragment containing the upstream loxP site and a neomycin resistance 
cassette was isolated from plasmid pL451 (Chapter 2; Figure 2.4) (Liu et al., 
2003) by a ClaI/NotI double restriction enzyme digest.  The neomycin 
resistance cassette was flanked by two FRT sites.  The FRT/Flip recombinase 
system is analogous to the loxP/Cre recombinase system, and therefore 
permits the selectable removal of the neomycin cassette from the targeting 
construct if required.  The isolated fragment containing these factors was 
inserted into the URA sub-clone at an open ScaI restriction site by a blunt-
ended ligation.  The URA sub-clone has three ScaI restriction sites, so 
insertion at the correct site had to be achieved by a partial digest to attain a 
linearised plasmid (Figure 6.2b).  Insertion at the correct ScaI restriction site 
was subsequently identified by diagnostic restriction digest analysis. 
 
6p1.2.1.3 Floxed Region and Downstream Recombination Arm  
Exons 2 – 5 of the Hsd11b2 gene had been chosen as the region to be removed 
under a Cre-loxP recombination event as deletion of this region in the 
original knock-out  mouse  had  been  show  to be  appropriate  for  full  
protein  ablation (Kotelevtsev et al., 1999).  The pS141 sub-clone containing 
exons 2 – 5 (labelled as “2” in Figure 6.1) required the insertion of a 
downstream loxP site to become the region to flox (R2F).     This was achieved 
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Figure 6.2. Hsd11b2 Floxed Construct Assembly. Agarose gel electrophoresis separation of 
URA sub-clone ScaI restriction enzyme partial digest for subsequent insertion of loxP-FRT-
Neomycin cassette by ligation.  5.5 Kb represents linearised DNA fragment, which was 
consequently excised from gel and DNA purified. Restriction digest times in minutes are 
illustrated along the top of figure. 
 
using the Linker Tailing Method (Lathe et al., 1984), as detailed in the 
Materials and Methods chapter. Briefly, forward and reverse transcribing 
oligonucleotides were designed to encode for a 34 bp loxP site, and a novel 3 
prime (3’) BamHI restriction site.  The ends of the oligonucleotides were 
designed to be compatible with an open BglII restriction site, and also to 
introduce a deliberate bp change to the original BglII restriction site to render 
it un-cleavable i.e. to destroy it.  The R2F sub-clone was opened at a BglII 
restriction site and the loxP-BamHI oligonucleotides were synthesised and 
inserted.  Correctly orientated clones were firstly identified by diagnostic 
restriction digest analysis, and loxP site orientation identified by bp 
sequencing.  The finished R2F insert was removed from its vector backbone 
by an XbaI restriction digest, and ligated into the downstream recombination 
5.5 Kb 
Ladder 5 10 15 20 25 30 40 35 45 50 55 60 90 120 




arm sub-clone (DRA; labelled as “3” in Figure 6.1) opened at its extreme 5’ 
XbaI restriction site.   
The DRA sub-clone contained exons 5 – 8 of the neighbouring ATP6V0D1 
gene (Pietrement et al., 2006) and required no further modifications.  The 
ATP6V0D1 gene runs in the opposite orientation to Hsd11b2, and the 
terminal exons of the gene are separated by only a short intron sequence (less 
than 1Kb).  As this sequence has the potential to contain important 
regulatory elements for the transcription of either or both genes, the decision 
was made to include this segment and ATP6V0D1 exons 5 - 8 in the DRA.  
The decision was also made to keep modifications within this region to a 
minimum during targeting construct building. 
The ligation of the R2F insert into the DRA was achieved by partial digestion, 
as described before with the URA, as the DRA has two XbaI restriction sites.  
The R2F/DRA insert was then excised from its vector backbone by another 
XbaI partial restriction digest, and ligated into the URA opened at an 
extreme 3’ SpeI restriction site.  This plasmid was then linearised by a SmaI 
restriction digest to give the final Hsd11b2 floxed targeting construct. 
 
6p1.2.1.4 5’ and 3’ External Probes 
5’ and 3’ EPs are required in order to verify homologous recombination of 
the targeting construct into the mouse genome.  This was performed by 
Southern hybridisation, which will be discussed in more detail later. The EPs 
must recognise an area out with the targeting construct so that they can 
distinguish between genomic DNA with and without the insertion of the 
targeting construct.  Probes were designed to give a different sized product 
for hybridisation depending upon whether the allele was wild type or gene 
targeted for Hsd11b2.   The probes were made mostly from exon sequence as 
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this is more sequence specific than intron sequence, and thus less likely to 
result in non-specific hybridisation and a false or ambiguous result.   
Briefly, the 5’ EP contained Hsd11b2 exon 1 and was isolated from the same 
pS141 sub-clone as the URA (discussed in section 6p1.2.2; Figure 6.1).  This 
was “trimmed” further to contain less non-specific intron sequence by 
isolating exon 1 with an XhoI/HpaI double restriction enzyme digest.  The 3’ 
EP was isolated directly from a pS141 sub-clone (labelled “4” in Figure 6.1) 
and contained exon 4 of the ATP6V0D1 gene.  The 3’ EP was also “trimmed” 
by a restriction enzyme digest (PstI/ScaI) to contain less intron sequence (to 
make it more sequence specific).     
 
6p1.2.2 Introducing the Hsd11b2 Targeting Construct into ES 
Cells 
 
6p1.2.2.1 Electroporation  
In order for a targeting construct to become incorporated into the mouse 
genomic DNA by homologous recombination, it must first be introduced 
into cultured embryonic stem (ES) cells.  To achieve this, the completed 
Hsd11b2 floxed construct was introduced into mouse ES cells (had been 
originally derived from a blastocyst inner cell mass (ICM)) in order to 
achieve stable inheritance of the transgenic allele (Evans and Kaufman, 1981).  
These ES cells had been previously derived from a 129 mouse line (chinchilla 
coat colour; E14TG2a cell line (129/OlaHsd)) (Hooper et al., 1987), and 
introduction of the targeting construct was performed by electroporation.  
The mouse ES cells were grown to 80% confluence in standard ES cell culture 
media (as detailed in the Materials and Methods chapter).  ES cells were then 
washed and pelleted (as described in the Materials and Methods chapter) 
ready for electroporation.  Meanwhile, approximately 20µg of linearised 
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Hsd11b2 floxed targeting construct DNA was prepared (as described in the 
Materials and Methods chapter).  This was then mixed with the pelleted ES 
cells, and the mix was electroporated at 240 Volts.   
 
6p1.2.2.2 Neomycin Selection of Positive ES Clones 
To establish which ES cells had integrated the construct into their genome, 
the neomycin antibiotic resistance cassette that had been incorporated into 
the final targeting construct was utilised.  G418 is an antibiotic used to select 
cells that contain the gene for neomycin resistance, and this was added to the 
culture media used to nurture the electroporated ES cells.  Cells that do not 
contain the neomycin gene (and therefore have not incorporated the 
targeting construct) will die in the presence of G418, and those that do 
contain it will thrive.  The cell cultures were incubated with G418 for up to 
two weeks, after which colonies derived from individual ES cell clones were 
selected and propagated in separate culture wells (see Materials and 
Methods chapter).  ES cells selected this way will contain the targeting 
construct, but this screening method can not differentiate between 
homologous recombination into the genome and a random insertion event.   
  
6p1.2.3 Screening for Homologous Recombination 
 
6p1.2.3.1 PCR Screening Results 
The recombination arms of the targeting construct should favour insertion by 
homologous recombination, but the construct may also be randomly inserted 
into the genome.  Traditionally, a Southern hybridisation screen involving 3’ 
and 5’ EPs is developed to screen for homologous recombination.  However, 
this is a lengthy and time-consuming process that requires high amounts of 
ES cell DNA and the use of radioactive isotopes.  A PCR screen was therefore 
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developed as a primary screen to identify ES cell clones that were likely to 
contain a homologous recombination event.  These ES cell clones were then 
taken forward for validation screening by Southern hybridisation.    
Primers were designed to amplify over regions of the Hsd11b2 gene that 
would reveal whether any targeting construct insertion was homologous or 
not (Figure 6.3).  A ubiquitous forward primer was designed to be paired 
with 3 different reverse primers (primer sequences are detailed in Materials 
and Methods chapter).  Primer pair A - B was designed check the integrity of 
the homologous recombination crossover point, and to give a size difference 
in product to indicate presence or absence of the targeting construct.  Primer 




Figure 6.3. Primer design and expected PCR product sizes for both wild type and gene-
targeted alleles.  Primer position on DNA represented by blue letters A - D.  Cross-over 







Gene-targeted Allele x x
A D BC
12.3Kb
1.4 Kb1.4 KbA - D
3.7 Kb-A - C




Forward Primer A (HSD2 exon 1) – 5’ - ctg ctg gct gct ctc gac tg - 3’
Reverse Primer B (HSD2 exon 2) – 5’ – tct tag ctg tct cct tgc ca – 3’
Reverse Primer C (Neo cassette) – 5’ – tgt caa gac cga cct gtc cg – 3’
Reverse Primer D (5’ Neo insert) – 5’ – ggc aga gcc tat aac gag tc – 3’
PCR ES Cell Screening Strategy  
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Neomycin resistance cassette, thus verifying the presence and position of the  
targeting construct.  Finally, primer pair A - D was also designed to ensure 
the integrity of the homologous recombination crossover point (a 
contingency in case the A - B PCR product was too large to synthesis 
efficiently).  PCR reaction conditions were optimised using un-transfected ES 
cell DNA as a template, and DNA extracted from neomycin-selected ES cells 
(as detailed in the Materials and Methods chapter) was screened initially 
using the A - B primer pair.  This proved to be a problematic PCR reaction to 
optimise, presumably because the expected PCR products were relatively 
large (wild type allele 3.2Kb and gene-targeted allele 5.2Kb).  Consequently, 
A - D and A - C primer pairs were attempted, but they too proved to be 
problematical, and a reliable and robust PCR assay proved difficult to 
establish. 
 
6p1.2.3.2 Fluorescent PCR Screening Results 
Due to the difficulties mentioned with the traditional PCR methods, a 
quantitative fluorescent-based approach for PCR screening was also 
developed.  This was similar to a real-time PCR approach, using the same 
instrument and reagents, but different in that an absolute detection of a 
specific a nucleic acid sequence was being looked for, not a relative 
quantification of that detection.  Primers were calculated using an online 
program for designing real-time assay primers (as described in detail in the 
Materials and Methods chapter), which are generally designed to amplify 
over an area up to a few hundred bp in length.   The optimal design for this 
new PCR assay was to amplify between Hsd11b2 exon 1 and the upstream 
loxP site, an area which covers approximately 2.8Kb.  This would result in a 
positive assay signal if the loxP site was in the correct region and no signal if 
it was not.  As described in the Materials and Methods chapter, a positive 
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control plasmid (containing Hsd11b2 exon 1 and a loxP site) was constructed 
using the 5’ EP and pL451 plasmid to act as a positive control in screening 
reactions.  This plasmid was designed to amplify a product that would be 
smaller in size than the real product, so that any suspicion of DNA sample 
contamination could be accounted for.  A primer matrix reaction was carried 
out using positive control DNA to analyse what concentrations would give 
the best results (Figure 6.4a).  This was performed using a SYBR Green 
probe, as this is activated for fluorescent detection by any double stranded 
DNA, thus removing the need for a DNA sequence-specific probe.  Once this 
had been calculated, the sensitivity of the assay was tested by using the 
positive control DNA at different concentrations per genome.  The outcome 
of the real-time PCR was validated by agarose gel electrophoresis to visualise 
the DNA product.  The DNA of the neomycin selection positive ES clones 
was then screened by this assay.  ES cell clones with a cross threshold value 
of over 30 (approximately 25% of total samples) were expanded and carried 
forward for further screening analysis by Southern hybridisation (Figure 6.4 
b).  
 
6p1.2.3.3 Southern Hybridisation Screening Results 
A Southern hybridisation screen was designed to verify homologous 
recombination of the targeting construct using EPs to the 5’ and 3’ ends 
(Figure 6.5; 6p1.2.4).  ES cell genomic DNA taken forward from primary 
fluorescent PCR screening was purified further using a phenol/chloroform 
protocol (see Materials and Methods chapter).  The DNA was then digested 
using the BamHI restriction enzyme for 3’ EP and HindIII restriction enzyme 
for 5’ EP.  3’ EP screening of the DNA was performed in the first instance, as 
the results of this screen had proved easier to interpret during optimisation 
























Figure 6.4. Real-time PCR screening strategy for ES cells. a) Bar chart showing the CTs for 
different combinations of Forward (F) and Reverse (R) primer concentrations in a SYBR 
Green fluorescent detection PCR reaction.  All primer concentrations are in nM.  NTC = no 
template control; NSC = non spike control. b) Example of results obtained from SYBR Green 
PCR screening of ES cells targeted for hsd11b2 floxed construct positive for neomycin 
selection, using primer concentration of 300nM forward and 900nM reverse.  Positive CT 
































a) SYBR Green PCR Primer Matrix CTs 
b)  CT Values for PCR ES Cell Screening 
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Figure 6.5. 3’ and 5’ external probe design. a) Schematic representation of the 3’ external 
probe (circled in red) and the different sizes that Southern hybridisation with the probe would 
generate according to wild type or gene-targeting allele after a BamHI restriction enzyme 
digest. b) Schematic representation of the 5’ external probe and the different sizes that 
Southern of hybridisation with the probe would generate according to wild type or gene-
targeting allele after a HindIII restriction enzyme digest. 
 
Digests were separated by agarose gel electrophoresis, transferred to a 
nitrocellulose membrane, and subsequently analysed for radioactively-
labelled probe hybridisation.  Clones that gave a positive result for the 3’ EP 
(Figure 6.6a) were consequently probed for the 5’ EP (Figure 6.6b), as 
verification of homologous recombination is required at both ends of the 
targeting construct.   






















a) 3’ External Probe Schematic 
b) 5’ External Probe Schematic 
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6p1.2.4 Blastocyst Injection and Chimeric Mouse Breeding 
 
6p1.2.4.1 Blastocyst Injection of ES Cells 
Three separate ES cell clones (named 28, 63 and 128) that were confirmed 
positive for both 5’ and 3’ end homologous recombination by Southern 
hybridisation were introduced from in vitro culture to a surrogate blastocyst 
by microinjection.  Karyotype was checked before injection (Figure 6.7; see 
Materials and Methods chapter for details). Manipulated blastocysts were 
then transplanted into psuedopregnant female mice for implantation and 
gestation.  The blastocyst injections and implantations were carried out by a 
University of Edinburgh in-house service (Genetic Intervention and 
Screening Technologies).  Refer to Table 6.1 for blastocyst injection statistics. 
 
6p1.2.4.2 Chimeras and Floxed Allele Germline Transmission 
During embryonic development of the injected blastocysts, the targeted 
floxed allele will become incorporated into the embryonic germline, where 
the pluripotency of the ES cells will allow them to become integrated into the 
embryo at all consequent tissue lineages (Ledermann, 2000).  As the resulting 
offspring are essentially derived from the cells of two different embryos (the 
targeted ES cells and the microinjected blastocyst), they are referred to as 
chimeras.  The production of a chimera is an essential stage in the generation 
of a transgenic mouse, and it can be used to advantage for screening of 
successful targeting allele genome integration.  If the ES cell line and the 
donor embryo are derived from mouse lineages that express different coat 
colours, then a chimeric offspring can be easily identified by its “patchy” coat 
appearance.  This is an indication that the genotypes from both the targeted 
ES cells and the donor blastocyst were incorporated into the germline of the 
resulting offspring.   
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Figure 6.6. Southern hybridisation blots of 3’ and 5’ external probes. a) Southern membrane 
of BamHI restriction enzyme digested ES cell DNA transferred from an agarose gel to a 
nitrocellulose membrane, probed with radioactively-labelled 3’ external probe.  Samples 16 
and 22 represent ES clones positive for insertion of the hsd11b2 floxed targeting construct 
by homologous recombination at the 3’ end. b) Southern membrane of HindIII restriction 
enzyme digested ES cell DNA transferred from an agarose gel to a nitrocellulose membrane, 
probed with radioactively-labelled 5’ external probe.  Samples 182 and 194 represent ES 
clones positive for insertion of the hsd11b2 floxed targeting construct by homologous 












a) 3’ External Probe Southern Hybridisation Blot 
b) 5’ External Probe Southern Hybridisation Blot 
 225 
 
Figure 6.7. ES cell karyotyping.  Photos of ES cell spreads for checking karyotypes of cells.  
Both ES cell clone 28 a) and 63 b) have a normal mouse karyotype of 40. 
 
For the Hsd11b2 floxed construct targeting, the ES cells used have been 
previously derived from a 129 mouse line (agouti coat colour) and they were 
injected into C57BL/6 blastocysts (black coat colour).  Any resultant offspring 
will be screened for floxed allele integration by chimeric coat colour (a 
mixture of black and agouti; see Figure 6.8 for photos).  In total, from five 
separate rounds of injections seven individual chimeras were obtained (refer 




Figure 6.8.  Photographs of chimera 1 and 4 representing “patchy” coat colouring 
characteristic of chimeric mice. 



















1 182 124 4 4 3 
2 182 61 3 9 0 
3 28 53 4 6 1 
4 63 130 8 27 0 
5 28 & 63 98 4 11 3 
 
Table 6.1. Blastocyst injection statistics 
 
Once chimeric offspring were weaned, a breeding program commenced, 
pairing them with C57BL/6 wild-type mice. The results of these breeding 
programs is the last step in producing a new transgenic mouse line, as for the 
new line to continue and be used experimentally, the targeted allele must be 
incorporated into the germline of the chimeric offspring.  That is, although all 
chimeric offspring will contain a mixture of cells derived from both the 
targeted ES cells and the donor blastocyst, if none of the targeted cells are 
being passed onto the next generation via the germline, then the targeted 
allele will not be transmitted.  Black coat-colour (blastocyst donor coat 
colour) progeny do not contain the introduced targeted allele, whereas 
successful germline transmission is detected by agouti coat-colour (ES cell 
line coat-colour).  The seven chimeras produced a combined total of 169 
weaned pups, all of which were black in coat colour (see Table 6.2 for 


















1 1 12/02/2008 Male 0 n/a n/a 
2 1 12/02/2008 Female 18 18 0 
3 1 12/02/2008 Male 66 66 0 
4 3 01/12/2008 Male 0 n/a n/a 
15 5 31/03/2009 Female 0 n/a n/a 
16 5 31/03/2009 Female 23 23 0 
29 5 31/03/2009 Male 62 62 0 
 
Table 6.2. Chimera Breeding Program Statistics 
 
As can be seen in Table 6.2, chimera 1, 4 and 15 did not produce any 
offspring.  Chimera 4 was in a breeding program for a number of months, 
but failed to produce any offspring (despite rotation of numerous female 
partners) so was presumed to be sterile.  Chimera 15 was found 
unexpectedly dead at 8 weeks old; no obvious cause of death could be 
identified from a basic autopsy.  Chimera 1 was found to have an infected 
abscess near his penis at 5 months of age and was consequently culled; this 
abscess being the presumed cause of his failure to produce any offspring.  
Approximately three months after the abscess was discovered in chimera 1, 
chimera 3 developed a similar lesion.  This time a full necropsy was 
performed by in-house rodent pathologist Dr David Brownstein, which 
identified the abscess as an infected preputial gland abscess with skin fistula 
(see Appendix 1).  A literature search for possible causes of the perputial 
gland abscess identified a Staphylococcus aureus bacterial infection as a 
possible cause (Hong and Ediger, 1978).  Tests for Staphylococcus aureus could 
have been carried out on tissue harvested from the autopsied male, but as 
this is a common infection found in a high percentage of the general 
Breeding Statistics 
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population (Wertheim et al., 2005; Yu et al., 2002), a positive result would be 
ambiguous. 
Unfortunately, all resulting progeny from the successfully breeding chimeras 
were black, signifying that the chimeras had not transmitted the transgenic 





6p1.3.1 Summary of Gene Targeting Construct 
 
The Hsd11b2 floxed gene targeting construct was designed and built to allow 
for conditional deletion of 11β-HSD2 in a site-specific manner using the 
Cre/loxP recombination technology.  The construct was specifically designed 
to include exons 2 - 5 of the Hsd11b2 gene.  These were flanked by two loxP 
sites facing in the same direction to allow for removal of this region of DNA 
from the genome upon exposure to Cre recombinase.  There was also a 
neomycin cassette flanked by two FRT sites (again facing in the same 
direction) positioned between the 5’ loxP site and Hsd11b2 exon 2.  This was 
to permit independent removal of the neomycin cassette in ES cells, if 
required.  Exons 5 - 8 of the neighbouring ATP6V0D1 gene are included 
within the DRA of the targeting construct for two main reasons.  Firstly, their 
inclusion allows for the recombination arm to be longer, as longer 
recombination arms have been shown to be beneficial in promoting a higher 
frequency of homologous recombination (Inbar et al., 2000).  Secondly, 
because these two genes terminate within a few Kbs of one another, this 
region is likely to be important for their transcriptional regulation, and so it 
is favourable to minimise sequence disruption within this region. 
Once the completed targeting construct had been verified by DNA 
sequencing, it was introduced into an ES cell line.  The ES cells were initially 
screened for integration of the introduced targeting construct by exploiting 
the antibiotic resistance of cells positive for integration (due to the neomycin 
cassette of the targeting construct).  However, while this screening method 
can reliably detect construct integration into the ES cell genome, it cannot 
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distinguish between a random insertion event and genuine homologous 
recombination.  In order to try and make the secondary screening for 
homologous recombination more efficient than the traditional approach by 
Southern hybridisation of EPs, a PCR-based screening strategy was 
developed.  This approach was first attempted using a traditional PCR 
strategy; however the long length of PCR products required to produce 
reliable evidence of a homologous recombination event proved difficult to 
optimise.  Consequently, a fluorescence-based PCR approach was instead 
adopted.  This proved more successful, and allowed the number of ES cell 
clones put forward for further screening by Southern hybridisation to be 
reduced by approximately two-thirds.  Southern hybridisation screening was 
first carried out using the 3’ EP.  Clones that were positive for this probe 
were then put forward for Southern hybridisation screening with the 5’ EP.  
Consequently, three separate ES cell clones were chosen to go forward for 
blastocyst injection. 
 
6p1.3.2 Chimera Breeding Program and Germline Transmission 
 
The results of the blastocyst injections were poorer than would normally be 
expected (Table 6.1); with the number of pregnant surrogates low, and live 
offspring production also lower than normal.  Despite this, seven chimeras 
were successfully produced, and were all entered into breeding programs 
with C57Bl6 mice.  Unfortunately, the floxed Hsd11b2 allele never progressed 
to germline status.  As a result of the poor blastocyst injection statistics and 
the resultant failure of the targeted allele to become germline, diagnostic tests 
were carried out upon the ES cell line to try and determine why this had 
happened.  These tests revealed that all three of the injected ES cell clones 
had a mycoplasma infection (mycoplasma testing performed by Mrs. Audrey 
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Peter, Senior Technician, Molecular Physiology Lab).  Mycoplasma-infected 
ES cells have been shown to affect germline transmission from chimeras 
(Markoullis et al., 2009).  Infection can also lead to a reduction in the number 
of pups born, a lower frequency of chimeric pups, and a higher frequency of 
embryo death and implanted blastocyst re-absorption (Bradley, 1987).  This 
is a likely explanation for the low numbers observed.  This then has a knock-
on effect regarding chimera numbers, as lower pregnancies means less 
chance of producing a germline chimera.  In addition, a mycoplasma 
infection can also cause genitourinary infections in humans, and so could be 
the cause of the infections that were observed affecting the genitalia of two 
male chimeras (Appendix 1).   
These unfortunate events mean the process of producing a floxed Hsd11b2 
transgenic line from start to finish could not be realised in the time frame of 
these studies.  However, there is the potential that the completed construct 
can be re-transfected into clean ES cells and the process carried forward to 
successful germline transmission of the floxed Hsd11b2 allele.   
 
6p1.3.3 Future Direction: the Importance of Phenotypic 
Characterisation Before Site-Specific Deletion of a Floxed Allele  
 
Once the Hsd11b2 floxed line has been successfully established, it will be 
important to establish its phenotype before selectively removing Hsd11b2 in 
the CD, especially on different sodium diets.  This will ensure that 
phenotypes observed in the CD-specific 11β-HSD2 knockout model (i.e. 
Hsd11b2 floxed/HoxB7 Cre line (to be discussed in more detail in Chapter 6 
Part 2) cross offspring) are due to the spatial removal of the gene of interest, 
and not an effect of floxing the gene; i.e. the gene of interest must function as 
normal until excised by interbreeding with a recombinase-expressing mouse 
 232 
line.  The insertion of extra regions of DNA (such as the neomycin selection 
cassette) in the introns or near the promoter of the gene of interest when 
generating a targeting construct can have stochastic effects upon the normal 
function of that gene (Kwan, 2002).  It can also have effects upon the 
transcriptional regulation of neighbouring genes (Olson et al., 1996).  These 
effects can be overcome by flanking the neomycin cassette for selectable 
removal, as was done with FRT in the floxed construct described here.  
Occasionally this phenomenon can render the transgenic allele hypomorphic; 
that is expression of the gene of interest may be reduced rather than ablated.  
This perceived shortcoming of gene targeting experiments has conversely 
been exploited by some researchers in order to produce models of gene 
mutations with varying degrees of phenotypic severity (Meyers et al., 1998; 





Chapter 6 Part 2 
 





As discussed in Part 1 of Chapter 2, a Cre/loxP transgenic approach is being 
undertaken in order establish spatial conditional deletion of 11β-HSD2 in a 
mouse model.  The kidney is an attractive candidate for first employing this 
technique, as it is a major expression site of 11β-HSD2, and SAME is 
classically held to be a renal disease.  This theory is supported by the 
observation that kidney transplantation in a SAME patient rescued the 
phenotype, and consequent clinical analysis revealed the new kidney was 
expressing functional 11β-HSD2 (Palermo et al., 2000).  Therefore, 
investigating the specific contribution of renal 11β-HSD2 towards the 
phenotypes reported in SAME patients, and the Hsd11b2-/- mouse model, will 
be important in understanding the pathology 11β-HSD2 ablation.  Also, the 
role of the kidney in the development of SS BP in the Hsd11b2+/- model (see 
Chapter 3) further strengthens the case for exploring the specific roles that 
renal 11β-HSD2 expression plays towards the pathology of impaired protein 
expression. 
The particular expression site of 11β-HSD2 within the mouse kidney is in the 
distal nephron (Condon et al., 1997).  More specifically, the connecting tubule 
(CNT) and the principal cells of the collecting duct (CD)  of mice show strong 
expression for 11β-HSD2 (Cole, 1995) (Campean et al., 2001).  One particular 
study also finds occasional 11β-HSD2 expression (at both RNA and protein 
levels) in the distal convoluted tubule (DCT) (Campean et al., 2001); although 
it must be pointed out that expression is seen in transitional segmental 
portions and in the minority of sections.  There are a small number of kidney 
Cre lines that would be appropriate for CD-specific deletion of 11β-HSD2 
(for review see (Rubera et al., 2009)).  One of these is the AQP2 Cre line, 
which has Cre recombinase expression under the control of the AQP2 gene 
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promoter with specific expression in the CD and the late CNT (Ronzaud et 
al., 2007).  Both the human and mouse AQP2 promoter have been previously 
used in Cre recombinase mouse lines to target floxed genes in the CD 
principal cells.  However, both of these models have been shown to have 
leaky expression patterns of transgene activity, with Cre recombinase 
expression demonstrated in non-renal tissues (Nelson et al., 1998) (Zharkikh 
et al., 2002) (Ge et al., 2005).  As 11β-HSD2 is expressed in other tissues, using 
this particular Cre could remove 11β-HSD2 in sites other than the kidney, 
thus compromising any observations made using the floxed Hsd11b2 model. 
An attractive alternative to the AQP2 Cre line is the HoxB7 Cre line.  This Cre 
line does not cover the entire 11β-HSD2 expression sites in the ASDN (CD 
only, not CNT or DCT). However, studies have suggested that the role of the 
proximal and the distal ASDN in water and sodium balance are different in 
that the proximal segments regulate balance short-term, where as the distal 
ASDN (i.e. CD) regulates the long-term balance (Rubera et al., 2003).  This 
makes the HoxB7 Cre a worthwhile model to investigate the role of 11β-
HSD2 expression in the long-term regulation of sodium and water balance 
homeostasis.   
 
6p2.1.1 Hox Genes 
 
The family of Homeobox genes (Hox) encode transcription factors that are 
key regulators of embryonic axis formation, and tight regulation of these 
genes is essential for embryonic morphogenesis (Deschamps et al., 1999).  In 
addition, the Hox family also specify additional differentiation events in both 
embryonic and adult tissues (Yaron et al., 2001).  39 different Hox genes have 
been identified over 4 different chromosomal compartments, and the genes 
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are sub-classed depending upon their chromosomal compartment 
positioning (Hox1 - 4).   
The particular Hox gene of interest here, HoxB7, was previously known as 
Hox2.3.  The initial expression characterisation of HoxB7 was performed by 
Northern hybridisation analysis in mouse embryonic tissues (Deschamps et 
al., 1987).  These experiments showed expression according to a temporally 
and spatially restricted pattern in the embryonic central and peripheral 
nervous system, and in derivatives of the axial, lateral plate and  
intermediate mesoderm (Deschamps et al., 1987).  To investigate the effects 
of different regions within the HoxB7 promoter and enhancer upon 
differential gene expression in vivo, Deschamps and colleagues generated 
several chimeric transcription units composed of HoxB7 upstream sequences 
encompassing its promoters and enhancers and the bacterial LacZ reporter 
gene to generate transgenic mouse lines (Kress et al., 1990).  One of the 
chimeric transgene constructs showed particularly strong expression in the 
epithelium within the urogenital system derived from the mesonephric duct, 
a site of high HoxB7 expression.  Expression of the construct (as identified by 
LacZ expression) was not observed in any other region of normal HoxB7 
expression.  This observation was later exploited by another group to 
develop Cre mouse line using the original vector described above containing 
a 1.3 kb HoxB7 enhancer/promoter that targets expression in the urogenital 
system only (Yu et al., 2002). 
 
6p2.1.2 HoxB7 Cre Line: Previously Published Observations 
 
The HoxB7 Cre reporter line expresses Cre recombinase under the control of 
the above described HoxB7 promoter/enhancer, specifically within the 
mesonephric duct and its derivatives (Yu et al., 2002).  The original paper 
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describing this model demonstrates detailed analysis of the spatial and 
temporal expression of the Cre recombinase using a ROSA 26 reporter mouse 
line.  Cre activity was detected in the mesonephric duct as early as 
embryonic day 9.5 (E9.5).  It was subsequently detected throughout the 
ureteric bud from its initiation at E10.25, and was clearly able to initiate 
recombination-mediated expression of the ROSA reporter gene in all ureteric 
bud epithelial cells by E12.5. 
Another study using the HoxB7 Cre line, this time to selectively remove α-
ENaC subunits from the CD, also investigated the expression of the 
recombinase at a tissue level (Rubera et al., 2003).  Again using the ROSA 26 
LacZ reporter line, they showed that Cre recombinase could be detected in 
the entire CD, and that tissue samples from lung, colon, skin, liver, heart and 
brain were all negative for expression.  This study also investigated the 
efficiency of recombination by the Cre recombinase in CD cells.  They 
demonstrated the efficiency to be high by using immunohistochemistry to 
detect the α-ENaC subunit; less than 1.5% α-ENaC positive cells were 
detected in the CDs of transgenic mice (Rubera et al., 2003).    
The HoxB7 Cre model was purchased as two breeding pairs from the Jackson 
Laboratories website (http://jaxmice.jax.org/info/index.html). The line is 
maintained on a hemizygous background (HoxB7+/-) as homozygocity is 
embryonic lethal.  For further detailed Cre expression characterisation for 
embryonic, post-natal and adult tissues, see Cre expression resource option 
on the Jackson Laboratories website (http://cre.jax.org/HoxB7/HoxB7-Cre.html). 
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6p2.2 Results  
 
6p2.2.1 Detecting Cre Recombinase Expression 
 
6p2.2.1.1 ROSA 26 LacZ Reporter Line 
Although the HoxB7 Cre line has previously been used to drive deletion in 
the CD, the specific location of Cre recombinase in the kidney was 
investigated by cross-breeding HoxB7+/- mice with the ROSA 26 LacZ Cre 
reporter strain (Friedrich and Soriano, 1991).  This transgenic reporter model 
expresses an introduced construct in all cell types that contains a LacZ 
expression gene.  The ubiquitous expression of the LacZ gene is prevented by 
a floxed stop codon.  In the presence of Cre recombinase, the stop codon is 
excised and expression of the LacZ gene will be observed in tissues where 
Cre is present.  LacZ gene expression is detected as β-galactosidase activity, 
and this is done by means of X-Gal staining.   
The kidneys of mice identified by PCR-based screening as heterozygous for 
both the HoxB7 and the ROSA 26 allele were perfusion-fixed with 
glutaraldehyde (HoxB7 Cre mice were used as negative controls), and stained 
for LacZ expression with X-Gal solution, as detailed in the Materials and 
Methods chapter.  The results showed positive staining of CDs, and this 
staining was not observed in control kidney sections (Figure 6.9).  As can be 
seen, the X-Gal staining is exclusive to a sub-population of cells within the 
CDs; as this population makes up the majority of the CD cells, these are most 
likely to be the principal cells, with the unstained remainder presumed to be 
the minority intercalated cell population. This study is consistent with the 
previous reports in the literature that HoxB7 Cre recombinase expression in 
the kidney is exclusive to the principal cells of the CD.   
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Renal HoxB7  Cre Recombinase Expression 
 
Figure 6.9. Kidney sections from a Hoxb7/ROSA26 heterozygote mouse stained with X-Gal 
to detect LacZ expression.  CD = collecting duct; G = glomerulosa; PT = proximal tubule.  
Blue staining represents LacZ expression. 
 
6p2.2.2 Characterising HoxB7 Cre Mice - Effects of a High 
Sodium Diet  
 
A detailed physiological assessment of the HoxB7 Cre line is lacking in the 
literature and will be important for characterisation of future CD-specific 














11β-HSD2 deletion.  It is important to define the phenotype in terms of 11β-
HSD2 deletion separately from contributions to the phenotype due to the 
HoxB7 transgene.  It is particularly important in this instance to establish any 
phenotypes associated with the HoxB7 Cre line in relation changes in sodium 
diet content, as the Hsd11b2+/- mice have been shown to have a SS phenotype 
(Chapter 3).  It is therefore essential to determine that these SS phenotypes 
are not present in the Cre line. The value of investigating hypomorphic 
alleles is previously discussed in Chapter 6 Part 1. 
Experiments for renal and blood pressure phenotyping was performed in 
anesthetised mice as before (Chapter 3).  Cohorts for the experiments 
consisted of HoxB7+/- mice and wild-type littermates (HoxB7+/+) maintained on 
either a normal sodium diet, or a high sodium diet for three weeks prior to 
phenotyping experiments.  As shown in Figure 6.10a, MABP was not 
different between the two genotypes, and was not influenced by dietary 
sodium content in either genotype.   
This strongly suggests that HoxB7+/- transgenic mice do not have a salt-
sensitive blood pressure phenotype.  Acute amiloride administration also did 
not significantly alter MABP in either genotype on both sodium diets (results 
not shown). 
Figure 6.10b shows that GFR values do not differ significantly between 
genotypes.   It can also be observed that sodium diet had no effect upon GFR 
in either genotype.  Urinary sodium excretion (ENa) was also measured in 
these groups of mice. On a standard sodium diet, both genotypes have 
similar levels ENa (Figure 6.10c).  After three weeks on a high sodium diet, the 
ENa is significantly increased to similar levels for both genotypes.  ENa was 
also measured after acute amiloride administration, and the difference 
between pre- and post-amiloride administration calculated (Δ amiloride).                        
 241 
                    





























































 mice after three weeks on either a standard (n = 7 for both groups) or 
high (n = 6 and 5, respectively) sodium diet. a) Overall statistical analysis of MABP after 
three weeks on either a standard or high sodium diet shows that there is no significant effect 
upon MABP of either diet or genotype. b) GFR values are expressed as mls of FITC-labelled 
inulin filtered across the glomerular filter barrier from plasma per minute, as measured from 
both urine and plasma.  Overall statistical analysis reveals that there is no significant effect 
of genotype or sodium diet upon GFR. c) Statistical analysis shows there is a significant 
effect of diet upon urinary sodium excretion (ENa) (** = P < 0.01), but that there is no 
significant effect of genotype upon the values on either dietary regime. d) Overall analysis 
shows there is a highly significant effect of dietary sodium upon Δ ENa after amiloride 
administration (*** = P < 0.001), but there is no significant effect of genotype either before or 
after.  Data are mean ± SEM.  Statistical analysis by 2 way ANOVA.   
 
These results show that on a standard sodium diet, both HoxB7+/+ and 
HoxB7+/- mice greatly increase their ENa, consistent with acute ENaC blockade 
(Figure 6.10d).  After three weeks on a high sodium diet, the Δ amiloride 
a) MABP  b) GFR  
c) ENa  d) Δ Amiloride ENa  
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ENa values are significantly lower than for those on the standard sodium 
diet for both genotypes, but this difference is equal between the two 
genotypes (Figure 6.10d).  This suggests that the HoxB7+/- mice are regulating 
their ENaC expression and sodium excretion appropriately for the level of 
sodium in their diet; deregulation in this system is a predominant finding 
reported in the characterisation of the Hsd11b2+/- mice on a high sodium diet.  
This is an important observation as it verifies that any changes to natriuresis, 
with particular reference to the role of ENaC in the process, which may occur 
when an Hsd11b2 conditional knockout model is produced, are not due to 





HoxB7 Cre will allow for conditional deletion of 11β-HSD2 when cross-bred 
with a floxed Hsd11b2 line.  In particular, the Hoxb7 Cre line will remove 11β-
HSD2 expression in the CD of the ASDN, which includes the cortical CD 
(CCD) and the outer and inner medullary CD (OMCD and IMCD, 
respectively) (Rubera et al., 2003).  Published observations and the LacZ 
reporter experiments described here demonstrate that Cre recombinase 
activity in this line is indeed confined to this region of the kidney (Rubera et 
al., 2003; Yu et al., 2002) and that the recombinase activity of the Cre is strong 
(Rubera et al., 2003).   
Just as it will be important to establish any baseline phenotypes in the 
Hsd11b2 floxed line, the same is true for the HoxB7 Cre line.  Any underlying 
phenotypes of the model that are not identified before cross-breeding with 
the Hsd11b2 floxed line could compromise the phenotypic investigations of 
the new conditional model.  The phenotyping experiments performed here 
suggest that the Cre transgene is not affecting the BP or renal sodium 
handling in the HoxB7 Cre line.  These investigations were pursued further 
by also assessing the mice under conditions of physiological stress; namely a 
high sodium diet regime.  The model did not differ in phenotype from the 
wild-type controls, again suggesting that the transgene is not having an 
influence upon phenotype. 
Overall, the investigations described in this chapter recommend the HoxB7 
Cre line as an appropriate choice for generating a kidney CD-specific 
Hsd11b2 knockout mouse model.  This model will be important for 
investigating the renal contributions towards the phenotypes of the already 












This thesis describes the initial characterisation of the SS phenotype of 
Hsd11b2+/- mice. The inspiration for these studies came from research into 
human populations which suggested that polymorphisms in the HSD11B2 
gene may be associated with essential and/or SS hypertension.  Ferrari et al 
identified the heterozygous parent of a SAME patient as having 
hypertension, as well as a homozygous SAME patient with a mild mutation 
that caused only a hypertensive phenotype rather than full blown SAME 
(Ferrari et al., 2000).  This led the authors to suggest that the degree of 11β-
HSD2 activity in vivo may influence the severity of the hypertensive 
phenotype.  They then went on to prove that a HSD11B2 polymorphism (CA 
repeat allele) was associated with SS hypertension.  Studies of cell lines 
transfected with HSD11B2 allele variants have highlighted the effects of 
different polymorphisms upon differences in enzyme activity (Alikhani-
Koupaei et al., 2007; Lavery et al., 2003).   Conversely,  a study by Melander 
et al found no correlation between HSD11B2 polymorphisms and essential 
hypertension using patients THF/THE ratio as a guide to in vivo 11β-HSD2 
activity (Melander et al., 2003).  However, another study by Poch et al 
demonstrated reduced 11β-HSD2 activity associated with essential 
hypertension in biopsied salivary glands of hypertensive patients for whom 
the THF/THE ratio was not significantly different compared to normotensive 
controls (Poch et al., 2001); they concluded that the THF/THE ratio is not an 
ideal marker of in vivo enzyme activity. 
We have advanced upon these human population association and in vitro cell 
line studies to provide the first direct in vivo evidence that reduced 11β-
HSD2 enzyme activity causes a SS BP phenotype.  This is an important 
finding as it supports the theory that HSD11B2 polymorphisms within the 
general population contribute towards essential and/or SS hypertension.  
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Therefore, the Hsd11b2+/- mouse is an excellent in vivo model to use for 
dissecting molecular mechanisms that underlie SS BP. 
The altered sodium handling and renal hemodynamics of Hsd11b2+/- mice on 
a high sodium diet is highly suggestive of a renal aspect to the BP phenotype.  
The major role that the kidney plays in BP homeostasis is well documented. 
The case study of a kidney transplant fully rescuing the phenotype of a 
SAME patient also highlights the important role of the kidney in the 
development of these phenotypes (Palermo et al., 2000)  Therefore, our 
investigations into the molecular mechanisms underlying the salt sensitivity 
of the Hsd11b2+/- mice focused upon the kidney in particular.  
Pharmacological interventions showed that the important renal sodium 
channel ENaC was playing a role in the development of SS phenotypes, as 
ENaC blockade prevented the phenotype from developing on a high sodium 
diet. Further studies into the involvement of ENaC in the Hsd11b2+/- SS 
phenotype could be carried out to enhance our understanding of this 
phenotype.  These studies could include quantifying the expression of ENaC 
subunits by performing quantitive PCR upon dissected collecting ducts from 
Hsd11b2+/- and Hsd11b2+/+ mice both before and after and high sodium diet, 
and seeing what effects diet and genotype have upon ENaC expression.  
Electrophysiology experiments could also be carried out upon split-open 
distal tubules from these mice to assess the functional activity of ENaC, and 
also immunostaining in order to determine the spatial location of ENaC at a 
cellular level.  The expression of ENaC regulators, such as SGK1 and Nedd 4, 
may also prove insightful. 
AngI and II dose response experiments highlighted the contributions that 
11β-HSD2 expression in the vasculature may also be making towards these 
phenotypes.   These experiments could be further developed by performing 
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quantitative PCR assays to assess AT receptor expression levels, and also 
myography of resistance vessels as the RVR and Ang I and II dose-response 
curves are suggestive of alterations in the vasculature of Hsd11b2+/- mice, 
particularly in the setting of a high sodium diet.  These studies could also be 
repeated using AT receptor antagonists, such as Losartan, to 
pharmacologically characterise the BP responses to Ang I and II. 
The ability of the Hsd11b2+/- mice to significantly reduce their aldosterone 
levels on a high sodium diet suggested that they are capable of regulating 
their RAAS in response to dietary salt load. An unexpected finding was the 
significant increases in corticosterone in these mice on a high sodium diet.  
These increased levels are most likely responsible for the phenotype of the 
Hsd11b2+/- mice, whether via MR, GR or, more likely, a combination of both. 
Studies performed in this thesis with the MR antagonist spironolactone 
proved inconclusive, and an investigation with a GR antagonist would be of 
great interest.  Since the completion of my PhD studies, these experiments 
have been successfully carried by others in the research group (see Appendix 
2 of this thesis for published scientific paper in the journal Hypertension that 
includes these further experiments). In addition, the elevated glucocorticoid 
levels suggested that a stress-related phenotype due to the high sodium diet 
may have developed.  HPA axis testing showed that the Hsd11b2+/- mice were 
not synthesising or releasing greater amounts of corticosterone in response to 
an acute stress on a high sodium diet.  However, this testing did highlight 
the impaired ability of the Hsd11b2+/- mice to metabolise corticosterone in 
comparison to the Hsd11b2+/+ mice, but only under high sodium diet 
conditions. This would suggest that the high sodium diet was affecting 11β-
HSD2 activity, but our enzyme activity assay showed this not to be the case.  
The high sodium diet may therefore be influencing other mediators of 
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corticosterone metabolism or regulation, such as the 5α- and β-reductases. It 
would be interesting to measure the THF/THE ration in these mice to see if a 
high sodium diet affects this pathway of glucocorticoid metabolism. We also 
thought it important to investigate other effects that a high sodium diet may 
be causing as the Hsd11b2+/- phenotype may arise as a failure of the mice to 
respond appropriately to the physiological stresses that associate with 
sodium loading. 
As previously mentioned, an interesting observation in these studies is that 
the Hsd11b2+/- mice only present with a phenotype different from the 
Hsd1b2+/+ mice when they are confronted with increased dietary sodium.  
Studies using cloned 11β-HSD2 protein have shown that in vitro conversion 
of cortisol to corticosterone displays a linear dose response (Ferrari et al., 
1996).  Glucocorticoids therefore technically have “improved” access to MR 
in the heterozygote model, but this appears to have no physiological 
consequences under normal salt conditions.  Further investigations studying 
the binding of tracer 3H-aldosterone in kidney, colon, heart and hippocampal 
extracts, suggest MR are always highly occupied by glucocorticoids, but not 
necessarily activated (Funder and Myles, 1996).  This poses the question why 
does glucocorticoid activation of MR, and the consequential detrimental 
effects, only occur when the Hsd11b2+/- mice are exposed to levels of 
increased sodium? 
A possible explanation begins with the observation in some studies showing 
a link between increased salt intake and renal oxidative stress (Gill and 
Wilcox, 2006).  It has been suggested that a change in the REDOX state of MR 
and 11β-HSD2 target tissues may change the ability of glucocorticoids to 
activate the MR (Funder, 2005).  That is, under a normal REDOX state, 
glucocorticoids can occupy the MR, but do not activate the MR.  However, 
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when something acts to change the intracellular REDOX state, such as high 
sodium diet, this permits the glucocorticoids to activate the MR.  The link 
between increased sodium and an altered REDOX state seems to arise from 
an increase in oxidative stress. Markers of oxidative stress, such as the 
isoprostanes and NADPH Oxidase subunits, have been found as up 
regulated in different models of experimental hypertension (Paravicini and 
Touyz, 2008).  Our studies showed that high sodium diet induced a urinary 
marker of oxidative stress in both genotypes, and that co-administration of 
an antioxidant drug with a high sodium diet alleviated the SS phenotype of 
Hsd11b2+/- mice.  However, the antioxidant drug did not attenuate the urinary 
oxidative stress marker, and so further experiments are required to fully 
analyse the contribution of oxidative stress to the phenotype of this model, 
such as quantitative PCR measurements of NADPH Oxidase subunits, as 
well as repeating the experiments with a antioxidant drug that works via a 
different mechanism(s) to assess the validity of the TEMPOL treatment. 
The link between Hsd11b2 heterozygosity, dietary sodium intake and our 
observed phenotype is likely to be a complicated one involving 
glucocorticoid regulation, MR target genes, and the control of ligand-
receptor regulation.  The most important factor is that despite the differences 
we see in phenotype between Hsd11b2+/- and Hsd11b2+/+ mice, these only 
present on a high sodium diet, and are therefore the result of a relationship 
between this and a decrease in 11β-HSD2 enzyme activity, and not either on 
its own.  Therefore, the important question that these studies have raised is 
why do Hsd11b2+/- mice only present with a phenotype under increased 
dietary sodium?  The answer to this is likely to prove insightful in clinical 
treatments for hypertension not only for individuals with HSD11B2 
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Investigator: Eilidh Craigie 
Date of necropsy: 14/10/08 
Path#: DB229/08 
Subject: chimeric male (129/B6) 
History: Proven breeder developed scrotal fistula ? Second chimera to develop one.  
 
Gross findings. Circular 1.5 mm penetrating ulcer of skin ventral midline 2 mm 
anterior to penis. Surrounding skin indurated.  
 
Underlying preputial gland swollen, irregular shape, cystic with inspissated pus. 





Preputial gland, abscess with skin fistula 
 
Comments. This is a common condition of male mice with both environmental and 
genetic elements.   
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